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ABSTRACT
There is increasing evidence to suggest that most antiepileptic drugs (AEDs) have 
multiple mechanisms of action which may contribute to their efficacy and/or toxicity. 
Of particular current interest is the effects of AEDs on the excitatory and inhibitory 
amino acid systems regulated by glutamate and y-aminobutyric acid (GABA), 
respectively.
Primary cultures of rat cortical astrocytes were employed to examine the effects of a 
range of AEDs on the uptake of GABA and glutamate and on the activity of the 
GABA-metabolizing enzyme GABA-transaminase (GABA-T). One hour exposures to 
sodium valproate (SVP), vigabatrin (VGB), felbamate (FBM) and tiagabine (TGB) 
significantly reduced GABA uptake into primary cultures of rat cortical astrocytes over 
a broad range of concentrations examined. Phenobarbitone (PB), phenytoin (PHT), 
carbamazepine (CBZ), lamotrigine (LTG), gabapentin (GBP), topiramate (TPM), 
levetiracetam (LEV) and desglycinyl-remacemide (DGR) were without effect.
A one hour exposure to PB resulted in a reduction in glutamate uptake into primary 
cultures of rat cortical astrocytes with the lowest three concentrations examined, with 
no effect on glutamate transport at the highest concentrations. TGB and DGR were 
also found to reduce glutamate uptake, however, the effects appeared to 
concentration-independent and not evident over the dose range. PHT, CBZ, SVP, 
VGB, LTG, FBM, GBP, TPM and LEV were without effect.
One hour exposures to VGB and DGR consistently reduced the activity of GABA-T in 
primary cultures of rat cortical astrocytes. SVP and TGB were also found to decrease
GABA-T activity, however, the effect was only evident at the highest concentration 
examined for each of the drugs. PB, PHT, CBZ, LTG, FBM, GBP, TPM and LEV 
were without effect.
Glutamine synthetase (GS) is a key enzyme in the regulation of glutamate 
neurotransmission in the central nervous system (CNS). The effects of single and 
repeated intraperitoneal (i.p.) administration of a range of AEDs on GS activity were 
investigated in mouse brain. Four hours after the final dose the animals were sacrificed 
and their brains removed for analysis of GS activity. Single doses of PHT and CBZ 
were found to dose-dependently reduce enzyme activity. Repeated doses of PB, PHT, 
CBZ, FBM and TPM dose-dependently reduced the activity of GS. SVP, VGB, LTG, 
GBP, TGB, LEV and DGR were without effect on enzyme activity.
In addition, due to the glial location of the enzyme, the effects of a range of AEDs on 
GS activity were examined in primary cultures of rat cortical astrocytes. A one hour 
exposure to PB reduced GS activity in primary cultures of rat cortical astrocytes. PHT, 
CBZ, SVP, VGB, LTG, FBM, GBP, TPM, TGB, LEV and DGR were without effect 
following a one hour exposure.
These results suggest that effects of these AEDs on the transport and metabolism of 
GABA and glutamate may contribute to the clinical effects of the drugs, and appear to 
support the observation that many AEDs have multiple mechanisms of action.
FBM, TPM and LEV are three new AEDs whose precise mechanism of action remains 
to be M y elucidated. Each has reported effects on amino acid neurotransmitter
systems. In light of this, the effects of single and repeated administration of FBM, TPM 
and LEV were investigated on GABA- and glutamate-related neurochemistry in mouse 
brain. Both single and repeated treatments with FBM, TPM and LEV were without 
significant effect on the concentrations of GABA glutamate and glutamine. Similarly, 
single and repeated treatments with all three drugs were without significant effect on 
the activities of GABA-T or glutamic acid decarboxylase (GAD). These results suggest 
that effects on GABAergic and glutamatergic systems are not involved in the 
mechanisms of action of these drugs.
Approximately 30% of patients with epilepsy do not respond to monotherapy and 
require treatment with two or more AEDs. However, there is very little scientific or 
clinical evidence highlighting the efficacy of particular combinations. Three of the new 
AEDs, LTG, GBP and TPM are commonly used as add-on therapy for refractory 
partial seizures. The effects of these drugs in single dose and in combination were 
examined on experimental seizures induced by the chemoconvulsant pentylenetetrazol 
(PTZ) in mice, in an attempt to identify efficacious combinations of new AEDs.
When administered alone, only the highest dose of LTG examined significantly 
increased the latency to the first PTZ-induced generalised seizure. Both GBP and TPM 
alone were without effect. Five of the nine combinations of LTG with GBP 
signficantly increased the seizure latency in mice. In addition, a combination of GBP 
with TPM was found to have a significant anticonvulsant effect when compared to 
control. All other combinations of AEDs examined were without effect on PTZ- 
induced generalised seizures at one hour post-administration. This preliminary study 
woud suggest that the combination of LTG with GBP, and possibly TPM with GBP,
may be an effective polytherapy regimen and require further detailed experimental and 
clinical investigation.
SVP, VGB and TGB were all found to exert effects on the GABAergic system when 
investigated in primary cultures of rat cortical astrocytes. It was of interest to examine 
the effects of these drugs on the uptake of GABA into primary cultures of human adult 
and foetal astrocytes. SVP, VGB and TGB significantly reduced the uptake of GABA 
into adult human astrocytes in primary culture following a one hour exposure. SVP 
and VGB also significantly reduced GABA uptake into primary cultures of human 
foetal astrocytes. However, TGB was without effect in the foetal astrocytes following 
a one hour exposure. The lack of effect of TGB in the human foetal astrocyte cultures 
may indicate the incomplete development of the GABA transporter GAT-1 in foetal 
brair. where TGB is known to act. The reduction in GABA uptake exerted by SVP and 
VGB in human foetal astrocytes may reflect a different mechanism of action of GABA 
uptate inhibition from that of TGB, possibly not involving GAT-1.
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CHAPTER ONE
INTRODUCTION
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1.1 EPILEPSY
Epilepsy is one of the most common serious neurological disorders in man, affecting 
around 50 million people world-wide (Shorvon, 1990). Approximately 0 .5-1% of the 
population are thought to be affected (Rogawski and Porter, 1990). The incidence 
varies with age, with rates greatest in childhood, falling to low levels in adult life and 
rising again among the elderly (Shorvon, 1996).
1.1.1 Definition of epilepsy
The term seizure refers to a transient alteration of behaviour due to abnormal 
synchronized and repetitive burst firing of neuronal populations in the central nervous 
system (CNS). Epilepsy is a syndrome of episodic brain dysfunction characterized by 
recurrent unpredictable spontaneous seizures (Shin and McNamara, 1994). A local 
abnormal discharge may spread to other areas of the brain. The site of the primary 
discharge and the speed and extent of its spread determines the symptoms that are 
produced. These range from a brief lapse of attention to a full-blown convulsive fit 
lasting for several minutes. The particular symptoms produced depend on the function 
of the affected brain region. In general, involvement of the motor cortex causes 
convulsions and involvement of the hypothalamus causes peripheral autonomic 
discharges. Loss of consciousness occurs if the reticular formation in the upper 
brainstem is affected (Rang and Dale, 1991).
1.1.2 Seizure classification
There are many different types of epileptic seizure. In 1969, the International League 
Against Epilepsy (ILAE) introduced a scheme for the classification of epileptic 
seizures. Since this publication, sophisticated techniques such as electroencephalogram
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(EEG) recording and radiotelemetry have become available, therefore, several other 
commissions on classification and terminology have convened to update, amend and 
improve the classification scheme (Commission on Classification and Terminology of 
the International League Against Epilepsy, 1981). There is a need for classification, as 
the choice of antiepileptic treatment will depend on the seizure type (Brodie and 
Dichter, 1996).
Seizures are divided fundamentally into two groups, namely partial and generalised. 
This concept dates back to Hughlings Jackson, but did not become common usage 
until developed by the Commission on Classification of the International League 
Against Epilepsy almost 40 years later (Commission on Classification and Terminology 
of the International League Against Epilepsy, 1981).
1.1.3 Partial (focal, local) seizures
Those seizures in which the first clinical and electroencephalographic changes indicate 
initial activation of a system of neurones limited to one part of the cerebral hemisphere 
are generally termed partial seizures. A partial seizure is classified primarily on the 
basis of whether or not consciousness is impaired. When consciousness is not impaired 
the seizure is classified as a simple partial seizure. When consciousness is impaired the 
seizure is classified as a complex partial. Simple partial seizures may evolve into 
complex partial seizures. A partial seizure may also progress to a generalised motor 
seizure (Commission on Classification and Terminology of the International League 
Against Epilepsy, 1981).
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1.1.4 Generalised (convulsive or non-convulsive) seizures
Those seizures in which the first clinical changes indicate initial involvement of both 
hemispheres are referred to as generalised seizures. Consciousness may be impaired. 
The ictal electroencephalographic patterns initially are bilateral and are thought to 
reflect neuronal discharge which is widespread in both hemispheres (Commission on 
Classification and Terminology of the International League Against Epilepsy, 1981). 
The generalised seizures include tonic-clonic (previously known as grand mat), 
absence (previously known as petit mal), myoclonic, atonic, clonic and tonic seizures.
1.1.5 Other seizure types
A third category of seizure types also exists. This group is referred to as unclassified 
seizure types, and includes all seizures which cannot be classified because of 
inadequate or incomplete data, and some which defy classification. Recently, a fourth 
category was added to the classification, which incorporates epileptic syndromes. This 
classification takes into account such factors as the age of the patient, type of seizure, 
presence or absence of an underlying neurologic lesion and a presence or absence of a 
family history (Brodie and Dichter, 1996). An epilepsy or epileptic syndrome is either 
idiopathic, which is virtually synonymous with genetic epilepsy, or symptomatic, i.e. 
due to structural lesion or major identifiable metabolic derangement (Commission on 
Classification and Terminology of the International League Against Epilepsy, 1989).
1.2 NEUROTRANSMITTERS AND EPILEPSY
The normal functioning of the CNS is thought to be maintained by a fine balance 
between excitation and inhibition. Disruption of this balance may result in the 
generation of abnormal electrical activity (Schwartzkroin, 1993). A deficiency in
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inhibitory y-aminobutyric acid (GABA) neurotransmission (Meldrum, 1984) or a 
disorder in glutamate-mediated excitatory neurotransmission (Bradford, 1995) have 
been proposed to contribute to seizure initiation.
1.2.1 Inhibitory neurotransmission
The neurotransmitters GABA, glycine, p-alanine and taurine play a role in inhibitory 
neurotransmission in the brain (Meldrum, 1984). GABA is the major inhibitory 
transmitter in the CNS of vertebrates, and plays a central role in neuronal function. It 
was first identified in the brain in 1950 (Awapara et al, 1950; Roberts and Frankel, 
1950).
GABA is synthesized, de novo, entirely from glutamate. This reaction is catalyzed by 
glutamic acid decarboxylase (GAD) in the presence of pyridoxal phosphate as a 
cofactor (Meldrum, 1975). GAD is localized exclusively in GABAergic neurones, and 
antibodies to this enzyme are used as a marker for GABAergic neurones in the CNS 
(Snead, 1983).
Traditionally GABA was thought to act on two subtypes of receptor, GABAa and 
GABAb. More recently several lines of evidence have indicated the existence of a third 
subtype of GABA receptor, GAB Ac (Bormann and Feigenspan, 1995). GABAa 
receptors consist of five variable subunits forming a ligand-gated chloride permeable 
ion channel and are located mainly postsynaptically. Activation of GABAa receptors 
leads to an increase in chloride permeability and thus hyperpolarization. GABA and 
muscimol act as agonists at this receptor. The GABAa receptor has modulatory sites 
for benzodiazepines, barbiturates, neurosteroids and ethanol. Antagonists at GABAa
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receptors, such as bicuculline and picrotoxin, increase excitability in the CNS and may 
cause convulsions (Stone, 1995).
GABAb receptors are G-protein linked receptors, located both pre- and 
postsynaptically. Activation of GABAb receptors usually leads to an increase in 
potassium conductance, resulting in hyperpolarization of neurones. GABA and 
baclofen act as agonists, and phaclofen as an antagonist at this receptor (Stone, 1995).
The GABAc receptor is pharmacologically distinct from GABAa and GABAb, and is 
located predominantly in the vertebrate retina. It is a chloride pore which is insensitive 
to both bicuculline and baclofen, and is activated selectively by cw-4-aminocrotonic 
acid (Bormann and Feigenspan, 1995).
Following neuronal release and receptor activation, GABA is removed from the 
synaptic cleft into both nerve terminals and astrocytes by several high affinity uptake 
carriers. Molecular cloning has revealed the existence of four GABA transporters 
named GAT-1, 2 and 3 and BGT-1 (Borden et al, 1994). Following uptake GABA is 
metabolized by two mitochondrial enzymes. GABA-transaminase (GABA-T) catalyzes 
the metabolism to succinic semialdehyde in the presence of a-ketoglutarate (a-KG) as 
a cofactor, and succinic semialdehyde dehydrogenase (SSAD) completes the 
metabolism to the inactive compound succinate in the presence of nicotinamide adenine 
dinucleotide (NAD; Meldrum, 1975).
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1.2.2 Evidence for the role of GABA in epilepsy
There is substantial evidence to indicate that a decreased inhibition by GABA may 
contribute to seizure generation and epilepsy.
• GABAergic impairment has been described as the basis for many of the chemically- 
induced seizures models (Fisher, 1989).
• GABA levels in the cerebrospinal fluid have been found to be reduced in patients 
with chronic epilepsy (Maynham et al, 1980).
• In surgical human epileptogenic tissue a decrease in GAD activity as well as an 
increase in GABA-T activity has been demonstrated (Lloyd et al, 1985).
• A 30-50% decrease in GABAergic neurones or nerve terminals has been observed 
in the amygdala of kindled rats (Loscher and Schwark, 1987).
• A 60-70% decrease in extracellular GABA levels in microdialysates from kindled rat 
amygdala has recently been reported (Kaura et al, 1995).
• A reduction in glutamate-induced GABA release has been observed in rat and 
human epileptic tissue, and has been postulated to be due to a significant reduction 
in the number or efficiency of GABA transporter proteins (During et al, 1995).
Manipulation of GABAergic neurotransmission remains one of the most attractive 
targets in the experimental and clinical investigation of epilepsy. Antiepileptic drugs 
(AEDs) can increase the inhibitory actions of GABA by decreasing GABA metabolism 
by GABA-T, decreasing the reuptake of GABA into neurones and glia, or by 
increasing the synthesis of GABA by GAD (Schachter, 1995).
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1.2.3 Excitatory neurotransmission
Glutamate is the predominant excitatory neurotransmitter in mammalian brain, 
proposed to be released at a large proportion of synapses in the CNS. It is present in 
the brain in a higher concentration than any other amino acid (Greenamyre and Porter, 
1994).
Glutamate has a number of synthetic pathways. It can be synthesized de novo from 
glucose; by the deamination of glutamine which is catalyzed by glutaminase; or by the 
transamination of 2-oxoglutarate catalyzed by aspartate aminotransferase (Fonnum, 
1984).
Glutamate release causes depolarization and thus excitation of neurones, by acting on a 
variety of receptors. The N-methyl-D-aspartate (NMDA), a-amino-3-hydroxy-5- 
methyl-isoxazole propionic acid (AMPA), and kainate are known as the ionotropic 
receptors. They form ion channels which are permeable to sodium, potassium and 
calcium ions, and are named according to the preferred analogue of glutamate to which 
they respond. As well as a binding site for NMDA or glutamate, the NMDA receptor 
has binding sites for glycine and polyamines. The ion channel of the NMDA receptor is 
subject to a voltage-dependent block by magnesium. A fourth type of glutamate 
receptor known as the metabotropic receptor also exists. This is a G-protein linked 
receptor coupled to effector systems which generate second messengers, and 
selectively responds to the agonist trans-1 -amino-cyclopentyl-1,3-dicarboxylate (trans- 
ACPD; Stone, 1995).
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Inactivation of glutamate following release occurs via a high affinity sodium- and 
energy-dependent uptake system present in nerve endings and glia. It is thought that 
glial uptake is physiologically more important than neuronal uptake (Schousboe, 
1981). Three different glutamate transporters have been identified as GLAST, GLT-1 
and EAAC-1 (Lehre et al, 1995).
Glutamate which is taken up into neurones can be metabolized by GAD to form 
GABA, or by glutamate dehydrogenase to from a-KG. Released glutamate, which is 
accumulated in astrocytes, is metabolized to glutamine via the enzyme glutamine 
synthetase (GS). This glutamine which is synthesized in astrocytes serves as a 
precursor for the formation of glutamate and GABA (Waniewski, 1992).
1.2.4 Evidence for the role of glutamate in epilepsy
Evidence also exists which indicates that an increase in excitatory glutamate 
neurotransmission may be involved in the aetiology of epilepsy.
• Glutamate is documented to be epileptogenic when applied directly to mammalian 
brain (Stone and Javid, 1983) or when administered systemically (Bradford and 
Dodd, 1975).
• Kainic acid and NMDA are used as chemoconvulsants in animals (Fisher, 1989).
• The phenomenon of kindling is reported to be highly dependent on NMDA-receptor 
activation (Cain et al, 1988).
• Antagonism of NMDA receptors has been shown to block the development of 
kindling (McNamara et al, 1988).
• An increase in glutamate receptor density has been demonstrated in children with
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generalised seizures (Represa et al, 1989), and in adults with temporal lobe epilepsy 
(Geddes et al, 1990).
• Patients with primary generalised or focal epilepsy are reported to have elevated 
plasma levels of glutamate (Janjua et al, 1982).
AEDs may diminish excitatory transmission by decreasing the rate of synthesis of 
glutamate, decreasing the synaptic release of glutamate or by blocking the post- 
synaptic actions of excitatory amino acids (Meldrum, 1984).
1.3 ASTROCYTES
Neuroglia were first recognised as distinct cellular elements in the CNS in 1846, but it 
took until the 1920’s for all of the major glial populations, namely astrocytes, 
oligodendrocytes, Schwann cells and microglial cells to be recognised. The term 
neuroglia (meaning “nerve glue”) was first used by the German pathologist Rudolf 
Virchow to describe regions between neurones that he considered analogous to the 
cementing connective tissue seen in other bodily organs (Kimelberg and Norenberg, 
1989).
In the late 1940’s neurones were clearly identified as the elements in the brain 
associated with electrical activity and the ability to transfer information via chemical 
synapse. The glial cells failed to generate this electrical excitability, and so were 
regarded as the silent elements of the brain (Kettenmann, 1996).
Astrocytes account for 50% of the total glial population (Kimelberg, 1983) and are 
estimated to comprise as much as 20 to 50% of the total volume in some brain areas.
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They are up to ten times more numerous in the CNS than neurones. Astrocytes, in 
general, are process-bearing cells, and a characteristic of all types is a large surface 
area owing to the extensive branching of the cellular processes (Juurlink and Hertz,
1992). Astrocytes have long been considered as playing structural and supporting 
roles, and reacting in a stereotypical manner to injury and disease. However, mainly 
due to advances in cell culture and specific identification of these cells, knowledge of 
astrocytic development, form and function, and roles in disease has increased 
substantially in recent years (Montgomery, 1994).
1.3.1 Types of astrocytes
There are two major types of astrocytes in the CNS; fibrous, which are found in the 
white matter, and protoplasmic which predominate in the grey matter (Fedoroff et al, 
1984). Protoplasmic and fibrous astrocytes are now more commonly classified as type 
I and type II, respectively. Fibrous astrocytes are small process-bearing cells, stellate in 
appearance, and characterized as having more intermediate filaments than protoplasmic 
astrocytes. A single acidic protein, namely glial fibrillary acidic protein (GFAP) has 
been reported to be the major component of the astrocytic filaments. Histological and 
immunofluorescence studies have confirmed that GFAP is selectively located in 
astrocytes, making it an unequivocal astrocytic marker in the CNS (Eng et al, 1971; 
Bignami and Dahl, 1977).
In addition to the type I and type II astrocytes, a few more specialized cells have been 
identified, such as the Bergman fibres in the cerebellum, Muller fibres in the retina and 
radial glia which are involved in brain development (Juurlink and Hertz, 1985; 
Kimelberg and Norenberg, 1989).
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1.3.2 Development of type 1 and type II astrocytes
Type I and type II astrocytes have been shown to be derived from separate glial 
progenitors. Their development in rat optic nerve cultures has been studied using 
immunofluorescence techniques. Type I astrocytes were found to differentiate on the 
16th embryonic day of prenatal development from a committed precursor cell, whereas 
type II astrocytes did not differentiate until the second postnatal week, and it was from 
a bipotential precursor cell that can also give rise to oligodendrocytes. This bipotential 
precursor cell is known as the 0-2A progenitor (Raff et al, 1983). It is thought that 
progenitor cell differentiation into type I is triggered by the culture medium, but that 
the differentiation of type II from progenitor cells requires a type I secreted factor 
(Tabemero et al, 1996). The 0-2A progenitor has been located in vivo in the optic 
nerve, cerebellar cortex and cerebral cortex (Juurlink and Hertz, 1992). In cell culture 
experiments it has been demonstrated that the 0-2A progenitor can differentiate into a 
type II astrocyte when cultured in medium containing 10% foetal calf serum. However, 
when the progenitors were cultured in serum-free medium they differentiated into 
oligodendrocytes (Temple and Raff, 1985).
Although the type II astrocyte has been identified in culture, its existence in vivo has 
not yet been fully established and remains controversial. However, several lines of 
evidence exist which favour the existence of type II astrocytes in vivo. The timing of 
the generation of type II astrocytes in culture is in agreement with the timing of the 
appearance in vivo of small numbers of cells with the type II astrocytic antigenic 
phenotype - monoclonal antibody A2B5 positive and GFAP positive (Noble, 1991). In 
addition, cells with the antigenic phenotype of type II astrocytes exist in freshly 
dissociated neonatal white matter but not grey, and in frozen sections of adult brain
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most astrocytes in white matter but not grey are A2B5 positive (Raff et al, 1983). The 
production of type II astrocytes in dissociated culture has a very specific and 
reproducible timing, which suggests that if the generation of type II in vitro is an 
artefact, then it is extremely well regulated. Type I and type II are not interconvertable 
which further suggests the existence of two distinct astrocyte types (Skoff and Knapp, 
1991). It remains to be clarified whether GFAP positive 0-2A lineage cells in the 
developing CNS are stable type II astrocytes or alternatively 0-2A progenitors which 
have been induced to express GFAP transiently before going on to become 
oligodendrocytes, as can happen in culture (Noble, 1991).
1.3.3 Role of astrocytes in the central nervous system
The astrocytes in the CNS are intimately associated with other cells. Astrocyte 
processes surround cell bodies and processes of neurones, and form a dense subpial 
network of fibres known as the glia limitans. Astrocyte processes completely encircle 
blood vessels, an observation which led some earlier investigators to wrongly identify 
this association as the site of the blood brain barrier. It is now known that astrocytic 
end feet are not the structural or anatomical site of the blood brain barrier as once 
believed (Kimelberg and Norenberg, 1989). Astrocytes do, however, play a role in the 
induction and maintenance of the blood brain barrier by forming tight junctions 
between the endothelial cells and modifying the transport properties of the cerebral 
endothelium (Montgomery, 1994).
Astrocytes are thought to be responsible for the maintenance of the extracellular 
environment in the brain, and regulate the physiological conditions at the synaptic cleft 
and the microenvironment around the neurones (Kimelberg, 1983). During
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neurotransmission there is a flux of potassium into the extracellular space. Astrocytes 
accumulate this potassium and are responsible for its movement away from areas of 
high neuronal activity to areas of low. This concept is known as spatial buffering 
(Montgomery, 1994). Glial cells have also been found to contain the enzyme carbonic 
anhydrase, suggesting an involvement in pH regulation (Church et al, 1980).
Astrocytes are regarded as actively participating in neurotransmission. Termination of 
transmission requires uptake of the neurotransmitters from the synaptic cleft, where the 
transmitter may be reused or metabolized. Astrocytes have been shown to possess 
mechanisms for the uptake and metabolism of neurotransmitters including GABA and 
glutamate (Schousboe, 1981). In addition, the uptake and metabolism of glutamate and 
ammonia by astrocytes via the enzyme GS represents an important detoxification 
mechanism in the brain (Meister, 1974). The finding that astrocytes express a wide 
variety of receptor types adds to the accumulating evidence indicating that they are 
responsive to neuronal signals and participate in neurotransmission (Murphy and 
Pearce, 1987).
The radial glia have been shown to play a key role in the guidance of neuronal 
migration during embryonic development of the brain. Neurones are thought to migrate 
from their points of origin in the CNS along the processes of glial cells to their final 
destination in the brain (Kimelberg and Norenberg, 1989).
The CNS has no lymphoid population or lymphatic drainage and was once viewed as 
being isolated from the body’s immune system. However, it is now recognised that 
astrocytes function as a liaison between the immune system and the CNS, behaving as
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macrophages, by functioning as antigen presenting cells and being capable of 
phagocytosis (Montgomery, 1994).
1.3.4 Functional differences between type I and type II astrocytes
As well as differing morphologically, type I and type II astrocytes differ functionally. 
Type I are the most common type of astrocyte in the CNS and actively proliferate in 
culture and respond to growth factors. It is type I astrocytes which undergo reactive 
gliosis in response to injury. In contrast, type II astrocytes do not proliferate actively in 
culture and fail to respond to growth factors. Type I astrocytes are involved in 
potassium homeostasis and accumulation of glutamate and other amino acid 
neurotransmitters, and express a wide variety of receptors for neurotransmitters. While 
type I astrocytes affect neurones in a mainly inhibitory manner, type II exert mainly 
excitatory effects on neurones. Type II astrocytes exhibit GABA uptake and release, 
but not metabolism. In contrast, type I astrocytes are incapable of GABA release, but 
release glutamate via a potassium-induced calcium-independent mechanism. Type II 
astrocytes have a greater basal activity of GS and a higher density of sodium channels 
than type I (Juurlink and Hertz, 1992).
1.3.5 Role of astrocytes in disease
In addition to roles in normal CNS functioning, astrocytes have also been shown to 
play a role in disease. In disease states cellular swelling and hypertrophy of astrocytes 
occur. Astrocyte swelling is thought to be due to an influx of potassium or glutamate. 
Head trauma, hypoxia-ischaemia and status epilepticus are accompanied by astrocytic 
swelling (Kimelberg and Norenberg, 1989). Astrocytes proliferate in response to 
injury. This phenomenon is known as reactive gliosis. Injured neurones release a
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substance which triggers astrocytic proliferation and it is thought that both mature 
astrocytes as well as precursor cells are involved in this response (FedorofF et al, 
1984).
1.3.6 Astrocytes and epilepsy
Theories linking astrocytes to seizure activity are based largely on their involvement in 
the regulation of the neural microenvironment. Failure in the buffering mechanisms by 
astrocytes has been proposed to be a significant factor in the aetiology of epilepsy 
(Castiglioni et al, 1990; Nilsson et al, 1992). Astrocytes from epileptic foci display 
morphologic changes such as an increase in orthogonal arrays at the pial surface 
compared to normal brain, and exhibit a decrease in extracellular potassium stimulated 
sodium-potassium ATPase (Montgomery, 1994).
Astrocytes cultured from audiogenic seizure-prone mice or from epileptic foci display 
an increase in carbonic anhydrase activity, and an increase in the uptake of glutamate. 
This is thought to be a protective mechanism, as the overall concentration of glutamate 
has been shown to be elevated in the cerebral cortex of audiogenic seizure-prone mice 
(Tiffany-Castiglioni and Castiglioni, 1986).
High levels of GS have been reported in glial cells of the CNS. Inhibition of this 
enzyme by methionine sulfoximine (MSO) leads to seizure generation in mice (Tiffany- 
Castiglioni and Castiglioni, 1986).
In recent years, a number of studies have been undertaken to assess the contribution of 
astrocytes to seizure mechanisms. Bordey and Sontheimer (1998) have recently
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characterized the properties of human glial cells associated with epileptic seizure foci. 
They reported that seizure-associated astrocytes had complex highly branched 
processes, were stellate in appearance and stained intensely for GFAP, as would be 
expected for reactive astrocytes. Glia associated with seizure foci were also found to 
express sodium channels at densities sufficient to generate slow action potentials in 
current clamp studies. In addition, these cells displayed a lack of inwardly rectifying 
potassium currents, which in normal astrocytes are implicated in the control of 
potassium levels. The results of this study suggest that astrocytes from seizure foci 
differ in morphological and physiological properties, and that glial potassium buffering 
could be impaired, thus contributing to the pathophysiology of seizures. Furthermore, 
impaired potassium homeostasis and permeability through glial inwardly rectifying 
potassium channels has been reported in a rodent experimental model of reactive 
gliosis (D’Ambrosio et al, 1998).
In support of the theories linking astrocytes to the pathology of epilepsy, O’Connor 
and colleagues (1998) demonstrated that hippocampal astrocytes from seizure foci 
have an impaired ability to clear the extracellular space of glutamate, an effect which 
has been proposed to contribute to increased neuronal excitability. In addition, it has 
been shown that fluorocitrate, a reversible and specific inhibitor of astrocytic 
metabolism, can precipitate seizures (Willoughby et al, 1998).
17
1.4 TREATMENT OF EPILEPSY
1.4.1 History of antiepileptic drug treatment
Epilepsy has been known since the beginning of recorded history, and has been referred 
to as “the dread disease”, “the sacred disease” and “the falling sickness”. The word 
‘epilepsy’ is derived from a Greek word meaning “to throw oneself’ (Patsalos and 
Duncan, 1994). The victims of this disease were thought to be “possessed”, 
“bewitched” or “inflicted by the Gods” (Swinyard, 1980). The treatment of epilepsy 
emerged from ignorance, superstition and religious beliefs. Until the 19th century, 
patients with epilepsy were subjected to prejudice, and treated with remedies of 
antiquity which often resulted in death.
During the 19th century, the understanding of the neuropathological basis of epilepsy, 
together with serendipitous drug discovery, and the development of synthetic 
chemistry and experimental animal models resulted in the first effective antiepileptic 
therapy (Patsalos and Sander, 1994). The introduction of bromide in the 1857 marked 
the first effective treatment for epilepsy (Harden, 1994). The drug was, however, 
associated with significant side effects, and is no longer used routinely in the treatment 
of epilepsy (Patsalos and Sander, 1994).
The sedative action of bromide correlated with seizure reduction, and led in 1912 to 
the discovery of the barbiturate phenobarbitone (PB), another sedative with efficacy in 
seizure disorders. The continued search for similar molecules with less sedative effects 
resulted in the development of numerous other barbiturates (Harden, 1994). Phenytoin 
(PHT) was introduced in 1938, followed by primidone (PRM) in 1952, ethosuximide
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(ESM) in 1958 and carbamazepine (CBZ) in 1967. In 1963, sodium valproate (SVP) 
was serendipitously discovered as having antiseizure properties when it was used as a 
solvent in a drug screening programme and was approved for use in Europe in 1974 
(Brodie and Dichter, 1997).
After a hiatus of nearly 20 years, no fewer than eight new AED’s; vigabatrin (VGB), 
lamotrigine (LTG), felbamate (FBM), gabapentin (GBP), oxcarbazepine (OXC), 
topiramate (TPM), zonisamide (ZNS) and tiagabine (TGB) have received a licence in 
at least one country during the 1990’s. More new agents, including levetiracetam 
(LEV), remacemide (RMD) and losigamone (LOS) are in development, with more 
than a few ‘numbered’ compounds undergoing phase one evaluation (Wilson and 
Brodie, 1996).
1.4.2 Strategies for the drug treatment of epilepsy
The past decades have witnessed an increase in our knowledge and understanding of 
the pathophysiology of brain diseases and basic mechanisms of drug activity. This 
knowledge has generated several rational strategies for drug development, aimed at 
identifying new anticonvulsant drugs with high specificity and/or selectivity of action. 
The most important strategies of rational design of anticonvulsant drugs have been 
enhancement of GABA-mediated neuronal inhibition, diminution of glutamate- 
mediated neuronal excitation and modulation of sodium, potassium and particularly 
calcium ion channels (Loscher, 1998). All of these targets for anticonvulsant drug 
development are thought to be critically involved in the pathophysiology of epileptic 
processes (Dichter, 1994).
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1.4.3 Established antiepileptic drugs
PHENOBARBITONE
PB is a barbiturate which has considerably greater anticonvulsant effect in relation to 
its sedative effect than other barbiturates. It is effective in the treatment of partial and 
generalised seizures, but its clinical usefulness in the developed world is limited by 
sedation. Other side effects of PB include alterations in mood, cognition and behaviour 
and memory impairment. The drug is an enzyme inducer so can accelerate the 
metabolism of many lipid soluble drugs (Brodie and Dichter, 1996).
PB is effective in both the maximal electroshock (MES) and pentylenetetrazol (PTZ) 
animal seizure models (Schachter, 1995). It binds to an allosteric regulatory site on the 
GABAa receptor and produces an increase in the affinity for GABA and a decrease in 
the rate of GABA dissociation (Yang and Olsen, 1987). This causes an increase in the 
mean GABAa receptor chloride channel opening time without affecting single channel 
conductance (Twyman et aU 1989). This effect is thought to contribute to the 
antiepileptic effects of PB, but additional mechanisms have been proposed to account 
for the relative antiepileptic potency of this drug over other more sedative barbiturate 
compounds. Such additional mechanisms include an inhibitory action on calcium influx 
through voltage-sensitive N- and L-type calcium channels (Gross and Macdonald,
1988), blockade of non-NMDA type excitatory amino acid receptors (Miljkovic and 
Macdonald, 1986) and enhancement of voltage-dependent potassium currents 
(Huguenard and Wilson, 1985).
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PHENYTOIN
PHT was the result of a search to find a non-sedating analogue of PB (Rogawski and 
Porter, 1990). It is effective for the treatment of partial and tonic-clonic seizures. Gum 
hypertrophy, acne, hirsuitism, drowsiness, ataxia and cognitive difficulties are some of 
the side effects experienced with the drug (Brodie and Dichter, 1996).
PHT can abolish the tonic phase, but may enhance or prolong the clonic phase of 
MES-induced seizures in animals. It has been shown to be ineffective against seizures 
induced by PTZ, bicuculline, picrotoxin, penicillin and strychnine (Rogawski and 
Porter, 1990).
PHT has been proposed to exert its antiepileptic effects by interacting with the voltage- 
activated sodium channels that are responsible for the action potential upstroke in a 
highly specific voltage- and frequency-dependent manner. It has been shown to 
stabilize the inactive form of the sodium channel in a voltage-dependent manner, to 
slow the rate of recovery from sodium channel inactivation, and to shift the steady- 
state sodium inactivation curve to more negative voltages (Macdonald and Kelly,
1993).
In addition to effects on sodium channels, PHT has been proposed to induce voltage- 
and frequency-dependent block of T-type calcium channels (Twombly et al, 1988), 
inhibitory effects on non-T-type calcium channels (Crowder and Bradford, 1987) and a 
potentiation of GABA-mediated synaptic inhibition (Raabe and Ayala, 1976; McLean 
and Macdonald, 1983).
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CARBAMAZEPINE
CBZ has a tricyclic structure similar to some of the standard antidepressant drugs. 
Pharmacologically and clinically its actions resemble those of PHT (Rang and Dale, 
1991). It is effective for the treatment of partial and generalised tonic-clonic seizures, 
but is ineffective, and can be deleterious, in patients with absence or myoclonic 
seizures. Adverse effects most often associated with CBZ therapy are diplopia, 
headache, dizziness and nausea (Brodie and Dichter, 1996).
CBZ and PHT have a similar spectrum of activity in animal seizure models. Both drugs 
selectively prevent tonic hindlimb extension in MES-induced seizures, and both are 
ineffective against seizures induced by PTZ. CBZ does, however, have a higher 
protective index than PHT.
CBZ has an active metabolite, carbamazepine-10,11-epoxide, which has a similar 
spectrum of anticonvulsant activity as the parent compound (Rogawski and Porter,
1990). Like PHT, CBZ has been proposed to exert its anticonvulsant effects by an 
inhibition of voltage-dependent sodium channels. However, PHT has been shown to 
have a more pronounced frequency-dependent block than CBZ, which may help to 
explain the subtle clinical differences between the drugs (Macdonald and Kelly, 1993).
Other proposed mechanisms of CBZ action include an inhibition of voltage-dependent 
non-T-type calcium influx (Crowder and Bradford, 1987) and antagonistic effects at 
brain adenosine Ai and A2 receptors. However, as adenosine is a putative endogenous 
anticonvulsant this would question the relationship between adenosine receptor 
antagonism and the antiepileptic effects of the drug (Rogawski and Porter, 1990).
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SODIUM VALPROATE
SVP is a broad spectrum anticonvulsant agent, with efficacy in many types of seizures, 
and especially in those with idiopathic generalised epilepsy. Treatment with SVP has 
been associated with a number of adverse effects including dose-related tremor, weight 
gain, thinning or loss of hair and menstrual irregularities. In addition, hepatotoxicity 
has also been observed, particularly in children under three years old who are receiving 
polytherapy (Brodie and Dichter, 1996).
In animal seizure models, SVP is effective against a wide variety of chemoconvulsants 
including PTZ-induced seizures, and is also effective in the MES test (Rogawski and 
Porter, 1990). Its mechanism of action is yet to be fully elucidated, but it is thought to 
exert its pharmacological effects by a combination of mechanisms.
SVP has been shown to increase GABA levels in animal brain (Loscher, 1981) and in 
the plasma and cerebrospinal fluid of treated patients (Loscher and Schmidt, 1980; 
Loscher and Siemes, 1984). The increase in GABA levels has been proposed to be due 
to an increased synthesis of GABA via a stimulatory action on GAD. Inhibitory actions 
of SVP on the GABA-degrading enzymes GABA-T, SSAD and aldehyde reductase 
have also been reported to contribute to the increase in GABA concentration 
(Rogawski and Porter, 1990). However, the blockade of GABA-T is thought to be 
weak and reversible, and may occur at doses above those therapeutically relevant 
(Nilsson et al 1992).
In a similar manner to PHT and CBZ, SVP has also been shown to exert a use- and 
voltage- dependent limitation of sustained repetitive firing of sodium dependent action
potentials (McLean and Macdonald, 1986).
The observation that SVP is effective against generalised absence seizures led to 
suggestions that, like ESM, it may interact with voltage-sensitive calcium channels. 
Initial studies with SVP failed to demonstrate an effect on the low-threshold calcium 
current. A later study, however, demonstrated that SVP modestly reduced T-type 
calcium currents in primary afferent neurones. The discrepancy in effects on calcium 
channels and the relevance of them require clarification (Macdonald and Kelly, 1993).
In addition to these effects, SVP has been consistently found to decrease levels of the 
excitatory amino acid aspartate in rodent brain (Schechter et al, 1978). The mechanism 
by which SVP reduces aspartate is at present unknown. The extent to which each of 
these proposed mechanisms contributes to the antiepileptic efficacy of SVP remains to 
be clarified.
The established AEDs PRM, ESM and the benzodiazepines (BZDs) are licenced for 
use in the UK, but were not investigated in this thesis.
PRIMIDONE
PRM is often considered as a pro-drug for its active metabolites PB and 
phenylethylmalonamide. The mechanism of action of PRM is less well documented 
than that of other barbiturate compounds. The actual role of the parent compound and 
the active metabolites in the clinical efficacy of the drug remain to be determined, but it 
is thought to act at the GABAa receptor in a similar manner to PB. (Rogawski and 
Porter, 1990). The efficacy of PRM is similar to that of PB, but it is less well tolerated
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(Brodie and Dichter, 1996).
ETHOSUXIMIDE
ESM was developed empirically by modification of the barbituric acid ring structure. 
The drug is efficacious in the treatment of absence seizures, but is inactive against 
other seizure types. Side effects of ESM mainly involve gastrointestinal disturbances 
such as nausea and vomiting, and CNS related effects such as lethargy, dizziness and 
ataxia. There are also rare reports of blood dyscrasias, some of which have been fatal 
(Brodie and Dichter, 1996).
In animal models, ESM specifically blocks PTZ- and bicuculline-induced clonic 
seizures, but fails to exert any activity against tonic seizures induced by MES 
(Rogawski and Porter, 1990). ESM acts by reducing low-threshold, transient, voltage- 
dependent T-type calcium channel conductance in thalamic neurones (Coulter et al,
1989).
BENZODIAZEPINES
There are over 50 chemically distinct BZDs marketed worldwide. They are potent 
anticonvulsants in a wide variety of animal seizure models including PTZ- and 
picrotoxin-induced seizures, and at higher doses block MES- and strychnine-induced 
seizures. Although pharmacokinetic differences exist and relative potencies vary 
between the BZDs, they all exhibit a similar anticonvulsant profile which is thought to 
relate to their common mechanism of action (Rogawski and Porter, 1990).
A receptor for BZDs is thought to exist on the GABAa receptor complex, where they
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act to enhance inhibitory responses to GABA. The BZDs have been shown to increase 
the frequency of the GABAa receptor chloride channel opening, without affecting 
single channel conductance or open time. This effect is in contrast to the barbiturates 
which prolong the channel opening time without increasing the frequency of opening 
(Twyman et al, 1989). Other mechanisms of BZD action include an inhibition of 
adenosine uptake and blockade of voltage-dependent sodium and calcium channels 
(Rogawski and Porter, 1990).
Diazepam (DZP) was introduced in 1968, and is used in the acute treatment of status 
epilepticus. The sedative effect and development of tolerance with most BZDs limits 
their use as maintenance anticonvulsant therapy (Rang and Dale, 1991). Clobazam 
(CLB) was introduced as an anxiolytic in 1975, and its anti-seizure activity was 
recognised soon after. It is a useful adjunctive drug in refractory epilepsy (Brodie and 
Dichter, 1997). Clonazepam (CZP) is thought to be relatively more selective as an 
anticonvulsant, and has limited use in the treatment of refractory myoclonic seizures 
(Brodie and Dichter, 1996).
1.4.4 Novel antiepileptic drugs
VIGABATRIN
VGB was the first AED to be developed on the basis of a targeted mechanism of 
action. It is a synthetic derivative of the inhibitory neurotransmitter GABA. The drug 
has two enantiomers, only one of which, the S-enantiomer, is pharmacologically active 
(Hannah et al, 1995). VGB was licenced for use in the UK in 1989 as add-on 
treatment for partial seizures (Reynolds et al, 1991). The drug is also useful in the 
treatment of infantile spasms (Wilson and Brodie, 1996). Sedation, dizziness and
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headache are the most frequently reported adverse events with VGB. Other reported 
problems include fatigue, weight gain, depression and behavioural problems (Hannah et 
a l  1995).
VGB has demonstrated efficacy against a range of experimental seizures, including 
those induced by picrotoxin (Bemasconi et al 1988) and amygdaloid-kindling (Loscher 
et a l  1989) and is also effective in genetic models of reflex epilepsy (Schechter et a l  
1977).
VGB exerts its antiepileptic effects by an enzyme-activated suicide inhibition of 
GABA-T, the enzyme directly responsible for the metabolic degradation of GABA 
(Lippert et a l  1977; Jacob et a l  1990). The drug has been shown to elevate GABA 
levels in plasma, cerebrospinal fluid and brain of experimental animals (Bohlen et a l  
1979), and in the plasma and cerebrospinal fluid in man (Ben-Menachem et al 1989). 
VGB has also been found, in our laboratory, to have an inhibitory effect on the uptake 
of GABA into astrocytes (Leach et al, 1996).
LAMOTRIGINE
LTG is a phenyltriazine with weak anti-folate properties. It emerged from a mass 
screening of anti-folate compounds for anticonvulsant activity. Structure-activity 
studies have failed to show a correlation between its anti-folate activity and 
anticonvulsant potency. It has been licenced as add-on therapy for refractory partial 
seizures with or without secondary generalisation in more than 70 countries, with 
approval for use as monotherapy and for use in children in many of these. LTG was 
licenced for use in the UK in 1991. There is also evidence to suggest that the drug may
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be effective for absence and myoclonic seizures (Wilson and Brodie, 1996). Adverse 
events most frequently reported for LTG include headache, nausea and vomiting, 
diplopia, dizziness, ataxia and tremor (Brodie, 1992b). The development of rash 
complicates the initial management of 3-5% of patients, but in mild cases it may 
subside spontaneously without withdrawal of the drug. However, in rare cases the 
Stevens-Johnson syndrome may develop. There is evidence to suggest that gradual 
introduction of LTG lessens the risk of rash (Dichter and Brodie, 1996).
In animal models LTG exhibits high potency in the MES test, and can also block the 
development of kindled seizures in rats. Like PHT, LTG is ineffective against both 
threshold and clonic seizures induced by PTZ, suggesting a similar mechanism of 
action (Rogawski and Porter, 1990).
In rat cerebral cortical slices LTG potently inhibited veratrine-evoked glutamate and 
aspartate release (Leach et al, 1986). It has been shown to limit the high frequency 
firing of sodium-dependent action potentials in cultured mouse spinal cord neurones 
(Cheung et al, 1992), therefore, suggesting a use- and frequency-dependent blockade 
of voltage-sensitive sodium channels similar to PHT and CBZ (Macdonald and Kelly,
1993). More recently, a number of studies have also indicated that LTG exhibits 
blockade of calcium currents (Wang et al, 1996; vonWegerer et al, 1997).
FELBAMATE
Felbamate (FBM) was approved for use in the United States in 1993, as monotherapy 
and adjunctive therapy for partial seizures with or without secondary generalisation. In 
children it is effective as adjunctive therapy in seizures of the Lennox-Gastaut
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syndrome. It is a dicarbamate, structurally related to, but less sedative than, the 
anxiolytic agent meprobamate (Pellock and Boggs, 1995). FBM is a broad spectrum 
anticonvulsive drug, but the occurrence of aplastic anaemia and hepatic failure (Pellock 
and Brodie, 1997) have limited its use to those patients with intractable epilepsy who 
have been unresponsive to alternative therapies (Leppik and Wolff, 1995). Other 
adverse events associated with FBM treatment include gastrointestinal and 
neurological symptoms such as anorexia, nausea and vomiting, weight loss, headache, 
dizziness and diplopia (Wilson and Brodie, 1996).
In animal models it has demonstrated efficacy against seizures induced by several 
chemoconvulsants including PTZ, picrotoxin, NMDA and quisqualate, and MES 
(Swinyard et al, 1986; White et al, 1992). It has been shown to be ineffective against 
bicuculline- and strychnine-induced seizures (Swinyard et al, 1986). FBM has been 
proposed to possess a broader spectrum of activity than the conventional AEDs PHT 
and CBZ (Rho et al, 1994). Its effectiveness in both chemically- and electrically- 
induced seizures has suggested that the drug exerts its anticonvulsant activity by 
increasing seizure threshold and preventing seizure spread (Swinyard et al, 1986). In 
addition to its antiepileptic activity, FBM has been shown to have a neuroprotective 
effect in animal models of hypoxic-ischaemic injury (Wasterlain et al, 1992; 
Chronopoulos et al, 1993; Wasterlain et al, 1994; Wallis and Panizzon, 1995; 
Wasterlain et al, 1996).
As yet, the precise mechanism of action of FBM remains to be determined. In ligand 
binding studies, FBM failed to interact with the GABAa receptor complex (Ticku et al,
1991). The drug has, however, been shown to enhance GABAa receptor-mediated
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chloride currents in rat hippocampal neurones (Rho et al, 1994). In addition, Gordon 
and colleagues (1991) reported that a sub-protective dose of FBM could potentiate the 
anticonvulsant effects of diazepam against seizures induced by MES, PTZ and 
isoniazid. The drug has also been shown to interact with the strychnine-insensitive 
glycine modulatory site of the glutamate NMDA receptor (McCabe et al, 1993; White 
etcd, 1995b).
In addition to its effects on amino acid systems, FBM has been reported to exert 
blockade of voltage dependent sodium channels (White et al, 1992), and inhibition of 
dihydropyridine-sensitive calcium channels (Stefani et al, 1996). It is likely that FBM 
possesses multiple mechanisms of action, but the exact contribution of each of these 
effects to the antiepileptic effects of the drug remain to be evaluated.
GABAPENTIN
GBP is a hydrophilic analogue of GABA which can freely cross the blood-brain barrier. 
It was licenced for use in the UK in 1993 as add-on therapy for the treatment of 
refractory partial seizures, with or without generalised tonic-clonic seizures. Side 
effects of GBP include somnolence, dizziness, ataxia, fatigue, nystagmus, headache, 
tremor, and less commonly, diplopia, nausea and vomiting (Wilson and Brodie, 1996).
GBP has an experimental and clinical profile similar to that of SVP. In animal 
experimental models GBP is effective against tonic seizures induced by a variety of 
chemoconvulsants and is also active in the MES test (Rogawski and Porter, 1990). At 
present the precise mechanism of action of GBP remains unclear. It has been suggested 
that it may interact specifically with a plasma membrane site proposed to be the system
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L-amino acid transporter (Stewart et al, 1993).
GBP has demonstrated only limited effects on the GABAergic system, and has been 
reported to exert no effects at GABA receptors or uptake carriers in the brain (Taylor 
et al, 1998). In animal studies the drug has been shown to increase GABA turnover in 
isolated regions of the brain (Loscher et al, 1991b), and there is evidence to suggest 
that GABA levels were elevated in the occipital cortex of patients undergoing a clinical 
trial (Petrofif et al, 1996). GBP has been reported to increase the activity of GAD, 
suggesting an increase in the synthesis of GABA from glutamate (Taylor et al, 1998). 
In addition, at high concentrations it has been shown to inhibit GABA-T. However, 
this effect is not thought to be clinically relevant (Goldlust et al, 1995). The drug has 
been reported to increase electrophysiological responses to GABA in the rat optic 
nerve (Kocsis and Honmou, 1994).
A recent study in our laboratory (Leach et al, 1997a) demonstrated that repeated GBP 
administration reduced whole brain glutamate levels. The mechanism by which the 
drug exerts this action is unclear. Goldlust and colleagues (1995) reported that GBP 
inhibited branched-chain amino acid aminotransferase, and this effect may contribute to 
the increased glutamate concentrations observed.
In addition to effects on amino acid systems, GBP has been reported to reduce 
sustained repetitive firing of neurones in a manner similar to PHT (Wamil and McLean,
1994), and has been demonstrated to bind with high affinity to a calcium channel 
subunit in the brain (Gee et al, 1996). Recently the drug was also shown to exert 
inhibitory effects on L-type voltage-gated calcium channels (Stefani et al, 1998).
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TOPIRAMATE
TPM, a sulphamate-substituted monosaccharide compound (Langtry et al, 1997), was 
licenced in the UK in 1995 for use as add-on therapy in refractory patients. It is 
effective in the treatment of partial-onset seizures with or without secondary 
generalisation. TPM can produce CNS-related side effects including ataxia, confusion, 
dizziness, fatigue, paraesthesia, somnolence and cognitive impairment. Less common 
problems are amnesia, anorexia and weight loss, diplopia, nausea and vomiting (Wilson 
and Brodie, 1996).
TPM prevents seizures in a number of animal models including tonic seizures induced 
by MES (Shank et al, 1994), amygdala-kindled rats (Wauquier and Zhou, 1996) and 
genetic models of epilepsy (Nakamura et al, 1994). It is ineffective in blocking 
chemically-induced seizures (Patsalos and Duncan, 1994). TPM is thought to act by 
blocking the spread of seizure discharges.
It appears likely that TPM possesses multiple mechanisms of action. It has been 
reported to exert blockade of voltage-activated sodium channels (Coulter et al, 1993; 
Kawasaki et al, 1996; Zona et al, 1997; Wu et al, 1998) and inhibitory effects on 
kainate-induced responses (Coulter et al, 1995). In addition, TPM reportedly 
potentiates responses to GABA at the GABAa receptor (White et al, 1995a; White et 
al, 1997) and may exert a weak carbonic anhydrase inhibition. Its antiepileptic 
properties are, however, thought to be independent of the carbonic anhydrase 
inhibition (Shank et al, 1994). It has also been reported that TPM may reduce 
abnormally high levels of glutamate and aspartate in the hippocampus of spontaneously 
epileptic rats (Kanda et al, 1996).
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TIAGABINE
TGB is a nipecotic acid analogue into which a lipophilic anchor has been incorporated 
to facilitate crossing of the blood-brain barrier after oral administration. It has proven 
efficacy as add-on therapy for patients with partial onset seizures including secondarily 
generalised tonic-clonic seizures, and was licenced for use in the UK in 1998. TGB 
appears to be well tolerated. Side effects of the drug include tiredness, dizziness, 
nervousness, tremor, confusion and gastrointestinal disturbances (Leach and Brodie, 
1998).
TGB is effective against audiogenic seizures in DBA/2 mice (Nielsen et al, 1991), the 
motor manifestations of amygdaloid kindled seizures (Pierce et al, 1991) and the tonic 
and clonic components of PTZ-induced seizures in rodents. It is said to be ineffective 
against MES-induced seizures (Nielsen et al, 1991).
TGB is mechanistically the most precise AED in clinical use. It is a potent and selective 
inhibitor of GABA uptake into neurones and glia, consequently increasing extracellular 
GABA levels (Suzdak and Jansen, 1995). It has been shown to specifically inhibit the 
GAT-1 GABA transporter, but is not a substrate for it (Borden et al, 1994). TGB is 
the first GABA uptake inhibitor to be introduced into clinical practice. It has no 
significant affinity for other uptake sites and does not affect sodium or calcium 
channels (Schachter, 1998). To date no other mechanism has been proposed to explain 
its antiepileptic activity.
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1.4.5 Novel antiepileptic drugs undergoing clinical evaluation
LEVETIRACETAM
LEV is the S enantiomer of the ethyl analogue of the nootropic agent piracetam 
(Loscher et al, 1996). It is currently undergoing clinical trial for the treatment of 
epilepsy. Initial reports are encouraging and indicate that the drug has efficacy against 
a wide range of seizure types (Stables et al, 1995). LEV has demonstrated a significant 
efficacy in patients with refractory complex partial seizures with or without secondary 
generalisation (Sharief et al, 1996). The drug is reported to be well tolerated with only 
mild or moderate adverse effects reported. These include drowsiness, memory 
impairment, dizziness, headache, depression and mood changes (Patsalos and Duncan, 
1994; Wilson and Brodie, 1996).
LEV has demonstrated a broad spectrum of activity in experimental animal models. It 
is reported to be effective against threshold and maximal PTZ- and electroshock- 
induced convulsions, and also protects against seizures induced by amygdaloid kindling 
and those precipitated by bicuculline, picrotoxin and NMD A (Gower et al, 1992; 
Loscher and Honack, 1993; Loscher et al, 1998). LEV has also demonstrated efficacy 
in two genetic models of epilepsy, namely the genetic absence epilepsy rat from 
Strasbourg (GAERS) and the audiogenic-seizure prone rat (Gower et al, 1995).
As with many of the other novel AEDs, the precise mechanism of action of LEV 
remains to be determined. The drug fails to interact with classical receptor and ion 
channel sites in the brain. LEV has, however, been proposed to bind in a stereospecific 
manner to a specific binding site in CNS membranes, where it is weakly displaced by 
PB and PTZ, suggesting that it may be GABA-related (Noyer et al, 1995). A study by
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Loscher and colleagues (1996) reported that treatment with LEV induced alterations in 
GABA metabolism and turnover in discrete areas of rat brain.
REMACEMIDE HYDROCHLORIDE
RMD is a novel AED which emerged from a drug discovery programme aimed at 
developing a novel compound with a three-dimensional structure similar to that of 
PHT (Rogawski and Porter, 1990). RMD is experimentally and clinically active, but 
undergoes significant metabolism to the desglycinyl derivative ARL 12495AA (DGR). 
This metabolite has a longer half-life than RMD (Stables et al, 1995) and a more 
potent pharmacological profile. It is currently undergoing clinical evaluation for the 
treatment of complex partial seizures with or without secondary generalisation. Initial 
studies show that the drug is well tolerated. The most common adverse effects 
reported are dose-dependent light-headedness, dizziness and gastrointestinal upset 
(Patsalos and Duncan, 1994).
Both RMD and DGR are effective against a range of experimental seizures, including 
those induced by MES, hippocampal kindling, NMD A, kainate and 4-aminopyrine 
(Stagnitto et al, 1990; Garske et al, 1991; Palmer et al, 1992; Cramer et al, 1994).
The precise mechanism of action of RMD remains to be determined. Both RMD and 
DGR prevent sustained repetitive firing of cultured spinal cord neurones (Wamil et al,
1996) and hippocampal CA1 neurones (Norris and King, 1997) via a blockade of 
voltage-sensitive sodium channels. DGR has also been shown to decrease glutamate 
and aspartate release from cortical slices (Srinivasan et al, 1995). There is evidence to 
suggest that the drug may also exert its antiepileptic effects by an action at the NMDA
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subtype of glutamate receptor (Hu and Davies, 1995; Subramaniam et al, 1996). RMD 
has been shown to weakly interact with the NMDA receptor. However, DGR 
reportedly displaces [3H]-dizocilpine binding to the NMDA ion channel at clinically 
relevant concentrations (Subramaniam et al, 1996). A recent study conducted in our 
laboratory demonstrated that repeated administration of DGR at high dose significantly 
increased GABA-T activity and decreased GAD activity (Leach et al, 1997b). These 
effects have been postulated to contribute to the proconvulsant action of the drug seen 
clinically at higher doses.
A number of other novel compounds are in the early stages of development. These 
include LOS (Leppik, 1994); retigabine, a potassium channel opener (Rundfelt, 1997); 
LY 300164, an antagonist at glutamate AMP A / kainate receptors (Czucwar et al, 
1998); ganaxolone, a neurosteroid which modulates the GABAa receptor (Carter et al,
1997); and SB 204269, an AED with a proposed novel mechanism of action (Herdon 
etal, 1997).
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AIMS
It would appear from the literature that the precise mechanism of action of many AEDs 
remains to be determined, and that most have multiple mechanisms of action. Many of 
these AEDs exert effects on the GABAergic and glutamatergic systems. The effects of 
AEDs on these amino acid neurotransmitter systems is of particular interest at present. 
In view of this, the aim of this study was to examine the effects of a range of 
established, novel and experimental AEDs on GABA and glutamate neurochemistry in 
primary cultures of rat cortical astrocytes and in mouse brain. As the vast majority of 
studies on neurochemical effects of AEDs employ rodent brain tissue, it was also of 
interest to investigate the effects of several of these drugs on GABA transport in 
primary cultures of human astrocytes. In addition, as many patients receiving therapy 
for epilepsy require two or more drugs, a preliminary study was undertaken in an 
attempt to identify potentially useful combinations of new AEDs in mice using the PTZ 
seizure model.
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CHAPTER TWO
MATERIALS AND METHODS
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2.1 MATERIALS
2.1.1 Chemicals: adenosine triphosphate (ATP), Amberlite CG-50 hydrogen form 
resin, y-aminobutyric acid (GABA), 2-aminoethylisothironium bromide (AET), 
ammonium chloride (NH4CI), boric acid, bovine serum albumin (BSA), calcium 
chloride (CaCl2), collagenase, 3’5’-dibutyryl cyclic adenosine monophosphate (cAMP), 
dithiothreitol (DTT), DNase I, ethylene diamine tetra-acetic acid (EDTA), gabaculline, 
gentamycin, D-glucose, L-glutamic acid, L-glutamine, HEPES, HEPES sodium salt, 
homoserine, imidazole-HCl, a-ketoglutaric acid (a-KG), magnesium sulphate 
(MgS04), 2-mercaptoethanol, 3-mercaptopropionic acid (3-MPA), methionine 
sulfoximine (MSO), D,L-norvaline, ouabain, papain, paraformaldehyde, 
pentylenetetrazol (PTZ), o-phthalaldehyde (OPA), polyethylene glycol 400 (PEG), 
poly-L-lysine, polyoxyethylene sorbitan monooleate (Tween 80), potassium chloride 
(KC1), potassium phosphate (KH2P04), pyridoxal-5’-phosphate (PLP), sodium azide, 
sodium bicarbonate (NaHC03), sodium chloride (NaCl), di-sodium hydrogen 
orthophosphate (Na2HP04), sodium di-hydrogen orthophosphate (NaH2P04), soya 
bean trypsin inhibitor, trypan blue, trypsin, were all obtained from the Sigma Chemical 
Company.
Glacial acetic acid, hydrochloric acid (HC1), magnesium chloride (MgCl2), perchloric 
acid (HC104) and sodium hydroxide (NaOH) were obtained from Merck.
Dulbecco’s Modified Eagle Medium (DMEM), Dulbecco’s Modified Eagle Medium- 
Hams F-12 (DMEM-F12), Dulbecco’s phosphate buffered saline (PBS), foetal calf 
serum (FCS), fungizone, L-glutamine, Hanks’ Balanced Salt Solution 10X (HBSS),
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horse serum (HS), new-born calf serum and penicillin-streptomycin were all obtained 
from Gibco BRL.
Picofluor 40 scintillation fluid and Ultima Gold XR scintillation fluid were purchased 
from Canberra Packard.
Coomassie Brilliant Blue G-259 protein assay dye reagent, Dowex AG1-X8 acetate 
form ion exchange resin, and Dowex AG50W-X8 hydrogen form ion exchange resin 
were obtained from BIORAD.
High performance liquid chromatography (HPLC) grade acetonitrile and methanol 
were obtained from Rathbum Chemicals Ltd.
L-/ra«s-pyrollidine-2,4-dicarboxylic acid (PDC) was purchased from Research 
Biochemicals International.
Citifluor AF1 antifadent solution was obtained from Citifluor Products.
2.1.2 Radioisotopes: y-[14C(U)]-aminobutyric acid and L-[14C(U)]-glutamic acid were 
purchased from NEN Research Products.
2.1.3 Antiepileptic drugs: Carbamazepine (5H-dibenz[b,f]azepine-5-carboxamide), 
phenobarbitone (5-ethyl-5-phenyl-2,4,6-trioxohexahydropyrimidine), phenytoin (5,5- 
diphenyl-2,4-imidazolidinedione), and sodium valproate (2-propylpentanoic acid ) were 
all purchased from Sigma Chemical Company; desglycinyl-remacemide (±)-l-methyl-
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1,2-diphenylethylamine) was a gift from Astra Chamwood; felbamate (2-phenyl-1,3- 
propanediol dicarbamate) from Schering-Plough Research Institute; gabapentin (1- 
(aminomethyl)-cyclohexaneacetic acid) from Parke-Davis Pharmaceutical Research; 
lamotrigine (6-(2,3-dichlorophenyl)-l,2,4-triazine-3,5-diamine) from Glaxo Wellcome 
Research and Development; levetiracetam ((S)-a-ethyl-2-oxo-pyrrolidine acetamide) 
from UCB Pharma; tiagabine ((R)-(-)-l-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3- 
piperidine-carboxylic acid, hydrochloride) from Novo Nordisk A/S; topiramate 
(2,3:4,5-bis-0-(l-methylethylidene)-p from the R.W. Johnson Pharmaceutical 
Research Institute; and vigabatrin (D,L-4-aminohex-5-enoic acid) from Hoechst 
Marion Roussel.
2.1.4 Antibodies: Rabbit Anti-Cow Polyclonal glial fibrillary acidic protein (GFAP) 
was purchased from DAKO Ltd., and Goat Anti-Rabbit IgG (y heavy chain specific) 
RITC-labelled from EURO-PATH Ltd.
2.1.5 Animals: ICR strain mice supplied by Harlan Olac were used for all 
neurochemical studies. Neonatal rat pups for astrocyte cultures were supplied by the 
Central Research Facility (CRF) at the University of Glasgow from a breeding colony 
of Sprague Dawley (SD) rats. Animals were housed in the CRF in a controlled 
temperature and humidity environment with day / night cycle conditions and access to 
food and water ad libitum. Experimental animals were kept for a minimum period of 
seven days prior to use to allow for acclimatisation. All experimental work was 
governed by the Animals (Scientific Procedures) Act, 1986 (UK).
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2.2 REMOVAL AND STORAGE OF BRAIN TISSUE
For radiochemical assays of glutamine synthetase (GS) and GABA-transaminase 
(GABA-T) activities, and determination of amino acid concentrations and glutamic 
acid decarboxylase (GAD) activity by HPLC, mouse brain tissue was removed in the 
following manner. Animals were sacrificed by a blow to the head and cervical 
dislocation, followed by decapitation. Brains were then carefully removed and placed 
in eppendorf tubes on dry ice until storage at -70°C. For some studies, the left and 
right hemispheres of the brain were separated by a midline incision and stored as 
described until required for assay. For cell culture [14C]-GABA and [14C]-glutamate 
uptake studies, cells were scraped and stored at -20°C prior to liquid scintillation 
counting and protein concentration determination. Cells for GS and GABA-T assays 
were scraped and stored at -70°C until required.
2.3 PRIMARY CULTURE OF RAT CORTICAL ASTROCYTES
This method was a modification of the methods of Larsson and colleagues (1981) and 
Bender and Hertz (1984).
2.3.1 Culture medium
Media were prepared under sterile conditions, and were filter sterilised through a 0.2 
pm pore filter prior to use. Media were stored sterile at 4°C for up to five days. 
Dissection medium consisted of DMEM supplemented with 20% HS (v/v), 2.5 mM L- 
glutamine, 100 I.U./ml penicillin, 100 pg/ml streptomycin, 0.1 mg/ml gentamycin and 
25 pg/ml fungizone. Culture medium consisted of DMEM supplemented with 20, 10 
or 5% (v/v) HS, 2.5 mM L-glutamine and 0.1 mg/ml gentamycin.
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2.3.2 Isolation of cells
One-day-old rat pups were decapitated, the cerebral cortices removed under aseptic 
conditions, and placed in a culture dish containing dissection medium. With the aid of a 
dissecting microscope, the cortices were carefully cleared of the olfactory bulbs, basal 
ganglia, hippocampal formations and meninges and placed in a sterile universal tube 
containing 6  ml dissection medium. The dissected neopalia were then cut into 0.5 mm3 
cubes by two passes (at 90°) in a Mcllwain tissue chopper. The chopped tissue was 
transferred to a sterile glass filter containing 80 pm nylon mesh and the filtrate 
collected in a sterile beaker. The material was washed through the filter with 20% HS- 
DMEM culture medium to give a final volume of 3 ml/brain. The filtrate was then 
passed through a sterile needle (BD Microlance 21G 0.8 x 40) three times to disperse 
cells. The volume of the resulting suspension was adjusted appropriately with 20% HS- 
DMEM culture medium. For [14C]-GABA and [14C]-glutamate uptake, and GABA-T 
activity studies, cells were plated onto 60 x 15 mm Falcon Primaria culture dishes 
allowing a 3 ml aliquot of adjusted cell suspension per culture dish in a ratio of 1 brain 
to 3 dishes. For GS activity studies, cells were plated onto 24 well Sarstedt tissue 
culture dishes allowing a 500 pi aliquot of adjusted cell suspension per well in a ratio 
of 1 brain to each 24 well dish. For GFAP staining, cells were plated onto glass 
coverslips (Chance No.l 13 mm round) coated with 150 pi of poly-L-lysine solution 
and placed in 24 well Sarstedt tissue culture dishes allowing a 500 pi aliquot of 
adjusted cell suspension per well in a ratio of 1 brain to each 24 well dish.
43
2.3.3 Culture maintenance
The cultures were maintained at 37°C in an environment of 95% air / 5% CO2 with a 
humidity of >90%. The culture medium was replaced every 3 - 4  days throughout. The 
HS concentration was reduced to 10% at the first medium change, with a final 
reduction to 5% at the second change. Once the cells reached confluence (around day 
14 in culture), the medium was supplemented with 0.25 mM cAMP to induce cell 
differentiation. Cultures were ready for use seven days after the addition of cAMP 
(around day 21). At this stage, the astrocytes were identified as positive for glial 
fibrillary acidic protein (GFAP) (section 2,5).
2.4 PRIMARY CULTURE OF HUMAN ASTROCYTES FROM FOETAL 
POST-MORTEM AND ADULT SURGICAL TISSUE
This method was a modification of the method of O’Connor and co-workers (1998).
2.4.1 Culture medium
Media were prepared under sterile conditions, and were stored sterile at 4°C for up to 
five days. Isolation medium consisted of DMEM-F12 supplemented with 100 I.U./ml 
penicillin, 100 pg/ml streptomycin, 0.1 mg/ml gentamycin and 25 pg/ml fungizone. 
Plating medium consisted of DMEM-F12 supplemented with 15% (v/v) FCS, 20 mM 
D-glucose, 100 I.U./ml penicillin, 100 pg/ml streptomycin, 0.1 mg/ml gentamycin and 
25 pg/ml fungizone, and the solution was filter sterilised through a 0.2 pm pore filter 
prior to use.
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2.4.2 Enzymatic digestion solutions
Each of these solutions was prepared fresh and filter sterilised through a 0.2 pm pore 
filter immediately prior to use. Solution 1 consisted of DMEM-F12 containing 0.125% 
(v/v) trypsin, 20 pg/ml DNase, 20 U/ml papain and 0.02% (v/v) collagenase. Solution 
2 consisted of DMEM-F12 containing 0.05% (v/v) trypsin, 20 pg/ml DNase, 0.02% 
(v/v) EDTA and 0.02% (v/v) collagenase. Solution 3 consisted of DMEM-F12 
containing 0.004% (v/v) DNase, 0.05% (v/v) soya bean trypsin inhibitor, and 0.16% 
(v/v) BSA.
2.4.3 Human brain tissue
Adult brain tissue was obtained from the temporal lobes of patients undergoing surgery 
for intractable epilepsy. Foetal tissue was obtained from the temporal lobes of 
spontaneously aborted foetuses (16-24 weeks gestation). Samples ranging from 7 to 
36 hours post-mortem were received and could be successfully cultured. Approval to 
work with the adult surgical and foetal post-mortem tissue was granted from the Ethics 
committees of the Southern General Hospital NHS Trust, Glasgow and Yorkhill NHS 
Trust, Glasgow, respectively.
2.4.4 Isolation of cells
All brain samples were collected in 10 ml of sterile isolation medium and kept on ice. 
Adult and foetal tissue were treated in an identical manner, and unless otherwise 
stated, all brain tissue was maintained on ice throughout the entire procedure. The 
tissue was cleaned of blood vessels, meninges and other debris, and cut mto 1 mm 
cubes by two passes (at 90°C) in a Mcllwain tissue chopper. The chopped tissue was 
transferred to a sterile tube containing 1 0  ml of fresh isolation medium, mixed gently to
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wash, and centrifuged (Heraeus Biofuge 15R) at 560 x g  for 5 minutes at 4°C. The 
supernatant was discarded and the tissue was then subjected to a series of enzymatic 
digestions. The tissue was first digested for 20 minutes at 37°C in 2 ml of Solution 1. 
Following a 20 minute incubation the solution was centrifuged at 560 x g  for 5 minutes 
at 4°C and the supernatant decanted into a sterile tube containing 10 ml of plating 
medium. The remaining pellet was digested for a further 20 minutes at 37°C in 2 ml of 
Solution 1 and centrifuged at 560 x g  for 5 minutes at 4°C. The supernatant was 
decanted into a second sterile tube containing 10 ml of plating medium. The resulting 
pellet was digested for 20 minutes at 37°C in 2 ml of Solution 2, centrifuged at 560 x g  
for 5 minutes at 4°C, and the supernatant decanted into a third sterile tube containing 
10 ml of plating medium. The remaining pellet underwent a final digestion for 5 
minutes at 37°C in 1 ml of Solution 3. The digested pellet was then gently triturated 15 
times using a sterile glass pipette and centrifuged at 560 x g  for 5 minutes at 4°C. The 
supernatant from this digestion was pooled with those from the previous three 
digestions and centrifuged at 315 x g  for 10 minutes at 4°C. The supernatant was 
discarded and the pellet resuspended in 2  ml of isolation medium. 2 0 pl of the 
resuspended cells were diluted in 30 pi serum free DMEM plus 50 pi trypan blue and 
vortex mixed. 1 0  pi of the diluted cell suspension was counted in a haemocytometer 
and the total number of cells was calculated. The volume of cell suspension was 
adjusted with plating medium to give a density of 80, 0 0 0  cells/cm2 in a final volume of 
200 pi per well in Primaria 24 well culture dishes. The cells were left in the incubator 
for 1 - 4 hours to allow for attachment to wells, then the existing medium was 
aspirated and cultures re-fed with 500 pi fresh plating medium.
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2.4.5 Culture maintenance
The cultures were maintained at 37°C in an environment of 95% air / 5% CO2 with a 
humidity of >90%. The culture medium was replaced every 3 -4  days throughout, until 
the cells reached confluence (around day 21). At this stage, the astrocytes were 
identified as positive for GFAP (section 2.5).
2.5 GLIAL FIBRILLARY ACIDIC PROTEIN IMMUNOFLUORESCENCE 
STAINING
2.5.1 Paraformaldehyde solution
A 4% paraformaldehyde solution was prepared by adding 4 g of paraformaldehyde to 
100 ml of sterile PBS and heated to 56°C. A few drops of 1 M NaOH were added to 
dissolve the paraformaldehyde. The solution was placed on ice to cool and the pH 
adjusted to 7.4 with 1 M NaOH. This was then aliquoted and stored at -20°C for up to 
six months.
2.5.2 Staining medium
Staining medium consisting of 20 ml new-born calf serum, 50 ml 10X HBSS, 2.5 ml of 
10% (v/v) sodium azide solution, 2.6 g HEPES sodium salt, 2.38 g HEPES and 427.5 
ml of sterile distilled water was prepared and stored at 4°C for three months.
2.5.3 Staining procedure
Astrocytes which had been grown on glass coverslips (section 2.3.2) were removed 
from 24 well culture dishes and placed on a petri dish to dry. A drop of the 4% 
paraformaldehyde solution was added to each coverslip and left for 30 minutes at room
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temperature to fix the cells. The coverslips were then rinsed in staining medium (by 
carefully holding the edge of the coverslips with watchmaker’s forceps and dipping 
into a vial of the medium). The primary antibody (Rabbit Anti Cow Polyclonal GFAP) 
was diluted 1 in 100 and 50 pi was added to each coverslip and left at room 
temperature for one hour, in a petri dish with the lid on to prevent drying. This 
antibody was removed by rinsing thoroughly in staining medium. The secondary 
antibody which carried the fluorescent tag (Goat Anti-Rabbit IgGy heavy chain 
specific RITC labelled) was then diluted 1 in 100 and 50 pi added to each coverslip 
and left as before for one hour. At the end of the incubation, the antibody was removed 
by rinsing in staining medium, followed by rinsing in distilled water (to prevent crystal 
formation). Each coverslip was then mounted face-down onto a glass slide containing a 
drop of Citifluor AF1 antifadant solution and left to dry.
2.5.4 Examination of slides
The stained astrocytes were stored at 4°C until required for examination (within 3 
months of staining) using a fluorescent microscope (Zeiss Axioplan with epi- 
illumination and phase contrast optics) and selected areas of the coverslips were 
photographed (MC 100 camera control unit and 35 mm film cassette).
2.6 DETERMINATION OF PROTEIN CONCENTRATION IN CULTURED 
RAT AND HUMAN ASTROCYTES AND MOUSE BRAIN
Protein concentrations were determined by the BIORAD method, which relies on the 
colour change of Coomassie Brilliant Blue G-250 dye. A duplicate set of standards 
were prepared over the range 0.25 - 2 pg/ml with BSA. Samples of unknown protein
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concentration were diluted within this range. BIORAD protein assay dye reagent was 
diluted 1 : 1 with water and an equal volume was added to standards and samples. 
Tubes were vortex mixed, incubated for 5 minutes at room temperature, then read at 
595 nm in a spectrophotometer (Dynex MR5000). Results were corrected for dilution 
and expressed in mg/ml.
2.7 [14C]-GABA UPTAKE INTO CULTURED RAT AND HUMAN 
ASTROCYTES
This method was a modification of the methods of Larsson and co-workers (1981) and 
Yu and colleagues (1984).
2.7.1 Balanced salt solution (BSS)
The BSS used throughout the [14C]-GABA uptake experiments consisted of 136 mM 
NaCl, 5 mM KC1, 0.8 mM MgS04, 2.6 mM NaHC03, 0.4 mM KH2P04, 0.34 mM 
Na2HP0 4, 1.3 mM CaCl2, 5.6 mM D-glucose and 15 mM HEPES. The solution was 
adjusted to pH 7.4 with 1 M NaOH, and stored at 4°C for up to five days.
2.7.2 [14C]-GABA uptake procedure
The cultures were removed from the incubator and the existing medium aspirated. 
Individual plates (rat astrocytes) or wells (human astrocytes) were washed twice (2 x 2  
ml plates; 2 x 200 pi wells) with BSS (which had been warmed to 37°C prior to use), 
and 2 ml (plates) or 200 pi (wells) of BSS containing the appropriate drug solution 
was added to each culture. Control groups received BSS alone. All cultures were 
returned to the incubator for one hour. After the incubation period a further 1 ml 
(plates) or 100 pi (wells) of BSS (with the appropriate drug or control treatment)
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containing 150 pM [14C]-GABA (specific activity = 1 mCi / mmol) was added to each 
plate or well. The cultures were incubated for a further five minutes, the BSS was 
aspirated and cultures washed (5 x 2 ml plates; 5 x 200 pi wells) with fresh BSS. Cells 
were removed from plates by scraping in 1 ml of ice cold 1 M NaOH, and from wells 
by scraping in 250 pi of ice cold I M NaOH. Aliquots were taken for protein 
concentration determination by the BIORAD method (section 2.6) and liquid 
scintillation counting in 6  ml of Picofluor 40 scintillation fluid.
2.7.3 Liquid scintillation counting
Samples were counted for 14C in a liquid scintillation counter (Canberra Packard 
2000CA TRI-CARB), which had previously been programmed to convert counts per 
minute (cpm) into disintegrations per minute (dpm), based on the counting efficiency. 
Counting efficiency in liquid scintillation counting is dependent upon the composition 
of the sample / scintillator complex. Efficiency may vary due to phenomena known as 
“quenching” which interfere either with the scintillation process itself or with the 
transmission of light to the photomultiplier.
The most commonly used standardisation method in liquid scintillation counting is the 
external standards ratio, whereby the sample is irradiated with a high activity external 
gamma source to superimpose a Compton spectrum on to that of the sample isotope. 
The ratio of the net Compton count rate can then be calculated by subtracting the 
sample counts from the gamma source counts. The counter is programmed by 
preparing a series of reference standards with the same composition as the samples and 
“quenched” to different degrees, to cover the quench range of the experimental 
samples. A calibration curve relating % efficiency to the external standards ratio was
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constructed and stored in the counter. Experimental samples were then automatically 
converted from cpm to dpm using the formula : dpm = Net cpmx 100
% Efficiency
The radioactive content of individual cultures was compared to known radioactive 
standards and the results quantified by the relation of GABA uptake to the protein 
concentration and expressed as pmol / minute / mg protein.
2.8 [,4C]-GLUTAMATE UPTAKE INTO CULTURED RAT ASTROCYTES
This method was a modification of the method of Yu and colleagues (1984).
2.8.1 [14C]-Glutamate uptake procedure
BSS was prepared as described in section 2.7.1. The cultures were removed from the 
incubator and the existing medium aspirated. Individual plates were washed twice (2 x 
2 ml) with BSS (which had been warmed to 37°C prior to use) and 2 ml of BSS 
containing the appropriate drug solution was added to each culture. Control groups 
received BSS alone. All cultures were returned to the incubator for one hour. After the 
incubation period a further 1ml of BSS (with the appropriate drug or control 
treatment) containing 150 pM [14C]-glutamate (specific activity = 1 mCi / mmol) was 
added to each plate or well. The cultures were incubated for a further five minutes, the 
BSS was aspirated and cultures washed (5 x 2  ml) with BSS. Cells were removed from 
plates by scraping in 1 ml of ice cold 1 M NaOH. Aliquots were taken for protein 
concentration determination by the BIORAD method (section 2.6) and liquid 
scintillation counting (section 2.7.3) in 6  ml of Picofluor 40 scintillation fluid. The 
radioactive content of individual cultures was compared to known radioactive
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standards and the results quantified by the relation of glutamate uptake to the protein 
concentration and expressed as pmol / minute / mg protein.
2.9 DETERMINATION OF GABA-TRANSAMINASE ACTIVITY IN 
CULTURED RAT ASTROCYTES AND IN MOUSE BRAIN
This method was a modification of the methods of White and Sato (1978) and Larsson 
and colleagues (1986).
2.9.1 Reagents
All solutions were prepared using deionised water. An EDTA buffer was prepared 
weekly and stored at 4°C. It consisted of 0.1 mM EDTA, 0.5 mM DTT, and 0.1 mM 
KH2PO4. 0.2 mM PLP was added daily as required and the pH was adjusted to 8  with 
1 M NaOH. A [14C]-GABA incubation medium, prepared monthly and stored at -20°C, 
consisted of 2.7 mM GABA (specific activity = 0.37 mCi / mmol), 1.8 mM EDTA and 
200 mM KH2PO4 with the pH adjusted to 8  with 1 M NaOH.
2.9.2 Preparation of ion exchange resin
Dowex AG50W-X8 resin was pre-washed five times with deionised water before use.
2.9.3 Sample preparation
Whole mouse brains, which had been stored at -70°C for up to one month, were 
thawed and homogenised (polytron PT 1200) in 4 volumes (v/w) of EDTA buffer. 
Cultured rat astrocytes which had been scraped and stored at -70°C in 500 pi EDTA 
buffer, were freeze / thawed three times then homogenised. All samples were then 
centrifuged (Heraeus Biofuge 15R) at 600 x g  for 20 minutes at 4°C and the
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supernatant decanted and its protein content determined by the BIORAD method 
(section 2.6). The remaining supernatant was adjusted with EDTA buffer to give a final 
protein concentration of 1 mg/ml for whole brain, or 0 . 2  mg/ml for astrocyte cultures.
2.9.4 GABA-transaminase assay
To a 50 pi volume of the adjusted supernatant, 25 pi of 0.68 mM a-KG and 25 pi of 
the [14C]-GABA incubation medium was added. Assays were performed in duplicate 
with a blank assay included for each sample by replacing the a-KG with 25 pi water. 
Samples were vortex mixed and incubated for 60 minutes at 37°C. The reaction was 
terminated by the addition of 10 pi 2 M HCL The incubated samples were mixed and 
applied to single use ion exchange columns (9 inch glass Pasteur pipettes plugged with 
a glass bead) containing 0.5 x 3 cm Dowex resin. Radioactive products were eluted 
directly into glass scintillation vials using 3 x 0.5 ml aliquots of deionised water. 
Twelve ml of Picofluor 40 scintillation fluid was added to each vial and radioactive 
content of the samples counted in a liquid scintillation counter (section 2.7.3). The 
radioactive content of samples was compared to known radioactive standards, 
corrected for background and blank sample counts, and related to protein content and 
reaction time. GABA-T activity was expressed as nmol / minute / mg protein.
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2.10 DETERMINATION OF GLUTAMINE SYNTHETASE ACTIVITY IN 
CULTURED RAT ASTROCYTES AND MOUSE BRAIN
This method was a modification of the method of Pishak and Phillips (1979).
2.10.1 Reagents
All solutions were prepared using deionised water. Imidazole-HCl buffers were 
prepared monthly and stored at 4°C. The 100 mM and 5 mM buffers consisted of 100 
mM and 5 mM imidazole-HCl, respectively, and were adjusted to pH 7.2 with 1 M 
NaOH. A test assay solution consisting of 4 mM 2-mercaptoethanol and 40 mM ATP 
in 100 mM imidazole-HCl buffer was prepared daily. A blank assay solution was 
prepared daily by omitting ATP from the test solution. A [14C] L-glutamic acid 
incubation medium, prepared monthly and stored at -20°C, consisted of 40 mM L- 
glutamic acid (specific activity = 0.12 mCi / mmol), 60 mM MgCk, 16 mM NH4CI and 
4 mM ouabain in 100 mM imidazole-HCl buffer.
2.10.2 Preparation of ion-exchange resins
The Amberlite CG-50 hydrogen form resin was pre-washed five times with 1 M 
NaOH, then five times with 1 M HC1, followed by five washes with deionised water 
before use. The Dowex AG1-X8 acetate form resin was pre-washed five times with 1 
M acetic acid, followed by five washes with deionised water before use.
2.10.3 Sample preparation
Whole mouse brains, which had been stored at -70°C for up to three months, were 
thawed and homogenised (polytron PT 1200) in 4 volumes (v/w) of 5 mM imidazole- 
HCl buffer. Cultured rat astrocytes which had been scraped and stored at -70°C in 250
54
pi 5 mM imidazole-HCl buffer, were freeze / thawed three times then vortex mixed. All 
samples were then centrifuged (Heraeus Biofuge 15R) at 800 x g  for 10 minutes at 4°C 
and the supernatant decanted and its protein content determined by the BIORAD 
method (section 2.6). The remaining supernatant was adjusted with 5 mM imidazole- 
HCl buffer to give a final protein concentration of 2 mg/ml for whole brain, or 0.1 
mg/ml for astrocyte cultures.
2.10.4 Glutamine synthetase assay
To a 50 pi volume of the adjusted supernatant, 25 pi of the test assay solution and 25 
pi of the [14C] L-glutamic acid incubation medium was added. Assays were performed 
in duplicate with a blank assay included for each sample. Samples were vortex mixed 
and incubated for 15 minutes at 37°C. The reaction was terminated by the addition of 1 
ml of ice cold deionised water. The incubated samples were mixed and applied to 
single use tandemly arranged chromatography columns (BIORAD). The first column 
contained 0.8 x 3.5 cm Dowex resin and was placed directly over a second column 
containing 0.8 x 3.5 cm Amberlite resin. One ml of ice cold deionised water was added 
to each column, but was not collected. Newly synthesised glutamine was eluted into 
plastic scintillation vials using 5 x 1 ml aliquots of deionised water. Ten ml of Ultima 
Gold XR scintillation fluid was added to each vial and the radioactive content of the 
samples determined in a liquid scintillation counter (section 2.7.3). The radioactive 
content of samples was compared to known radioactive standards, corrected for 
background and blank sample counts, and related to protein content and reaction time. 
GS activity was expressed as nmol / minute / mg protein.
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2.11 DETERMINATION OF AMINO ACID NEUROTRANSMITTER 
CONCENTRATIONS BY HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY
This method was a modification of the method of Durkin and colleagues (1988).
2.11.1 Equipment
All HPLC analyses were performed at room temperature on a Beckman Ultrasphere 25 
cm x 4.6 mm internal diameter, 5 pm reversed phase column. The system consisted of 
a Shimadzu LC-10AT pump, a Shimadzu SIL-9A auto-injector and a Perkin-Elmer 
LS-5 fluorescence spectrophotometer. The excitation and emission wavelengths were 
330 and 440 nm, respectively, with slit widths set at 15 and 20 nm, respectively. Data 
was recorded and integrated on a Jones JCL6000 chromatography data system.
2.11.2 Reagents
Stock solutions of amino acid standards (GABA, glutamate and glutamine) and internal 
standards (homoserine and D,L-norvaline) - 1 mg/ml in distilled water, were prepared 
monthly and stored at -20°C. All standards were diluted daily as required. A borate 
buffer was prepared monthly (and stored at room temperature), by adjusting 0.5 M 
boric acid to pH 9.5 with 3 M NaOH. The derivatization reagent (OPA - 3-MPA) was 
prepared weekly (and stored dark at 4°C) by dissolving 50 mg OPA in 4.5 ml methanol 
and 0.5 ml borate buffer then adding 50 pi 3-MPA.
2.11.3 Mobile phase
GABA was determined in a mobile phase consisting of 60 : 40 (v/v) 0.2 M acetate 
buffer (pH 3.7, containing 100 mg/1 EDTA) / acetonitrile. Acetate buffer (0.2 M) was
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prepared by diluting 11.5 ml glacial acetic acid to 1 litre with water, adding 100 mg 
EDTA and adjusting the pH to 3.7 with 3 M NaOH. Glutamate and glutamine were 
determined simultaneously in a mobile phase consisting of 80 : 20 (v/v) 0.57 M acetate 
buffer (pH 3.7, containing 100 mg/1 EDTA) / acetonitrile. Acetate buffer (0.57 M) was 
prepared by diluting 32.8 ml glacial acetic acid to 1 litre with water, adding 100 mg 
EDTA and adjusting the pH to 3.7 with 3 M NaOH. Flow rates were 1 ml/min 
throughout.
2.11.4 Calibration
Standard curves were constructed for GABA (2 - 20 pg/ml), glutamate (15 - 150 
pg/ml) and glutamine (5 - 50 pg/ml) and were found to be linear (r > 0.970) in all 
cases. The limits of detection in a 50 pi sample were found to be 5 ng/ml, 25 ng/ml and
12.5 ng/ml for GABA, glutamate and glutamine, respectively. Intra- and inter-assay 
variations were calculated at 2.8% and 7.9% for GABA (5 pg/ml), 4.7% and 9.2% for 
glutamate (30 pg/ml) and 4.1% and 8.5% for glutamine (10 pg/ml), respectively.
2.11.5 Extraction
Mouse brain samples (previously stored at -70°C) were weighed and homogenised 
(polytron PT 1200) in 10 volumes (v/w) of 1% perchloric acid. Samples were then 
centrifuged (Heraeus Biofuge 15R) at 1440 x g  for 5 minutes at 4°C and the 
supernatant decanted and diluted 1 in 1 0  with water prior to derivatization.
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2.11.6 Derivatization
A 50 pi aliquot of the diluted supernatant was reacted with 400 pi methanol, 400 pi 
borate buffer and 100 pi OPA - 3-MPA solution. 50 pi of 1 pg/ml D,L-norvaline was 
added to samples as an internal standard for GABA samples, and 50 pi of 1 pg/ml 
homoserine was added to samples as an internal standard for glutamate and glutamine. 
Reaction mixtures were vortex mixed and allowed to stand at room temperature for 5 
minutes prior to a 10 pi injection onto the column. Amino acid concentrations were 
calculated by comparison of peak height ratios of analyte to internal standard, 
quantified in relation to wet weight of tissue, and expressed as pg/g.
2.12 DETERMINATION OF GLUTAMIC ACID DECARBOXYLASE 
ACTIVITY BY HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY
This method was a modification of the methods of Kochhar and co-workers (1989) 
and Wolf and Klemisch (1991).
2.12.1 Reagents
A sodium phosphate-AET buffer was prepared weekly (and stored at 4°C) and 
consisted of 0.1 M Na2HP0 4  and 1 mM AET. The buffer was adjusted to pH 7 with 
0.1 M NaH2P0 4 . An incubation medium was prepared daily and consisted of 50 mM L- 
glutamic acid, 250 pM PLP, 0.4% 2-mercaptoethanol and 57 pM gabaculline in 
sodium phosphate-AET buffer.
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2.12.2 Sample preparation
Mouse brain samples (previously stored at -70°C for up to 1 month) were thawed and 
homogenised (polytron PT 1200) in 10 volumes (v/w) of sodium phosphate-AET 
buffer. Samples were then centrifuged (Heraeus Biofuge 15R) at 1440 x g  for 10 
minutes at 4°C, the supernatant decanted and its protein content determined by the 
BIORAD method (section 2.6). Remaining supernatant was then adjusted to 1 mg/ml 
with sodium phosphate-AET buffer.
2.12.3 Glutamic acid decarboxylase assay
1 0 0  jul of incubation medium was added to each of two 1 0 0  pi aliquots of adjusted 
supernatant per sample. The reaction in one (blank) was terminated immediately by the 
addition of 1 0 0  pi 1% perchloric acid, while the other (test) was allowed to continue 
for 30 minutes at 37°C. This was also terminated by the addition of 100 pi 1% 
perchloric acid. Terminated blank and test reaction mixtures were stored at -20°C until 
required for assay. Samples were thawed and centrifuged (Heraeus Biofuge 15R) at 
1440 x g  for 10 minutes at 4°C and the resulting supernatant diluted 1 in 10 with water 
prior to GABA content measurement by HPLC (section 2.11). GAD activity was 
calculated by subtraction of the blank GABA concentration from the test GABA 
concentration, giving a value for GABA production during the incubation period. 
Results were quantified in relation to reaction time and protein concentration, and 
expressed as nmol / min / mg protein.
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2.13 PENTYLENETETRAZOL TESTING
This test was performed by the method of Loscher & Schmidt (1988). PTZ was 
prepared for injection in 0.9% saline. 85 mg/kg PTZ was warmed to 37°C and 0.3 ml 
administered subcutaneously (s.c.) in the back of the neck. The time to the first 
generalised seizure with loss of the righting reflex was recorded in individual mice. A 
cut-off time of 15 minutes was chosen. Animals were sacrificed immediately after the 
seizure or after the 15 minute cut-off time if no seizure had occurred.
2.14 DATA ANALYSIS AND STATISTICAL METHODS
Statistical analysis was performed using MINITAB for Windows statistical package 
(version 10.1) on an Elonex PC-5120/1 microcomputer. All results were calculated as 
the percentage of mean control values. Group results were then expressed as the mean 
percentage + the standard error of the mean (S.E.M.). Drug treated groups were 
compared to control using one-way analysis of variance with Dunnett correction for 
multiple comparisons.
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CHAPTER THREE
EFFECTS OF ANTIEPILEPTIC DRUGS ON THE TRANSPORT OF GABA 
AND GLUTAMATE AND THE METABOLISM OF GABA IN PRIMARY 
CULTURES OF RAT CORTICAL ASTROCYTES
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3.1 INTRODUCTION
3.1.1 Astrocytes
Astrocytes account for more than half of the glial cell population in the brain and are 
estimated to comprise as much as 20 to 50% of the total volume in some brain areas. 
They are up to ten times more numerous in the CNS than neurones (Kimelberg, 1983; 
Kimelberg and Norenberg, 1989). Astrocytes were once regarded as playing only 
structural and supporting roles in the nervous system, but are now widely accepted to 
be responsible for the maintenance of the extracellular environment in the brain, 
regulating the microenvironment around the synaptic cleft and neurones (Montgomery, 
1994). Failure in this regulation by astrocytes has been proposed to be a significant 
factor in the aetiology of epilepsy (Tiffany-Castiglioni and Castiglioni, 1986; 
Castiglioni et al, 1990; Nilsson et al, 1992).
3.1.2 Uptake and metabolism of neurotransmitters in astrocytes
There is substantial evidence to suggest that the principal mode of inactivation of 
amino acid neurotransmitters released from nerve endings is by reuptake (Snyder et al, 
1970; Iversen, 1972; De Feudis, 1975). Studies using synaptosomes, brain slices and 
cultured cells have shown that the inhibitory and excitatory amino acid 
neurotransmitters are taken up by high affinity transport systems (Borg et al, 1979; 
Hertz, 1979; Schousboe, 1981; Fonnum, 1984). Both neurones and glial cells have 
been demonstrated to be involved in the uptake of amino acids (Hamberger, 1971; 
Henn and Hamberger, 1971; Iversen and Kelly, 1975). It is thought that GABA is 
released predominantly from neurones (Hertz and Schousboe, 1980) and studies on its 
transport have shown that most synaptically released GABA is reaccumulated into
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presynaptic nerve endings, and that a smaller fraction is taken up into surrounding 
astrocytes. In contrast to this, the rate and capacity of astrocytic accumulation of 
glutamate is significantly higher than of the uptake into neurones (Schousboe et al, 
1992). GABA-T, the only GABA metabolizing enzyme of physiological importance, is 
located intracellularly with approximately equal activities in neurones and glial cells 
(Schousboe, 1981). The intracellular location of GABA-T indicates the importance of 
the uptake of GABA into cells in the termination of its actions (Hertz and Schousboe, 
1980). Glutamate which is taken up into neurones is largely converted to GABA via 
the neuronal-specific enzyme GAD, and that which is taken up into astrocytes is 
metabolized to glutamine by the glial-specific enzyme GS (Schousboe, 1981).
3.1.3 History of brain cell culture
The first nerve tissue cultured successfully was by Harrison in 1907, where a small 
portion of early frog neural tube was grown in clotted lymph as an explant culture. The 
earliest documented primary cultures enriched in astroglial cells were obtained by 
Shein (1965), and later by Varon and Raibom (1969). However, it was Booher and 
Sensenbrenner (1972) who were the first to use the developmental characteristics of 
different neural cell types to achieve separation between cultures consisting almost 
exclusively of glial cells and those highly enriched in neurones. Today, virtually all of 
the techniques available for the preparation of astrocyte cultures are based on 
modifications of this method. Obtaining cultures enriched in astrocytes is dependent on 
selecting a time in the development of a particular brain region where neuronogenesis 
is complete and there are a large number of proliferating immature astroglial cells. In 
the rat and mouse this stage is new-born, where the neopallium (cortex and underlying 
intermediate and subventricular zones) contains many proliferating astroglial
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precursors (Juurlink and Hertz, 1985; 1992). In the human brain, immature glia can be 
identified by GFAP in the spinal cord by eight weeks, and in the cerebrum by ten 
weeks gestation (Rutka et al, 1987).
3.2 AIMS
GABA and glutamate are the major inhibitory and excitatory, respectively, 
neurotransmitters in the brain and the effect of AEDs on these systems is of particular 
importance in epilepsy research (discussed in chapter 1). Primary cultures of astrocytes 
from the cerebral cortex have been proposed as a model system for studies on the 
transport of GABA, glutamate and glutamine (Schousboe et al, 1983a). To date, the 
precise mechanisms of action of many of the frequently used AEDs remains to be 
elucidated. PB, PHT, CBZ, SVP, LTG, FBM, GBP, TPM and DGR would all appear 
to possess multiple mechanisms of action (Hannah et al, 1995; Dichter and Brodie, 
1996; Leach et al, 1997b). In contrast, VGB and TGB are two new AEDs which are 
reported to exert their anticonvulsant actions via single and specific effects on the 
GABA system, VGB by an irreversible inhibition of the enzyme GABA-T, and TGB by 
blockade of neuronal and glial GABA uptake (Lippert et al, 1977; Nielsen et al, 1991). 
However, a recent study performed in our laboratory employing primary cultures of rat 
cortical astrocytes suggested that VGB may additionally block the uptake of GABA as 
well as inhibiting GABA-T (Leach et al, 1996). Despite numerous studies, the precise 
mechanism of action of the experimental anticonvulsant LEV (Margineanu and 
Wulfert, 1995; Noyer et al, 1995; Loscher et al, 1996) remains to be characterized. 
The aim of this study was, therefore, to examine the actions of these established, new, 
and experimental AEDs on the uptake and metabolism of GABA. In addition, 
validation of the glutamate uptake assay was performed and the effects on glutamate
64
uptake were also examined. The effects of AEDs on the metabolism of glutamate is not 
included here as it will be examined in detail in chapter 4.
3.3 EXPERIMENTAL PROTOCOLS AND RESULTS
3.3.1 Effects of new and established antiepileptic drugs on the uptake of [14C]- 
GABA into primary cultures of rat cortical astrocytes
EXPERIMENTAL PROTOCOL: Rat brain tissue was isolated and cultured as 
described in section 2.3. Astrocytes were identified as positive for GFAP, and 
photographed as described in section 2.5 (photograph 1). For each of the 12 drug 
experiments, cultures were randomly separated into six (SVP, VGB, GBP, TGB and 
LEV) or seven (PB, PHT, CBZ, LTG, FBM, TPM and DGR) groups (n = 8  / group),
and exposed to the following drugs in BSS (stock solutions of CBZ, PHT and FBM
were dissolved in 500 pi ethanol prior to dilution with BSS):
PB:- 1, 3, 10, 30, 100, 300 and 1000 pM 
PHT:- 1, 3, 10, 30, 100, 300 and 1000 pM 
CBZ:- 1, 3, 10, 30, 100, 300 and 1000 pM 
SVP:- 50, 250, 500, 1250, 2500 and 5000 pM 
VGB:- 10, 50, 100, 250, 500 and 1000 pM 
LTG:- 0.3, 1, 3, 10, 30, 100 and 300 pM 
FBM:- 3, 10, 30, 100, 300, 1000 and 3000 pM 
GBP:- 10, 50, 100, 250, 500 and 1000 pM 
TPM:- 1, 3, 10, 30, 100, 300 and 1000 pM 
TGB:- 10, 50, 100, 250, 500 and 1000 nM
65
LEV:- 10, 50, 100, 250, 500 and 1000 pM 
DGR:- 1, 3, 10, 30, 100, 300 and 1000 pM
Drug concentrations used were relative to therapeutic doses, and were based on 
effective concentrations stated in the literature. For each drug experiment, a control 
group (n = 8 ) was exposed to BSS alone. After a one hour incubation, cells were 
assayed for GABA uptake as described in section 2.7.
RESULTS: All results are summarised in table 1. SVP (50, 250, 500, 1250, 2500 and 
5000 pM; figure 4), VGB (100, 250, 500 and 1000 pM; figure 5), FBM (3, 10, 30, 
100, 300, 1000 and 3000 pM; figure 7) and TGB (10, 50, 100, 250, 500 and 1000 nM; 
figure 10) all significantly (P < 0.05) reduced the uptake of GABA into primary 
cultures of rat cortical astrocytes. PB (figure 1), PHT (figure 2), CBZ (figure 3), LTG 
(figure 6 ), GBP (figure 8 ), TPM (figure 9), LEV (figure 11) and DGR (figure 12) were 
found to have no significant effect on the transport of GABA.
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PHOTOGRAPH 1. Rat cortical astrocytes in primary culture (day 21) stained with 
glial fibrillary acidic protein (GFAP) and examined using a fluorescent microscope (x 
450).
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FIGURE 1. Effect of phenobarbitone (PB; 0 - 1000 pM) on the uptake of GABA into 
primary cultures of rat cortical astrocytes. Results (n = 8 ) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.).
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FIGURE 2. Effect of phenytoin (PHT; 0 - 1000 pM) on the uptake of GABA into 
primary cultures of rat cortical astrocytes. Results (n = 8 ) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.).
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FIGURE 3. Effect of carbamazepine (CBZ; 0 - 1000 pM) on the uptake of GABA 
into primary cultures of rat cortical astrocytes. Results (n = 8 ) are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.).
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FIGURE 4. Effect of sodium valproate (SVP; 0 - 5000 pM) on the uptake of GABA 
into primary cultures of rat cortical astrocytes. Results (n = 8 ) are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.). Statistical significance (* P < 0.05) was determined by one way 
analysis of variance with Dunnett correction for multiple comparisons.
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FIGURE 5. Effect of vigabatrin (VGB; 0 - 1000 fiM) on the uptake of GABA into 
primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.). Statistical significance (* P < 0.05) was determined by one way analysis of 
variance with Dunnett correction for multiple comparisons.
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FIGURE 6 . Effect of lamotrigine (LTG; 0 - 300 jliM ) on the uptake of GABA into 
primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.).
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FIGURE 7. Effect of felbamate (FBM; 0 - 3000 pM) on the uptake of GABA into 
primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.). Statistical significance (* P < 0.05) was determined by one way analysis of 
variance with Dunnett correction for multiple comparisons.
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FIGURE 8. Effect of gabapentin (GBP; 0 - 1000 pM) on the uptake of GABA into 
primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.).
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FIGURE 9. Effect of topiramate (TPM; 0 - 1000 pM) on the uptake of GABA into 
primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.).
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FIGURE 10. Effect of tiagabine (TGB; 0 - 1000 nM) on the uptake of GABA into 
primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.). Statistical significance (* P < 0.05) was determined by one way analysis of 
variance with Dunnett correction for multiple comparisons.
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FIGURE 11. Effect of levetiracetam (LEV; 0 - 1000 pM) on the uptake of GABA 
into primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.).
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FIGURE 12. Effect of desglycinyl-remacemide (DGR; 0 - 1000 pM) on the uptake of 
GABA into primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as 
the mean percentage of mean control values and error bars denote the standard error of 
the mean (S.E.M.).
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3.3.2 Validation of the [14C]-glutamate uptake assay in primary cultures of rat 
cortical astrocytes
EXPERIMENTAL PROTOCOL: Rat brain tissue was isolated and cultured as 
described in section 2.3. Cultures were randomly separated into six groups (n = 5 / 
group) and exposed to the glutamate uptake blocker PDC (1, 3, 10, 30, 100 and 300 
pM) in BSS. A control group (n = 5) was exposed to BSS alone. After a one hour 
incubation, cells were assayed for glutamate uptake as described in section 2.8.
RESULTS: PDC (10, 30, 100 and 300 pM; figure 13) was found to significantly (P < 
0.05) reduce the uptake of [14C]-glutamate (to 20% of control value) into primary 
cultures of rat cortical astrocytes. 1 and 3 pM PDC were found to have no effect. The 
reduction in glutamate uptake exhibited by the glutamate uptake blocker PDC confirms 
the validity of this assay for use in the following AED experiments.
3.3.3 Effects of new and established antiepileptic drugs on the uptake of [14C]- 
glutamate into primary cultures of rat cortical astrocytes
EXPERIMENTAL PROTOCOL: Rat brain tissue was isolated and cultured as 
described in section 2.3. For each of the 12 drug experiments, cultures were randomly 
separated into seven groups (n = 8 / group) and exposed to the following drugs in BSS
(stock solutions of CBZ, PHT and FBM were dissolved in 500 pi ethanol prior to
dilution with BSS):
PB:- 1, 3, 10, 30, 100, 300 and 1000 pM 
PHT:- 1, 3, 10, 30, 100, 300 and 1000 pM 
CBZ:- 1, 3, 10, 30, 100, 300 and 1000 pM
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SVP:- 3, 10, 30, 100, 300, 1000 and 3000 pM 
VGB:- 1, 3, 10, 30, 100, 300 and 1000 pM 
LTG:- 0.3, 1, 3, 10, 30, 100 and 300 pM 
FBM:- 3, 10, 30, 100, 300, 1000 and 3000 pM 
GBP:- 1, 3, 10, 30, 100, 300 and 1000 pM 
TPM:- 1, 3, 10, 30, 100, 300 and 1000 pM 
TGB:- 0.1, 0.3, 1, 3, 10, 30 and 100 pM 
LEV:- 1, 3, 10, 30, 100, 300 and 1000 pM 
DGR:- 1, 3, 10, 30, 100, 300 and 1000 pM
For each drug experiment, a control group (n = 8) was exposed to BSS alone. After a 
one hour incubation, cells were assayed for glutamate uptake as described in section 
2 .8 .
RESULTS: PB (1, 3 and 10 pM; figure 14), TGB (1 and 30 pM; figure 23) and DGR 
(10, 300 and 1000 pM; figure 25) all significantly (P < 0.05) reduced the uptake of 
glutamate into primary cultures of rat cortical astrocytes. PHT (figure 15), CBZ (figure 
16), SVP (figure 17), VGB (figure 18), LTG (figure 19), FBM (figure 20), GBP 
(figure 21), TPM (figure 22) and LEV (figure 24) were found to have no significant 
effect on the transport of glutamate.
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FIGURE 13. Effect of L-£ra«.s-pyrollidine-2,4-dicarboxylic acid (PDC; 0-300 pM) 
on the uptake of glutamate into primary cultures of rat cortical astrocytes. Results (n = 
8) are expressed as the mean percentage of mean control values and error bars denote 
the standard error of the mean (S.E.M.). Statistical significance (* P < 0.05) was 
determined by one way analysis of variance with Dunnett correction for multiple 
comparisons.
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FIGURE 14. Effect of phenobarbitone (PB; 0 - 1000 pM) on the uptake of glutamate 
into primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.). Statistical significance (* P < 0.05) was determined by one way 
analysis of variance with Dunnett correction for multiple comparisons.
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FIGURE 15. Effect of phenytoin (PHT; 0 - 1000 pM) on the uptake of glutamate into 
primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.).
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FIGURE 16. Effect of carbamazepine (CBZ; 0 - 1000 pM) on the uptake of glutamate 
into primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.).
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FIGURE 17. Effect of sodium valproate (SVP; 0 - 3000 pM) on the uptake of 
glutamate into primary cultures of rat cortical astrocytes. Results (n = 8) are expressed 
as the mean percentage of mean control values and error bars denote the standard error 
of the mean (S.E.M.).
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FIGURE 18. Effect of vigabatrin (VGB; 0 - 1000 pM) on the uptake of glutamate 
into primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.).
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FIGURE 19. Effect of lamotrigine (LTG; 0 - 300 pM) on the uptake of glutamate into 
primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.).
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FIGURE 20. Effect of felbamate (FBM; 0 - 3000 pM) on the uptake of glutamate into 
primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.).
89
150n
^  125- 
O
co
O
100 -
&
>
~  75 o
<
o
<0
50-Q.I )
0)
CS
E
3 251
e>
| I I I | I I 11 [ — ~l~ IT pi'll] I 1 I | I I 111
10 100 1000
GBP Concentration ( ^M)
FIGURE 21. Effect of gabapentin (GBP; 0 - 1000 pM) on the uptake of glutamate 
into primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.).
90
150~i
125-
OL.-4-1
co
o
«*-o
so0s*
100
75-+■»O
<
<D
(0*-»
a>
w
E
CO
3 25
o
o 1 100010 100
TPM Concentration (jj,M)
FIGURE 22. Effect of topiramate (TPM; 0 - 1000 pM) on the uptake of glutamate 
into primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.).
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FIGURE 23. Effect of tiagabine (TGB; 0-100 jiM) on the uptake of glutamate into 
primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.). Statistical significance (* P < 0.05) was determined by one way analysis of 
variance with Dunnett correction for multiple comparisons.
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FIGURE 24. Effect of levetiracetam (LEV; 0 - 1000 pM) on the uptake of glutamate 
into primary cultures of rat cortical astrocytes. Results (n = 8) are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.).
93
125 i
O 100
50
Q.
0 1 100 100010
DGR Concentration ( jiM)
FIGURE 25. Effect of desglycinyl-remacemide (DGR; 0 - 1000 pM) on the uptake of 
glutamate into primary cultures of rat cortical astrocytes. Results (n = 8) are expressed 
as the mean percentage of mean control values and error bars denote the standard error 
of the mean (S.E.M.). Statistical significance (* P < 0.05) was determined by one way 
analysis of variance with Dunnett correction for multiple comparisons.
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3.3.4 Effects of new and established antiepileptic drugs on the metabolism of 
GABA in primary cultures of rat cortical astrocytes
EXPERIMENTAL PROTOCOL: Rat brain tissue was isolated and cultured as 
described in section 2.3. For each of the 12 drug experiments, cultures were randomly 
separated into six (SVP, VGB, GBP, TGB and LEV) or seven (PB, PHT, CBZ, LTG, 
FBM, TPM and DGR) groups (n = 8 / group), and exposed to the following drugs in
BSS (stock solutions of CBZ, PHT and FBM were dissolved in 500 pi ethanol prior to
dilution with BSS):
PB:- 1, 3, 10, 30, 100, 300 and 1000 pM 
PHT:- 1, 3, 10, 30, 100, 300 and 1000 pM 
CBZ:- 1, 3, 10, 30, 100, 300 and 1000 pM 
SVP:- 50, 250, 500, 1250, 2500 and 5000 pM 
VGB:- 10, 50, 100, 250, 500 and 1000 pM 
LTG:- 0.3, 1, 3, 10, 30, 100 and 300 pM 
FBM:- 3, 10, 30, 100, 300, 1000 and 3000 pM 
GBP:- 10, 50, 100, 250, 500 and 1000 pM 
TPM:- 1, 3, 10, 30, 100, 300 and 1000 pM 
TGB:- 10, 50, 100, 250, 500 and 1000 nM 
LEV:- 10, 50, 100, 250, 500 and 1000 pM 
DGR:- 1, 3, 10, 30, 100, 300 and 1000 pM
For each drug experiment, a control group (n = 8) was exposed to BSS alone. After a 
one hour incubation, cells were assayed for GABA-T activity as described in section 
2.9.
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RESULTS: SVP (5000 pM; figure 29), VGB (50, 100, 250, 500 and 1000 jaM; figure 
30), TGB (1000 nM; figure 35) and DGR (30, 100, 300 and 1000 pM; figure 37) all 
significantly (P < 0.05) reduced the activity of GABA-T in primary cultures of rat 
cortical astrocytes. PB (figure 26), PHT (figure 27), CBZ (figure 28), LTG (figure 31), 
FBM (figure 32), GBP (figure 33), TPM (figure 34) and LEV (figure 36) were found 
to have no significant effect on the metabolism of GABA.
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FIGURE 26. Effect of phenobarbitone (PB; 0 - 1000 pM) on the activity of GABA- 
transaminase (GABA-T) in primary cultures of rat cortical astrocytes. Results (n = 8) 
are expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 27. Effect of phenytoin (PHT; 0 - 1000 pM) on the activity of GABA- 
transaminase (GABA-T) in primary cultures of rat cortical astrocytes. Results (n = 8) 
are expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 28. Effect of carbamazepine (CBZ; 0 - 1000 pM) on the activity of GABA- 
transaminase (GABA-T) in primary cultures of rat cortical astrocytes. Results (n = 8) 
are expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 29. Effect of sodium valproate (SVP; 0 - 5000 pM) on the activity of 
GABA-transaminase (GABA-T) in primary cultures of rat cortical astrocytes. Results 
(n = 8) are expressed as the mean percentage of mean control values and error bars 
denote the standard error of the mean (S.E.M.). Statistical significance (* P < 0.05) 
was determined by one way analysis of variance with Dunnett correction for multiple 
comparisons.
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FIGURE 30. Effect of vigabatrin (VGB; 0 - 1000 |aM) on the activity of GABA- 
transaminase (GABA-T) in primary cultures of rat cortical astrocytes. Results (n = 8) 
are expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.). Statistical significance (* P < 0.05) was 
determined by one way analysis of variance with Dunnett correction for multiple 
comparisons.
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FIGURE 31. Effect of lamotrigine (LTG; 0 - 300 pM) on the activity of GABA- 
transaminase (GABA-T) in primary cultures of rat cortical astrocytes. Results (n = 8) 
are expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 32. Effect of felbamate (FBM; 0 - 3000 pM) on the activity of GABA- 
transaminase (GABA-T) in primary cultures of rat cortical astrocytes. Results (n = 8) 
are expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 33. Effect of gabapentin (GBP; 0 - 1000 pM) on the activity of GABA- 
transaminase (GABA-T) in primary cultures of rat cortical astrocytes. Results (n = 8) 
are expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 34. Effect of topiramate (TPM; 0 - 1000 pM) on the activity of GABA- 
transaminase (GABA-T) in primary cultures of rat cortical astrocytes. Results (n = 8) 
are expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 35. Effect of tiagabine (TGB; 0 - 1000 nM) on the activity of GABA- 
transaminase (GABA-T) in primary cultures of rat cortical astrocytes. Results (n = 8) 
are expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.). Statistical significance (* P < 0.05) was 
determined by one way analysis of variance with Dunnett correction for multiple 
comparisons.
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FIGURE 36. Effect of levetiracetam (LEV; 0 - 1000 pM) on the activity of GABA- 
transaminase (GABA-T) in primary cultures of rat cortical astrocytes. Results (n = 8) 
are expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 37. Effect of desglycinyl-remacemide (DGR; 0 - 1000 pM) on the activity of 
GABA-transaminase (GABA-T) in primary cultures of rat cortical astrocytes. Results 
(n = 8) are expressed as the mean percentage of mean control values and error bars 
denote the standard error of the mean (S.E.M.). Statistical significance (* P < 0.05) 
was determined by one way analysis of variance with Dunnett correction for multiple 
comparisons.
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TABLE 1. Effects of antiepileptic drugs on the uptake of GABA and glutamate and 
GABA-transaminase activity in primary cultures of rat cortical astrocytes following a 
one hour exposure - summary of results (NS = no significant effect, SIG i  = significant 
reductionp  < 0.05).
AED GABA uptake Glutamate uptake GABA-transaminase
Phenobarbitone NS 1-10 pM SIG -I NS
(1 - 1000 pM)
Phenytoin NS NS NS
(1 - 1000 pM)
Carbamazepine NS NS NS
(1 - 1000 pM)
Sodium valproate 50 -  5000 pM SIG 4- NS 5000 pM SIG 4^
(3 - 5000 pM)
Vigabatrin 100 -  1000 pM SIG I NS 5 0 - 1000 pM SIG I
(1 - 1000 pM)
Lamotrigine NS NS NS
(0.3 - 300 pM)
Felbamate 3 -  3000 pM SIG I  NS NS
(3 - 3000 pM)
Gabapentin NS NS NS
(1 - 1000 pM)
Topiramate NS NS NS
(1 - 1000 pM)
Tiagabine 0.01 -  1 pM SIG -I 1 & 30 pM SIG 4- 1 pM SIG 4-
(0.01 - 100 pM)
Levetiracetam NS NS NS
(1 - 1000 pM)
Desglycinyl remacemide NS 10, 300 & 1000 pM SIG 4^ 30 -  1000 pM SIG 4-
(1 - 1000 pM)
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3.4 DISCUSSION
The aim of these studies was to determine the effects of a range of AEDs on the 
transport of GABA and glutamate, and the metabolism of GABA, in primary cultures 
of rat cortical astrocytes.
3.4.1 Effects of antiepileptic drugs on the transport of GABA in primary 
cultures of rat cortical astrocytes
SVP, VGB, FBM and TGB were all found to significantly reduce the uptake of GABA 
into primary cultures of rat cortical astrocytes. SVP, at all concentrations examined 
was found to reduce the transport of GABA into these cells. This effect is in agreement 
with a previous study, where Nilsson and colleagues (1992) found that acute treatment 
of rat cortical astrocytes with SVP resulted in a decreased affinity for the transport of 
GABA. In addition to the documented inhibition of GABA-T (Lippert et al, 1997; 
Jacob et al, 1990), VGB was also found to reduce the transport of GABA into 
cultured rat astrocytes. This result is consistent with the earlier study carried out in our 
laboratory (Leach et al, 1996), and adds further weight to the proposal that VGB does 
not exert its effects via a single mechanism of action. At all doses examined, FBM 
significantly reduced the uptake of GABA following a one hour exposure. This effect 
has not previously been reported and is in addition to several other possible 
mechanisms of action of the drug. These include enhancement of GABAa receptor- 
mediated responses (Rho et al, 1994), interaction with the strychnine-insensitive 
glycine modulatory site of the NMD A receptor (McCabe et al, 1993) and inhibitory 
effects on voltage-dependent sodium channels (White et al, 1992) and dihydropyridine- 
sensitive calcium channels (Stefani et al, 1996). The reduction in GABA uptake 
exhibited by TGB in this study is in agreement with its documented mechanism of
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action (Suzdak and Jansen, 1995). All other drugs examined were found to have no 
significant effect on the transport of GABA following a one hour exposure. The failure 
to observe significant effects with PB, PHT and CBZ may possibly be due to the large 
standard errors present. This may be a result of batch variation in cultures as all 
graphed results in this chapter are pooled from two separate batches of cultured cells. 
The failure of GBP to exert an effect on GABA uptake in this study is in keeping with 
the experiments of Su and colleagues (1995), who reported that GBP exerted no effect 
on the uptake of GABA in glial or neuronal cultures. The lack of effect of TPM on 
GABA uptake in this study is not in agreement with a recent study conducted in our 
laboratory, where TPM was found to significantly reduce the uptake of GABA into 
primary cultures of rat cortical astrocytes (Sills et al, 1998). The reason for this 
discrepancy is unknown, but may be due to heterogeneity between batches of cultured 
astrocytes. Further work is required to clarify the actions of TPM on GABA uptake.
3.4.2 Effects of antiepileptic drugs on the transport of glutamate in primary 
cultures of rat cortical astrocytes
The lowest three concentrations of PB (1, 3 and 10 pM) examined in this study 
significantly reduced glutamate uptake into cultured rat cortical astrocytes. This effect 
was not, however, evident at the higher concentrations of 30 -  1000 pM. The reason 
for the lack of effect at higher concentrations is unknown, but may indicate that at 
higher concentrations PB is exerting additional effects which may be acting in a 
compensatory manner. It remains possible that a PB-induced e.g. reduction in the 
synthesis or an increase in the metabolism of glutamate would mask any reduction in 
glutamate uptake exerted by the drug. Concentrations of 1 and 30 pM TGB were 
found to exert inhibitory effects on the transport of glutamate into cultured rat
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astrocytes. This effect has not been reported previously. All other concentrations (0.1, 
0.3, 3, 10 and 100 pM) of TGB examined in this study failed to exert a significant 
effect on glutamate transport. Further work is required to clarify the actions of TGB 
on glutamate transport and to determine the clinical relevance of the effect. 
Concentrations of 10, 300 and 1000 pM DGR exerted inhibitory effects on the 
transport of glutamate into cultured rat astrocytes, whereas 1, 3, 30 and 100 pM were 
without effect. The reduction in glutamate uptake induced by DGR has not previously 
been reported. Due to the lack of concentration-dependency of the effect and the large 
standard errors present, it appears unlikely that this effect would contribute to the 
clinical efficacy of the drug. It is possible that this effect is an artefact of the culture 
process and not an AED-induced effect. However, no conclusions can be made 
without further work. All other drugs examined had no significant effect on the 
transport of glutamate following a one hour exposure.
3.4.3 Effects of antiepileptic drugs on the metabolism of GABA in primary 
cultures of rat cortical astrocytes
SVP, VGB, TGB and DGR all significantly reduced the activity of GABA-T in primary 
cultures of rat cortical astrocytes. The reduction induced by SVP has been reported 
previously (Larsson et al, 1986). However, as it occurred only at the highest 
concentration (5000 pM), it may not contribute to the clinical efficacy of the drug. The 
reduction in GABA-T exhibited by VGB reproduced the recognised mechanism of 
action of the drug (Lippert et al, 1977; Jacob et al, 1990). At the highest concentration 
examined (1000 nM), TGB was also found to reduce the activity of the enzyme. This 
effect has not previously been reported. TGB reportedly exhibits its antiepileptic
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actions via a single action, namely inhibition of GABA uptake (Suzdak and Jansen, 
1995). This study would suggest that the drug does not act via a single effect, and that 
it may too possess multiple mechanisms of action. The reduction in enzyme activity 
induced by the experimental drug DGR is a previously unreported effect. DGR reduced 
GABA-T activity at concentrations of 30, 100, 300 and 1000 pM, suggesting that this 
effect may contribute to the clinical actions of the drug. All other AEDs examined had 
no effect on GABA-T activity following a one hour exposure.
3.5 CONCLUSIONS
In conclusion, several of the AEDs examined in this study had previously unreported 
effects on the uptake of GABA and glutamate and on the metabolism of GABA. 
Inhibition of GABA uptake is the reported mechanism of action of TGB, but 
additionally may contribute to the clinical efficacy of SVP, VGB and FBM. It is 
unknown if the reduction in glutamate uptake induced by PB, TGB and DGR is 
involved in the mechanism of action of the drugs. More work is required before any 
firm conclusions can be drawn from this study. The inhibition of GABA-T exerted by 
VGB confirms its recognised mechanism of action, but this effect may also contribute 
to the anticonvulsant effects of DGR. As the reduction in GABA-T activity exerted by 
SVP occurred only at the highest concentration examined, the clinical relevance of this 
effect remains to be determined. The TGB-induced inhibition of GABA-T activity 
suggests that, at higher doses, this may be an additional mechanism of action of the 
drug. This study would suggest that VGB and TGB may not give rise to their 
antiepileptic effects via a single mechanism of action as previously thought, and adds to 
the increasing evidence suggesting that most AEDs have multiple mechanisms of 
action.
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CHAPTER FOUR
EFFECTS OF ANTIEPILEPTIC DRUGS ON GLUTAMINE SYNTHETASE 
ACTIVITY IN MOUSE BRAIN AND PRIMARY CULTURES OF RAT
CORTICAL ASTROCYTES
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4.1 INTRODUCTION
4.1.1 Glutamine synthetase
GS is a key enzyme in the regulation of glutamate neurotransmission in the CNS. It 
catalyzes the synthesis of glutamine from glutamate, and is responsible for the 
detoxification of ammonia in the brain (Meister, 1974). GS is crucial for nitrogen 
homeostasis, as the glutamine formed by this enzyme is a constituent of proteins and 
serves as a nitrogen source for a number of biosynthetic pathways (Meister, 1980). It 
has been demonstrated to be specifically located in the glial fraction of the brain, 
primarily in astrocytes (Martinez-Hemandez et al, 1977; Norenberg, 1979; Norenberg 
and Martinez-Hemandez, 1979). Glutamine which is synthesized in astrocytes via GS 
is then transported into neurones, where it serves as a precursor for the formation of 
the neurotransmitters glutamate and GAB A (Waniewski and Martin, 1986; Waniewski, 
1992). GS is said to be of particular importance in the brain, as although glutamate has 
a number of metabolic enzymes, the only known pathway for the synthesis of 
glutamine is via GS (Cooper et al, 1983). However, the direct uptake of glutamine 
from the blood would provide a non-enzymatic source of glutamine independent of 
GS.
4.1.2 Glutamine synthetase and epilepsy
It is well documented that systemic administration of MSO, the classical inhibitor of 
GS, precipitates seizures in many species (Peters and Tower, 1959; Sellinger et al, 
1984; Swanson et al, 1990). The convulsant activity of MSO has been attributed to its 
inhibition of GS (Meister, 1980), where an increase in glutamate and enhanced 
excitation at neuronal sites is thought to be responsible for seizure activity. It has been
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demonstrated that genetically epilepsy-prone rats have a significantly lower brain GS 
activity than control rats, and this has been proposed to result in the increased seizure 
susceptibility exhibited by these animals (Carl et al, 1993). Seizure-prone gerbils have 
also been shown to exhibit a reduced brain GS activity compared to normal gerbils 
(Laming et al, 1989), which adds further support to the link between a reduction in GS 
and seizure activity.
4.2 AIMS
It has been reported that the AED SVP stimulates GS activity in rat cortical and 
cerebellar homogenates (Nolan et al, 1985; Phelan et al, 1985). In light of the finding 
that GS may be involved in AED action, and the evidence suggesting a role in seizure 
generation, the aim of this study was to investigate the effects of single and repeated 
administration of a range of established, new and experimental AEDs on enzyme 
activity in mouse brain. In addition, due to the glial location of the enzyme, the effects 
of these drugs on GS activity was determined in primary cultures of rat cortical 
astrocytes.
4.3 EXPERIMENTAL PROTOCOLS AND RESULTS
4.3.1 Validation of the glutamine synthetase assay in mouse brain
EXPERIMENTAL PROTOCOL: The brains were removed from two adult male ICR 
mice, and samples prepared for assay as described in section 2.10.3. Samples were 
randomly separated into five groups (n = 4 / group) and MSO (0.1, 0.3, 1, 3 and 10 
mM) was incorporated into the reaction mixture. A sixth group (control; n = 4) of 
samples had no MSO added. GS activity was determined as described in section 2.10.
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RESULTS: All concentrations (0.1, 0.3, 1, 3 and 10 mM) of MSO examined were 
found to significantly (P < 0,05) reduce the activity of GS in mouse brain (figure 38).
4.3.2 Glutamine synthetase activity versus protein concentration in mouse brain
EXPERIMENTAL PROTOCOL: The brains were removed from two adult male ICR 
mice, and samples prepared for assay as described in section 2.10.3. Protein levels 
were determined as described in section 2.6, and diluted appropriately to give the 
following concentrations: 0.5, 1, 1.5, 2, 2.5, 3 and 6 mg/ml (n = 4 / concentration) GS 
activity was determined as described in section 2.10.
RESULTS: A protein concentration of 2 mg/ml was found to be the optimal for GS 
activity in mouse brain (figure 39).
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FIGURE 38. Effect of methionine sulfoximine (MSO; 0.1 - 10 mM) on the activity of 
glutamine synthetase (GS) in mouse brain. Results (n = 4) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.). Statistical significance (* P < 0.05) was determined by one way analysis of 
variance with Dunnett correction for multiple comparisons.
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FIGURE 39. Effect of protein concentration on the activity of glutamine synthetase 
(GS) in mouse brain. Results (n = 4) are expressed as nmol / min / mg protein and 
error bars denote the standard error of the mean (S.E.M.).
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4.3.3 Effects of antiepileptic drugs on glutamine synthetase activity in mouse 
brain
EXPERIMENTAL PROTOCOL: All drugs were prepared daily for i.p. injection. 
SVP, VGB, LTG, GBP, TGB, LEV and DGR were dissolved in 0.9% saline. PB, 
PHT, CBZ and TPM were prepared as a suspension in 0.5% TWEEN 80. FBM was 
suspended in 30 / 70 (v/v) PEG 400 / water. For each of the 12 drug studies, adult
male ICR mice were randomised into six groups (n = 12 / group). The following doses
of drugs were administered:
PB:- 0.1, 0.3, 1,3, 10 and 30 mg/kg 
PHT:- 0.3, 1, 3, 10, 30 and 100 mg/kg 
CBZ:- 0.1, 0.3, 1, 3, 10 and 30 mg/kg 
SVP:- 3, 10, 30, 100, 300 and 1000 mg/kg 
VGB:- 3, 10, 30, 100, 300 and 1000 mg/kg 
LTG:- 0.3, 1, 3, 10, 30 and 100 mg/kg 
FBM:- 1, 3, 10, 30, 100 and 300 mg/kg 
GBP:- 1, 3, 10, 30, 100 and 300 mg/kg 
TPM:- 0.3, 1, 3, 10, 30 and 100 mg/kg 
TGB:- 0.1, 0.3, 1,3, 10 and 30 mg/kg 
LEV:- 1, 3, 10, 30, 100 and 300 mg/kg 
DGR:- 0.3, 1, 3, 10, 30 and 100 mg/kg
For each drug experiment, a control group (n = 12) received the appropriate vehicle 
alone. Four hours after the first dose, six animals from each group were sacrificed, and 
their brains removed and stored at -70°C until required for assay. In the six remaining 
mice from each group, treatment was continued twice daily (8 am and 4 pm) for five 
days, with the exception of VGB which was administered once daily. At four hours
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after the final dose of the repeated treatment regimen, the remaining animals were 
sacrificed and their brains removed and stored at -70°C until required for assay. A 
general four hour time period between injecting and sacrificing was chosen to allow 
time for the drug to be absorbed, enter the brain and an effect on enzyme levels to be 
seen. GS activity was determined as described in section 2.10. TPM doses of 300 and 
1000 mg/kg were not examined in this study due to adverse effects (see chapter 5).
RESULTS: Results are summarised in table 2. Both single and repeated treatments 
with PHT (figure 41) and CBZ (figure 42) significantly (P < 0.05) reduced the activity 
of GS four hours after the final dose. No results are shown for repeated 100 mg/kg 
PHT, as treatment was discontinued in this group due to adverse effects. Single doses 
of PB (figure 40), FBM (figure 46) and TPM (figure 48) were without effect on 
enzyme activity, although repeated administration of these drugs significantly (P < 
0.05) reduced GS activity at 4 h post-administration. Single and repeated treatments 
with SVP (figure 43), VGB (figure 44), LTG (figure 45), GBP (figure 47), TGB 
(figure 49), LEV (figure 50), and DGR (figure 51) were without effect on mouse brain 
GS activity at four hours post-administration.
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FIGURE 40. Effect of phenobarbitone (PB; 0 - 3 0  mg/kg) on mouse brain glutamine 
synthetase (GS) activity at four hours after acute (single dose; left) and chronic (twice 
daily for five days; right) administration. Results (n = 6) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.). Statistical significance (*P < 0.05) was determined by one way analysis of 
variance with Dunnett correction for multiple comparisons.
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FIGURE 41. Effect of phenytoin (PHT; 0 - 1 0 0  mg/kg) on mouse brain glutamine 
synthetase (GS) activity at four hours after acute (single dose; left) and chronic (twice 
daily for five days; right) administration. Results (n = 6) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.). Statistical significance (*P < 0.05) was determined by one way analysis of 
variance with Dunnett correction for multiple comparisons.
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FIGURE 42. Effect of carbamazepine (CBZ; 0 - 3 0  mg/kg) on mouse brain glutamine 
synthetase (GS) activity at four hours after acute (single dose; left) and chronic (twice 
daily for five days; right) administration. Results (n = 6) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.). Statistical significance (*P < 0.05) was determined by one way analysis of 
variance with Dunnett correction for multiple comparisons.
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FIGURE 43. Effect of sodium valproate (SVP; 0 - 1000 mg/kg) on mouse brain 
glutamine synthetase (GS) activity at four hours after acute (single dose; left) and 
chronic (twice daily for five days; right) administration. Results (n = 6) are expressed 
as the mean percentage of mean control values and error bars denote the standard error 
of the mean (S.E.M.).
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FIGURE 44. Effect of vigabatrin (VGB; 0 - 1000 mg/kg) on mouse brain glutamine 
synthetase (GS) activity at four hours after acute (single dose; left) and chronic (once 
daily for five days; right) administration. Results (n = 6) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.).
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FIGURE 45. Effect of lamotrigine (LTG; 0 - 1 0 0  mg/kg) on mouse brain glutamine 
synthetase (GS) activity at four hours after acute (single dose; left) and chronic (twice 
daily for five days; right) administration. Results (n = 6) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.).
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FIGURE 46. Effect of felbamate (FBM; 0 - 300 mg/kg) on mouse brain glutamine 
synthetase (GS) activity at four hours after acute (single dose; left) and chronic (twice 
daily for five days; right) administration. Results (n = 6) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.). Statistical significance (*P < 0.05) was determined by one way analysis of 
variance with Dunnett correction for multiple comparisons.
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FIGURE 47. Effect of gabapentin (GBP; 0 - 300 mg/kg) on mouse brain glutamine 
synthetase (GS) activity at four hours after acute (single dose; left) and chronic (twice 
daily for five days; right) administration. Results (n = 6) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.).
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FIGURE 48. Effect of topiramate (TPM; 0 - 1 0 0  mg/kg) on mouse brain glutamine 
synthetase (GS) activity at four hours after acute (single dose; left) and chronic (twice 
daily for five days; right) administration. Results (n = 6) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.). Statistical significance (*P < 0.05) was determined by one way analysis of 
variance with Dunnett correction for multiple comparisons.
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FIGURE 49. Effect of tiagabine (TGB; 0 - 3 0  mg/kg) on mouse brain glutamine 
synthetase (GS) activity at four hours after acute (single dose; left) and chronic (twice 
daily for five days; right) administration. Results (n = 6) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.).
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FIGURE 50. Effect of levetiracetam (LEV; 0 - 300 mg/kg) on mouse brain glutamine 
synthetase (GS) activity at four hours after acute (single dose; left) and chronic (twice 
daily for five days; right) administration. Results (n = 6) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.).
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FIGURE 51. Effect of desglycinyl-remacemide (DGR; 0 - 100 mg/kg) on mouse brain 
glutamine synthetase (GS) activity at four hours after acute (single dose; left) and 
chronic (twice daily for five days; right) administration. Results (n = 6) are expressed 
as the mean percentage of mean control values and error bars denote the standard error 
of the mean (S.E.M.).
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4.3.4 Validation of the glutamine synthetase assay in primary cultures of rat 
cortical astrocytes
EXPERIMENTAL PROTOCOL: Rat brain tissue was isolated and cultured as 
described in section 2.3. Astrocytes were randomly separated into five groups (n = 4 / 
group) and exposed to 0.1, 0.3, 1, 3 and 10 mM of MSO (the glutamine synthetase 
inhibitor) in BSS. A sixth group (control; n = 4) of astrocytes were exposed to BSS 
alone. After a one hour incubation, cells were assayed for GS activity as described in 
section 2.10.
RESULTS: All concentrations (0.1, 0.3, 1, 3 and 10 mM) of MSO examined were 
found to significantly (P < 0.05) reduce the activity of GS in primary cultures of rat 
cortical astrocytes (figure 52).
4.3.5 Glutamine synthetase activity versus protein concentration in primary 
cultures of rat cortical astrocytes
EXPERIMENTAL PROTOCOL: Rat brain was isolated and cultured as described in 
section 2.3. The existing medium was aspirated and cultures were washed three times 
with 500 pi BSS. Individual wells were scraped and stored at -70°C in 250 pi 5 mM 
imidazole buffer. Cultures were then freeze / thawed three times, and vortex mixed. 
Protein levels were determined as described in section 2.6, and diluted appropriately to 
give the following concentrations: 0.1, 0.2, 0.3, 0.4, 0.5, 0.6 and 0.7 mg/mg (n = 4 / 
concentration). GS activity was determined as described in section 2.10.
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RESULTS: A protein concentration of 0.1 mg/ml was found to be optimal for GS 
activity in primary cultures of rat cortical astrocytes (figure 53).
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FIGURE 52. Effect of methionine sulfoximine (MSO; 0.1 - 10 mM) on the activity of 
glutamine synthetase (GS) in primary cultures of rat cortical astrocytes. Results (n = 4) 
are expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.). Statistical significance (* P < 0.05) was 
determined by one way analysis of variance with Dunnet correction for multiple 
comparisons.
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FIGURE 53. Effect of protein concentration on the activity of glutamine synthetase 
(GS) in primary cultures of rat cortical astrocytes. Results (n = 4) are expressed as 
nmol / min / mg protein and error bars denote the standard error of the mean (S.E.M.).
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4.3.6 Effects of antiepileptic drugs on glutamine synthetase activity in primary 
cultures of rat cortical astrocytes
EXPERIMENTAL PROTOCOL: Rat brain tissue was isolated and cultured as 
described in section 2.3. For each of the 12 drug experiments, cultures were randomly 
separated into seven groups (n = 4 / group), and exposed to the following drugs in 
BSS (stock solutions of CBZ, PHT and FBM were dissolved in 500 pi ethanol prior to 
dilution with BSS):
PB:- 1, 3, 10, 30, 100, 300 and 1000 pM 
PHT:- 1, 3, 10, 30, 100, 300 and 1000 pM 
CBZ:- 1, 3, 10, 30, 100, 300 and 1000 pM 
SVP:- 3,10, 30,100, 300, 1000 and 3000 pM 
VGB:- 1, 3, 10, 30, 100, 300 and 1000 pM 
LTG:- 0.3, 1, 3, 10, 30, 100 and 300 pM 
FBM:- 3, 10, 30, 100, 300, 1000 and 3000 pM 
GBP:- 1, 3, 10, 30, 100, 300 and 1000 pM 
TPM:- 1, 3, 10, 30, 100, 300 and 1000 pM 
TGB:- 0.1, 0.3, 1, 3, 10, 30 and 100 pM 
LEV:- 1, 3, 10, 30, 100, 300 and 1000 pM 
DGR:- 1, 3, 10, 30, 100, 300 and 1000 pM
For each drug experiment, a control group (n = 4) was exposed to BSS alone. After a
one hour incubation, cells were assayed for GS activity as described in section 2.10. A
one hour incubation period (as opposed to a four hour incubation as in the mouse brain 
experiments) was chosen as it was assumed that as the drugs were being applied 
directly to the cells that any effects on enzyme levels would be seen rapidly.
138
RESULTS: Results are summarised in table 3. PB (30, 100 and 300 jiM; figure 54) 
significantly {P < 0.05) reduced the activity of GS in primary cultures of rat cortical 
astrocytes. PHT (figure 55), CBZ (figure 56), SVP (figure 57), VGB (figure 58), LTG 
(figure 59), FBM (figure 60), GBP (figure 61), TPM (figure 62), TGB (figure 63), 
LEV (figure 64) and DGR (figure 65) were all found to have no significant effect on 
the activity of GS in primary cultures of rat cortical astrocytes following a one hour 
exposure.
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FIGURE 54. Effect of phenobarbitone (PB; 0 - 1000 pM) on the activity of glutamine 
synthetase (GS) in primary cultures of rat cortical astrocytes. Results (n = 4) are 
expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.). Statistical analysis was determined by one way 
analysis of variance with Dunnett correction for multiple comparisons.
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FIGURE 55. Effect of phenytoin (PHT; 0 - 1000 pM) on the activity of glutamine 
synthetase (GS) in primary cultures of rat cortical astrocytes. Results (n = 4) are 
expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 56. Effect of carbamazepine (CBZ; 0 - 1000 pM) on the activity of 
glutamine synthetase (GS) in primary cultures of rat cortical astrocytes. Results (n = 4) 
are expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 57. Effect of sodium valproate (SVP; 0 - 3000 pM) on the activity of 
glutamine synthetase (GS) in primary cultures of rat cortical astrocytes. Results (n = 4) 
are expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 58. Effect of vigabatrin (VGB; 0 - 1000 jliM ) on the activity of glutamine 
synthetase (GS) in primary cultures of rat cortical astrocytes. Results (n = 4) are 
expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 59. Effect of lamotrigine (LTG; 0 - 300 jiM ) on the activity of glutamine 
synthetase (GS) in primary cultures of rat cortical astrocytes. Results (n = 4) are 
expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 60. Effect of felbamate (FBM; 0 - 3000 pM) on the activity of glutamine 
synthetase (GS) in primary cultures of rat cortical astrocytes. Results (n = 4) are 
expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 61. Effect of gabapentin (GBP; 0 - 1000 pM) on the activity of glutamine 
synthetase (GS) in primary cultures of rat cortical astrocytes. Results (n = 4) are 
expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 62. Effect of topiramate (TPM; 0 - 1000 pM) on the activity of glutamine 
synthetase (GS) in primary cultures of rat cortical astrocytes. Results (n = 4) are 
expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 63. Effect of tiagabine (TGB; 0 - 1 0 0  pM) on the activity of glutamine 
synthetase (GS) in primary cultures of rat cortical astrocytes. Results (n = 4) are 
expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 64. Effect of levetiracetam (LEV; 0 - 1000 |iM) on the activity of glutamine 
synthetase (GS) in primary cultures of rat cortical astrocytes. Results (n = 4) are 
expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 65. Effect of desglycinyl-remacemide (DGR; 0 - 1000 fiM) on the activity of 
glutamine synthetase (GS) in primary cultures of rat cortical astrocytes. Results (n = 4) 
are expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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TABLE 2. Effects of antiepileptic drugs on the activity of glutamine synthetase in 
mouse brain following acute (single dose) and chronic (twice daily for five days) 
administration - summary of results (NS = no significant effect, SIG i  = significant 
reduction p  < 0.05).
Glutamine Synthetase Activity 
AED Acute Chronic
NS 1 - 3 0  mg/kg SIG 4-Phenobarbitone 
(0.1 - 30 mg/kg)
Phenytoin 
(0.3 - 100 mg/kg)
Carbamazepine 
(0.1 - 30 mg/kg)
1 -  100 mg/kg SIG <1 3 -  30 mg/kg SIG i  
1 - 3 0  mg/kg SIG -I 3 - 3 0  mg/kg SIG
Sodium valproate NS
(3 - 1000 mg/kg)
Vigabatrin NS
(3 - 1000 mg/kg)
Lamotrigine NS
(0.3 -100 mg/kg)
Felbamate NS
(1 - 300 mg/kg)
Gabapentin NS
(1 - 300 mg/kg)
Topiramate NS
(0.3 - 100 mg/kg)
Tiagabine NS
(0.1 - 30 mg/kg)
Levetiracetam NS
(1 - 300 mg/kg)
Desglycinyl-remacemide NS
(0.3 -100 mg/kg)
NS
NS
NS
1 -300  mg/kg SIG I
NS
3 -  100 mg/kg SIG I
NS
NS
NS
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TABLE 3. Effects of antiepileptic drugs on the activity of glutamine synthetase in 
primary cultures of rat cortical astrocytes following a one hour exposure - summary of 
results (NS = no significant effect, SIG i  = significant reductionp  < 0.05).
AED Glutamine Synthetase Activity
Phenobarbitone 30 -  300 pM SIG 4*
(1 - 1000 pM)
Phenytoin NS
(1 - 1000 pM)
Carbamazepine NS
(1 - 1000 pM)
Sodium valproate NS
(3 - 3000 pM)
Vigabatrin NS
(1 - 1000 pM)
Lamotrigine NS
(0.3 - 300 pM)
Felbamate NS
(3 - 3000 pM)
Gabapentin NS
(1 - 1000 pM)
Topiramate NS
(1 - 1000 pM)
Tiagabine NS
(0.1 - 100 pM)
Levetiracetam NS
(1 - 1000 pM)
Desglycinyl-remacemide NS
(1 - 1000 pM)
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4.4 DISCUSSION
In light of the importance of GS in regulating glutamate neurotransmission, and it’s 
possible involvement in seizure generation and AED action, the effects of single and 
repeated administration of a range of AEDs on its activity was determined in mouse 
brain. Additionally, as the enzyme is specifically located in astrocytes, the effects of 
these AEDs on GS activity was also examined in primary cultures of rat cortical 
astrocytes.
4.4.1 Effects of antiepileptic drugs on glutamine synthetase activity in mouse 
brain
Both single and repeated treatments with PHT and CBZ, and repeated administration 
of PB, FBM and TPM significantly and dose-dependently reduced the activity of GS. 
Given that an inhibition of this enzyme results in a diminished capacity for the brain to 
metabolize, and thereby detoxify glutamate and ammonia, it would appear unlikely that 
the reduction in activity demonstrated contributes to the antiepileptic actions of these 
drugs. Accumulation of glutamate and ammonia may be expected to facilitate neuronal 
excitation, and precipitate seizures, as seen with the GS inhibitor MSO. It is therefore 
possible that the inhibition of GS may decrease anticonvulsant effect or contribute to 
the toxicity of these compounds. Interestingly, those drugs with an inhibitory action on 
the enzyme are those which most frequently exhibit CNS-related toxicity, such as 
ataxia, sedation, dizziness and cognitive impairment (Rogawski and Porter, 1990; 
Dichter and Brodie, 1996).
Both single and repeated treatments with SVP, VGB, LTG, GBP, TGB, LEV and 
DGR were found to have no effect on the activity of GS, suggesting that an action on
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the enzyme is not involved in the antiepileptic or toxic mechanisms of these drugs. The 
failure to demonstrate the SVP-induced potentiation reported by other groups (Nolan 
et al, 1985; Phelan et al, 1985) may have been due to differences in experimental 
design. The other groups added SVP directly to the enzyme incubation medium and 
observed an in vitro response, whereas in this study, I have examined the ex vivo 
effects of the AEDs on enzyme activity. In a study using primary cultures of rat 
cortical astrocytes, Collins and colleagues (1994) reported that when added to intact 
cultures, SVP significantly reduced that activity of GS. However, when incorporated 
directly into the assay tubes, SVP was found to stimulate enzyme activity.
4.4.2 Toxicity of antiepileptic drugs
It is well documented that AED treatment may worsen seizures, either by aggravating 
pre-existing ones, or by inducing new seizure types (Troupin and Ojemann, 1975; 
Osorio et al, 1989; Murphy et al, 1991; Loiseau, 1998; Perucca et al, 1998). This 
phenomenon is referred to as paradoxical intoxication and is most commonly reported 
in patients treated with PHT (Osorio et al, 1989; Murphy et al, 1991; Perucca, et al, 
1998), and CBZ (Troupin and Ojemann, 1975; Perucca et al, 1998). Experiments on 
glial cell cultures have suggested that at higher PHT concentrations, the cells appear to 
be less able to regulate extracellular potassium (White et al, 1985). This has been 
proposed to partially explain the excitatory effects of the drug seen clinically at high 
therapeutic doses. It has also been reported that PB (Perucca et al, 1998), FBM (Wolff 
et al, 1994) and TPM (Eiger et al, 1998) may increase seizure frequency in some 
patients. From this evidence, it is possible that the occurrence of paradoxical 
intoxication may be related to the reduction in GS activity exerted by these drugs, in 
particular CBZ and PHT, the two most commonly linked to paradoxical intoxication,
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and the only AEDs found to have both acute and chronic effects on GS activity in this 
study.
As with the incidence of paradoxical intoxication, the tendency to reduce enzyme 
activity is more prominent in the established AEDs, with a reduction in GS only 
evident following repeated administration with two of the newer drugs, FBM and 
TPM. The most marked reduction in enzyme activity was evident following single and 
repeated dosing with two of the established AEDs, CBZ and PHT, which are known to 
exert their antiepileptic effects via blockade of voltage-dependent sodium channels 
(Rogawski and Porter, 1990). Interestingly, LTG, a new AED Whose antiepileptic 
mechanism of action is also thought to be mediated via blockade of sodium channels 
(Cheung et al, 1992), had no effect on the activity of GS. Similarly, DGR, the 
experimental drug with proposed sodium channel blocking effects (Wamil et al, 1996) 
failed to influence the activity of the enzyme.
It is unclear why CBZ and PHT reduced GS activity following a single dose, while no 
other drug examined had acute effects. The mechanism of the inhibition may differ 
between the AEDs with acute effects and those with effects only after chronic 
treatment. It is possible that CBZ and PHT are interacting with the active site of the 
enzyme, resulting in direct inhibition evident following a single dose. PB, FBM and 
TPM, the AEDs which had effects following only repeated administration, may be 
reducing enzyme activity via an indirect mechanism, such as an effect on protein 
synthesis or gene expression. The possibility that these AEDs are actually reducing the 
amount of enzyme present and not simply inhibiting it cannot be excluded without 
further investigation. The inhibition may also be indirect, in that it is occurring
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secondary to a change in the concentration of a neurotransmitter, or activity of another 
enzyme in the brain. Such effects may take time to develop, therefore only becoming 
apparent following repeated administration. Each of these possibilities require further 
detailed investigation in order to determine the nature of the inhibition of GS.
4.4.3 Effects of antiepileptic drugs on glutamine synthetase activity in primary 
cultures of rat cortical astrocytes
Of the twelve AEDs examined, only PB was found to significantly reduce the activity 
of GS in primary cultures of rat cortical astrocytes. This effect is consistent with the 
reduction in enzyme activity induced by PB in mouse brain. The effect of PB on the 
activity of GS in cultured astrocytes has been examined previously in other studies. In 
primary cultures of mouse cortical astrocytes, a seven day exposure to PB was found 
to have no effect on GS activity (Swaiman and Machen, 1991). In contrast to this, a 
more recent study examined the effects of PB in rat brain aggregate cultures, and 
reported a slight increase in the activity of GS following an eight day exposure to the 
drug (Schilter et al, 1995). More work is required to clarify the effects of PB on GS 
activity in cultured cells.
PHT, CBZ, FBM and TPM significantly reduced GS activity in mouse brain, but all 
failed to exert any significant effect on enzyme activity in the cultured cells. As GS is 
specifically located in glia, it is unclear why these AEDs which had effects in whole 
brain had no effect in the cultured cells. A previous study using primary cultures of rat 
cortical astrocytes found that when SVP (1.2 mM) was incorporated into the culture 
medium, there was no significant effect noted until day two of exposure, where the 
activity of GS was reduced. Enzyme activity was further reduced after three and four
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days in culture (Collins et al, 1994). This would suggest that the one hour exposure of 
the AEDs in this study may not be sufficient to exert an effect, and that a longer 
incubation period should be examined. However, in primary cultures of mouse cortical 
astrocytes, a seven day exposure to PHT was still without effect on the activity of GS 
(Swaiman and Machen, 1991). Similarly, in rat brain aggregate cultures, eight day 
exposures to CBZ and SVP were without significant effect on the activity of the 
enzyme (Schilter et al, 1995). More work is therefore required to determine the 
exposure time of the drugs and enzyme activity.
Another possible explanation for the lack of effect of PHT, CBZ, FBM and TPM in the 
astrocyte cultures could be due to a species difference. It remains possible that the 
drugs are effective at reducing enzyme activity in mouse brain and that no effect is seen 
in the astrocyte cultures as they are derived from rat brain. It may be useful to carry 
out experiments using astrocytes cultured from mouse brain to investigate the 
significance of species difference. Alternatively, the lack of effect of these AEDs in the 
cultured astrocytes may simply be due to the large SEM values observed in these 
experiments. It is possible that variability between astrocyte cultures is preventing any 
true AED-induced effects from being observed.
4.5 CONCLUSIONS
In conclusion, the reduction in GS activity in mouse brain following both single and 
repeated treatments with PHT and CBZ, and repeated treatments with PB, FBM and 
TPM is unlikely to be related to the antiepileptic actions of these drugs. It is possible 
that inhibition of this enzyme may contribute to the toxicity of these drugs, particularly 
CNS-related adverse effects. It is also possible that this reduction in GS activity may be
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contributing to the phenomenon of paradoxical intoxication seen clinically with these 
drugs in some patients. The inhibition in GS activity induced by PB in the astrocyte 
cultures further supports the suggestion that this effect may be implicated in its clinical 
toxicity. However, the results obtained from the cell culture experiments are 
inconclusive and further work is required.
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CHAPTER FIVE
GABA- AND GLUTAMATE-RELATED NEUROCHEMICAL EFFECTS OF 
THE NEW ANTIEPILEPTIC DRUGS FELBAMATE, TOPIRAMATE AND 
LEVETIRACETAM IN MOUSE BRAIN
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5.1 INTRODUCTION
In recent years, a significant number of new drugs for the treatment of epilepsy have 
entered clinical trials or have been licensed for use. FBM, TPM and LEV are three 
novel AEDs, at various stages in development, but all whose precise mechanism of 
action remains to be determined.
5.1.1 Felbamate
A number of mechanisms for the antiepileptic and neuroprotective effects of FBM have 
been proposed, but the precise action, or actions, of the drug remain to be determined. 
FBM has demonstrated potentiation of inhibitory GABA neurotransmission as well as 
attenuation of glutamate responses. FBM enhances GABAa receptor-mediated chloride 
currents in rat hippocampal neurones (Rho et al, 1994), and has been shown to interact 
with the strychnine-insensitive glycine modulatory site of the NMDA receptor 
(McCabe et al, 1993; McCabe et al, 1998). However, in ligand binding studies, FBM 
failed to interact with the GABAa receptor complex (Ticku et al, 1991). It has been 
reported that a sub-protective dose of FBM could potentiate the anticonvulsant effects 
of diazepam against seizures induced by MES, PTZ and isoniazid (Gordon et al, 
1991). In addition to its effects on amino acid systems, FBM has been reported to 
block voltage-dependent sodium channels (White et al, 1992) and dihydropyridine- 
sensitive calcium channels (Stefani et al, 1996).
5.1.2 Topiramate
As yet the precise mechanism of TPM’s anticonvulsant activity remains to be 
established. It appears to possess multiple mechanisms of action including blockade of 
voltage-activated sodium channels (Coulter et al, 1993; Kawasaki et al, 1996; Zona et
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al, 1997; Wu et al, 1998) and inhibitory effects on kainate-induced responses (Coulter 
et al, 1995). In addition, TPM reportedly potentiates responses to GAB A at the 
GABAa receptor (White et al, 1995a; White et al, 1997) and may exert a weak 
carbonic anhydrase inhibition (Shank et al, 1994). Recent evidence has also suggested 
that TPM may reduce abnormally high levels of glutamate and aspartate in the 
hippocampus of spontaneously epileptic rats (Kanda et al, 1996).
5.1.3 Levetiracetam
The precise mechanism of action of LEV remains to be determined. Its anticonvulsant 
activity is highly stereospecific. However, no significant affinity for known receptors 
has been found and the drug fails to interact with ion channel sites in the brain (Noyer 
et al, 1995). LEV has, however, been proposed to act via a specific binding site in 
CNS membranes, which has not yet been characterized, where it is weakly displaced by 
PB and PTZ, suggesting it may be GABA-related (Noyer et al, 1995). In addition, a 
recent study reported that treatment with LEV induced alterations in GABA 
metabolism and turnover in discrete areas of rat brain (Loscher et al, 1996).
5.2 AIMS
Due to lack of precise mechanism of action data and reported effects on GABA and 
glutamate neurotransmitter systems, the aim of this study was to investigate the effects 
of single and repeated administration of FBM, TPM and LEV on GABA- and 
glutamate-related neurochemistry in mouse brain.
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5.3 EXPERIMENTAL PROTOCOLS AND RESULTS
5.3.1 Neurochemical effects of felbamate in mouse brain
EXPERIMENTAL PROTOCOL: FBM was prepared daily for i.p. injection as a 
suspension in 30 / 70 (v/v) PEG 400 / water. In both single and multiple dose studies, 
adult male ICR mice were randomised into five treatment groups (n = 12 / group) and 
administered FBM 1, 3, 10, 30 and 100 mg/kg. (The 300 mg/kg dose which was 
previously used in chapter 4 could not be used here as there was not enough drug left). 
A sixth group of 12 mice (control) received vehicle alone. In the multiple dose phase of 
the study, treatment was continued twice daily (8 am and 4 pm) for five days. (A five 
day study with twice daily dosing was chosen to avoid weekend injections). In both 
phases, four hours after the final dose, the animals were sacrificed and their brains 
removed. Brains were divided into two hemispheres by a midline incision and stored at 
-70°C until required for assay. Six left hemispheres from each of the groups (single and 
multiple dose; control and drug treated) were assayed for GABA concentrations as 
described in section 2.11. Glutamate and glutamine were measured simultaneously in 
six right hemispheres from each group as described in section 2.11. The remaining six 
left hemispheres from each group were assayed for GABA-T activity as described in 
section 2.9., and the remaining six right hemispheres from each group were assayed for 
GAD activity as described in section 2.12.
RESULTS: At all doses examined, both single and repeated treatments with FBM 
were without significant effect on the concentrations of GABA (figure 66), glutamate
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(figure 67) or glutamine (figure 68). Similarly, single and repeated treatments were 
without effect on the activities of GABA-T (figure 69) or GAD (figure 70).
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FIGURE 66. Effect of felbamate (FBM; 0 - 1 0 0  mg/kg) on mouse brain GABA 
concentration at four hours after acute (single dose; left graph) and chronic (twice 
daily for five days; right graph) administration. Results (n = 6) are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.).
165
Acute ChronicC150I
125
= SO 1 
(D 0 1 10 100 0 100
FBM dose (mg/kg)
FIGURE 67. Effect of felbamate (FBM; 0 - 1 0 0  mg/kg) on mouse brain glutamate 
concentration at four hours after acute (single dose; left graph) and chronic (twice 
daily for five days; right graph) administration. Results (n = 6) are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.).
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FIGURE 68. Effect of felbamate (FBM; 0 - 1 0 0  mg/kg) on mouse brain glutamine 
concentration at four hours after acute (single dose; left graph) and chronic (twice 
daily for five days; right graph) administration. Results (n = 6) are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.).
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FIGURE 69. Effect of felbamate (FBM; 0 - 1 0 0  mg/kg) on mouse brain GABA- 
transaminase (GABA-T) activity at four hours after acute (single dose; left graph) and 
chronic (twice daily for five days; right graph) administration. Results (n = 6) are 
expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 70. Effect of felbamate (FBM; 0-100 mg/kg) on mouse brain glutamic acid 
decarboxylase (GAD) activity at four hours after acute (single dose; left graph) and 
chronic (twice daily for five days; right graph) administration. Results (n = 6) are 
expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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5.3.2 Neurochemical effects of topiramate in mouse brain
EXPERIMENTAL PROTOCOL: TPM was prepared daily for i.p. injection as a 
suspension in 0.5% TWEEN 80. In both single and multiple dose studies, adult male 
ICR mice were randomised into nine treatment groups (n = 20 / group), and 
administered TPM 0.1, 0.3, 1, 3, 10, 30, 100, 300 and 1000 mg/kg. A tenth group of 
20 mice (control) received vehicle alone. In the multiple dose phase of the study, 
treatment was continued once daily for eight days. In both phases, four hours after the 
final dose, the animals were sacrificed and their brains removed. Brains were divided 
into two hemispheres by a midline incision and stored at -70°C until required for assay. 
Ten left hemispheres from each of the groups (single and multiple dose; control and 
drug treated) were assayed for GABA concentrations as described in section 2.11. 
Glutamate and glutamine were measured simultaneously in ten right hemispheres from 
each group as described in section 2.11. The remaining ten left hemispheres from each 
group were assayed for GABA-T activity as described in section 2.9., and the 
remaining ten right hemispheres from each group were assayed for GAD activity as 
described in section 2.12.
RESULTS: Repeated administration of 1000 mg/kg TPM resulted in the death of all 
20 animals prior to the end of the eight day treatment period. At all doses examined, 
both single and repeated treatments with TPM were without significant effect on the 
concentrations of GABA (figure 71), glutamate (figure 72) or glutamine (figure 73). 
Similarly, single and repeated treatments were without effect on the activities of 
GABA-T (figure 74) or GAD (figure 75).
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FIGURE 71. Effect of topiramate (TPM; 0 - 1000 mg/kg) on mouse brain GABA 
concentration at four hours after acute (single dose; left graph) and chronic (once daily 
for eight days; right graph) administration. Results (n = 10) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.).
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FIGURE 72. Effect of topiramate (TPM; 0 - 1000 mg/kg) on mouse brain glutamate 
concentration at four hours after acute (single dose; left graph) and chronic (once daily 
for eight days; right graph) administration. Results (n = 10) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.).
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FIGURE 73. Effect of topiramate (TPM; 0 - 1000 mg/kg) on mouse brain glutamine 
concentration at four hours after acute (single dose; left graph) and chronic (once daily 
for eight days; right graph) administration. Results (n = 10) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.).
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FIGURE 74. Effect of topiramate (TPM; 0 - 1000 mg/kg) on mouse brain GABA- 
transaminase (GABA-T) activity at four hours after acute (single dose; left graph) and 
chronic (once daily for eight days; right graph) administration. Results (n = 10) are 
expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 75. Effect of topiramate (TPM; 0 - 1000 mg/kg) on mouse brain glutamic 
acid decarboxylase (GAD) activity at four hours after acute (single dose; left graph) 
and chronic (once daily for eight days; right graph) administration. Results (n = 10) are 
expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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5.3.3 Neurochemical effects of levetiracetam in mouse brain
EXPERIMENTAL PROTOCOL: LEV was prepared daily for i.p. injection in 0.9% 
saline. In both single and multiple dose studies, adult male ICR mice were randomised 
into six treatment groups (n = 12 / group), and administered LEV 1,3, 10, 30, 100 and 
300 mg/kg. A seventh group of 12 mice (control) received vehicle alone. In the 
multiple dose phase of the study, treatment was continued twice daily (8 am and 4 pm) 
for five days. (A five day study with twice daily dosing was chosen to avoid weekend 
injections). In both phases, four hours after the final dose, the animals were sacrificed 
and their brains removed. Brains were divided into two hemispheres by a midline 
incision and stored at -70°C until required for assay. Six left hemispheres from each of 
the groups (single and multiple dose; control and drug treated) were assayed for 
GABA concentrations as described in section 2.11. Glutamate and glutamine were 
measured simultaneously in six right hemispheres from each group as described in 
section 2.11. The remaining six left hemispheres from each group were assayed for 
GABA-T activity as described in section 2.9, and the remaining six right hemispheres 
from each group were assayed for GAD activity as described in section 2.12.
RESULTS: At all doses examined, both single and repeated treatments with LEV were 
without significant effect on the concentrations of GABA (figure 76), glutamate (figure 
77) or glutamine (figure 78). Similarly, single and repeated treatments were without 
effect on the activities of GABA-T (figure 79) or GAD (figure 80).
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FIGURE 76. Effect of levetiracetam (LEV; 0 - 300 mg/kg) on mouse brain GABA 
concentration at four hours after acute (single dose; left graph) and chronic (twice 
daily for five days; right graph) administration. Results (n = 6) are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.).
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FIGURE 77. Effect of levetiracetam (LEV; 0 -  300 mg/kg) on mouse brain glutamate 
concentration at four hours after acute (single dose; left graph) and chronic (twice 
daily for five days; right graph) administration. Results (n = 6) are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.),
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FIGURE 78. Effect of levetiracetam (LEV; 0 - 300 mg/kg) on mouse brain glutamine 
concentration at four hours after acute (single dose; left graph) and chronic (twice 
daily for five days; right graph) administration. Results (n = 6) are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.).
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FIGURE 79. Effect of levetiracetam (LEV; 0 - 300 mg/kg) on mouse brain GABA- 
transaminase (GABA-T) activity at four hours after acute (single dose; left graph) and 
chronic (twice daily for five days; right graph) administration. Results (n = 6) are 
expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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FIGURE 80. Effect of levetiracetam (LEV; 0 - 300 mg/kg) on mouse brain glutamic 
acid decarboxylase (GAD) activity at four hours after acute (single dose; left graph) 
and chronic (twice daily for five days; right graph) administration. Results (n = 6) are 
expressed as the mean percentage of mean control values and error bars denote the 
standard error of the mean (S.E.M.).
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5.4 DISCUSSION
As yet, the precise mechanisms of action of FBM, TPM and LEV remain to be 
determined. Several reports have suggested that actions on GABAergic and/or 
glutamatergic systems contribute to the antiepileptic effects of these drugs. The aim of 
this study was, therefore, to investigate the GABA- and glutamate-related 
neurochemical effects of the drugs in mouse brain.
5.4.1 Effects of single and repeated administration of felbamate on GABA- and 
glutamate-related neurochemistry in mouse brain
FBM was without significant effect on the concentrations of GABA, glutamate and 
glutamine following both single and repeated administration. Similarly, there was no 
effect on the activity of the enzyme GABA-T. Following repeated treatment with 
higher doses of FBM, there was a trend toward increased GAD activity. However, this 
effect failed to reach statistical significance and was observed at supra-therapeutic 
doses which would question its clinical relevance. Taken together, these results would 
suggest that the antiepileptic effects of FBM are not mediated by an action on the 
neurotransmitters and/or enzymes of the GABAergic and glutamatergic systems.
The lack of effect of repeated FBM administration on glutamate and glutamine 
concentrations in mouse brain would not appear to be in agreement with the results 
obtained with FBM in the GS study. Repeated administration of FBM (1 -  300 mg/kg) 
was previously shown (chapter 4) to significantly reduce the activity of GS. As GS is 
the enzyme responsible for the synthesis of glutamine from glutamate, such a reduction 
in its activity would possibly be expected to result in reduced glutamine and increased 
glutamate brain concentrations. However, this was not found to be the case, and
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suggests that the decrease in GS activity is being compensated for by some other 
mechanism, such as an increase in the clearance of glutamate from the synapse or an 
increase in the synthesis of glutamine from e.g. glucose. Further work is required to 
clarify these conflicting results.
Despite the inability of FBM to influence GABAergic neurochemistry in this study, and 
its reported failure in radioligand binding studies to interact with the GABAa receptor 
complex (Ticku et al, 1991), voltage-clamp recordings from cultured rat hippocampal 
(Rho et al, 1994) and mouse cortical neurones (Kume et al, 1996) have clearly 
demonstrated a FBM-induced enhancement of GABA responses. In addition, Gordon 
and colleagues (1991) reported that a sub-protective dose of FBM could potentiate the 
anticonvulsant effects of diazepam against seizures induced by MES, PTZ and 
isoniazid.
In addition to effects on the GABA system, there is also evidence to suggest that FBM 
may interfere with glutamate-mediated neurotransmission. In mice, it effectively 
prevented seizures induced by NMDA and quisqualate (White et al, 1992), suggesting 
activity on the glutamatergic system. Although reports regarding the interaction of 
FBM within the ion channel of the NMDA receptor are conflicting (White et al, 1992; 
Subramaniam et al, 1995), the drug has been shown to inhibit the binding of 5,7- 
dichlorokynurenic acid to the strychnine-insensitive glycine site on the extracellular 
domain of this receptor (McCabe et al, 1993). White and colleagues (1995b) have 
similarly demonstrated a modulatory effect of the drug at this site. The effective 
concentrations of FBM were comparable in both studies and correlated closely with 
those proposed to evoke the antiepileptic and neuroprotective actions of the drug.
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Thus, despite the failure of FBM to influence glutamate-related neurochemistry in this 
study, there is substantial evidence to suggest that it has the ability to modulate the 
activity of the NMDA sub-type of glutamate receptor and that such an effect may be 
relevant to its clinical actions.
The lack of effect of FBM on GABA- and glutamate-related neurotransmission in this 
study may be due to the limitations of the methods employed. It is possible that 
regional changes in amino acid concentrations or enzyme activities remained 
undetected due to the volume of tissue analyzed. Similarly, effects on neurotransmitter 
turnover cannot be excluded. It may, therefore, be beneficial to carry out a more 
detailed neurochemical study, employing techniques such as microdissection and 
microdialysis to clarify this issue. It is worth noting that the methods used in this study 
have been used in our laboratory to highlight previously unreported neurochemical 
effects of GBP (Leach et al, 1997a) and DGR (Leach et al, 1997b).
5.4.2 Effects of single and repeated administration of topiramate on GABA- 
and glutamate-related neurochemistry in mouse brain
TPM failed to influence the concentrations of GABA, glutamate or glutamine 
following both single and repeated treatment at all doses examined. Similarly, it was 
without significant effect on the activities of GABA-T and GAD. These results would 
suggest that an interaction with GABA- and glutamate-related neurochemical 
parameters is not involved in the mechanism of action of the drug.
TPM has recently been reported to increase brain GABA levels in healthy volunteers 
(Kuzniecky et al, 1998) and in patients with epilepsy (Petroff et al, 1999). This effect
has been proposed to contribute to the antiepileptic effects of the drug. However, the 
increase in brain GABA concentrations could not be demonstrated in mice treated with 
TPM in this study, and may reflect a species difference. As TPM has been shown to 
potentiate responses to GABA at the GABAa receptor (White et al, 1995a; White et 
al, 1997), and has inhibitory actions at the AMPA / kainate subtype of glutamate 
NMDA receptors (Coulter et al, 1995), effects on these amino acid systems cannot be 
excluded. As with the lack of effect of FBM in this study, it is possible that TPM may 
be exerting regional effects on the amino acid systems, and that these effects are being 
masked by the volume of tissue employed for analyses.
There are a number of studies demonstrating TPM-induced blockade of voltage- 
dependent sodium channels (Coulter et al, 1993; Kawasaki et al, 1996; Zona et al, 
1996). In experimental animal models, TPM is effective against MES (Shank et al, 
1994), audiogenic (Nakamura et al, 1994) and amygdaloid-kindled seizures (Wauquier 
and Zhou, 1996). It has only weak activity in the subcutaneous PTZ test (Shank et al, 
1994), exhibiting a profile similar to that of PHT and CBZ, the AEDs which act at 
voltage dependent sodium channels. However, TPM clearly differs from these 
established compounds, in that it has a wider range of in vitro actions and a broader 
clinical spectrum of anticonvulsant activity. Therefore, despite the results of this study 
indicating that the drug does not act via effects on the amino acid systems, the 
suggestion that TPM has a multifactorial mode of action cannot be excluded.
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5.4.3 Effects of single and repeated administration of levetiracetam on GABA- 
and glutamate-related neurochemistry in mouse brain
LEV failed to influence the concentrations of GABA, glutamate and glutamine in 
mouse brain following both single and repeated administration. It was similarly without 
significant effect on the activities of GABA-T and GAD. These results imply that the 
mechanism of action of the drug does not involve an action on these amino acid 
systems.
LEV has been proposed to act via a novel binding site in the brain where it is weakly 
displaced by several other AEDs and GABA-related substances (Noyer et al, 1995), 
and has been shown to reduce bicuculline-induced hyperexcitability in rat hippocampal 
CA3. Margineanu and Wulfert (1995) have, however, proposed that this effect is 
manifested via a non-GABAergic mechanism. In addition, the efficacy of the drug in 
GAERS genetic model of absence seizures (Gower et al, 1995) lends further weight to 
the non-GABAergic theory of action, as it is thought that drugs which exert their 
effects via a GABAergic mechanism of action exacerbate the spontaneous discharges 
observed in this model (Vergnes et al, 1984).
The efficacy of LEV against MES (Gower et al, 1992), audiogenic seizures in 
genetically epilepsy-prone rats (Gower et al, 1995) and amygdaloid-kindled seizures 
(Loscher and Honack, 1993) might suggest a similar profile to those AEDs which 
exhibit inhibitory actions at voltage-sensitive sodium channels (Loscher and Schmidt, 
1988; Rogawski and Porter, 1990). There is, however, no evidence at present to 
suggest that LEV has any activity at this site (Saccan and Lloyd, 1994). In summary, it 
appears that LEV has a wide spectrum of anticonvulsant activity and a multifactorial
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mode of action. However, the results of this study are inconclusive and the mechanism 
by which it exerts its anticonvulsant activity remains to be determined.
5.5 CONCLUSIONS
In conclusion, FBM, TPM and LEV failed to influence several GABA- and glutamate- 
related neurochemical parameters in mouse brain, suggesting that such actions do not 
contribute to the antiepileptic effects of these drugs. However, in light of their broad 
anticonvulsant profiles, it remains possible that all three possess multiple mechanisms 
of action and effects on GABA and glutamate neurochemistry cannot be ruled out 
without further more detailed investigations.
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CHAPTER SIX
EFFECTS OF COMBINATIONS OF NEW ANTIEPILEPTIC DRUGS ON 
PENTYLENETETRAZOL-INDUCED SEIZURES IN MICE
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6.1 INTRODUCTION
6.1.1 Monotherapy versus polytherapy
Management of seizures with a single AED is the treatment regimen of choice 
(Schmidt and Gram, 1995), and up to 70% of newly diagnosed patients can be 
effectively treated with a single AED (Perucca, 1997). However, it is estimated that in 
around 30% of patients suffering from epilepsy, treatment with a single AED does not 
provide satisfactory seizure control, and treatment with two or more AEDs is required 
- with many still not seizure free (Ferrendelli, 1995; Brodie and Dichter, 1996). In 
recent years, an increase in polypharmacy has been observed as many of the newer 
AEDs are introduced as add-on therapy (Genton and Roger, 1997). Although the 
practice of combining anticonvulsant medication is common, the theoretical basis for 
this practice has not been studied systematically (Chez et al, 1994). There is 
insufficient clinical data available to support the use of particular efficacious 
combinations of AEDs (Brodie, 1992a).
Many of the older drugs have previously been examined in combination using 
experimental animal models, such as PHT and VPA (Chez et al, 1994), VPA and PB 
(Bourgeois, 1988a), VPA and CBZ (Bourgeois, 1988a), VPA and ESM (Bourgeois, 
1988b), and CBZ and PB (Bourgeois and Wad, 1988). Combinations of VPA and CZP 
(Mireles and Leppik, 1985), and VPA and ESM - for the treatment of absence seizures 
(Rowan et al, 1983) have been used clinically. However, the established AEDs are not 
ideal candidates for polytherapy (Schmidt and Gram, 1995), with complex and 
overlapping mechanisms of action, and frequent drug interactions (Brodie, 1992a). It is 
thought that combinations of the newer AEDs, with more predictable pharmacokinetics
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and fewer drug interactions, may prove to be better tolerated (Leach, 1997). Recently 
it was noted that LTG with TPM appeared to be a useful combination in several 
patients in our research group. In support of this observation, a combination of LTG 
with TPM was also found to protect mice from PTZ-induced seizures (Stephen et al, 
1998).
6.1.2 Pentylenetetrazol seizure model
Following systemic administration, there are numerous chemicals which can induce 
seizures at toxic doses. These include PTZ, GABA antagonists such as bicuculline, 
picrotoxin and penicillin, inhibitors of GABA synthesis, inverse benzodiazepine 
receptor agonists, the glycine antagonist strychnine, the cholinomimetic drug 
pilocarpine, and NMDA and kainate glutamate receptor agonists. Of these 
chemoconvulsants, PTZ is the most commonly employed (Loscher and Schmidt, 
1988). The AED development program of the National Institutes of Health (NIH) 
USA, which since its initiation in 1975 has stimulated the development of various new 
AEDs, is primarily based on only two seizure models, namely, the MES test and the 
s.c. PTZ test (Loscher and Schmidt, 1988). PTZ is thought to produce myoclonic, 
generalised clonic and at higher doses tonic convulsions (Fisher, 1989), by interacting 
with the GABAa receptor - chloride ionophore complex, thereby reducing GABA 
mediated inhibition (Wilson and Escueta, 1974). There are two animal models which 
rely on PTZ to produce convulsions, namely the threshold for clonic seizures after i.v. 
infusion of PTZ, and the s.c. CD97 PTZ test (Loscher et al, 1991a). The s.c. CD97 is 
the most commonly used PTZ model and involves the administration of a dose of PTZ 
(usually between 80 and 100 mg/kg in mice) which induces generalised clonic seizures 
in all animals of a group. The seizure susceptibility of the particular strain can be
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determined by dose-effect measurement, and the CD97 (i.e. the dose causing clonic 
seizures in 97% of the animals) can be calculated prior to AED evaluation by the test 
(Loscher et al, 1991a). The endpoints used in this model differ in that some researchers 
use the first episode of continuous generalised clonic activity of at least five seconds 
(Swinyard, 1949), whereas others have used the first generalised clonic seizure with 
loss of the righting reflex as the endpoint (Loscher and Schmidt, 1988). The s.c. PTZ 
test identifies compounds that are efficacious against generalised absence and 
myoclonic seizures, and is one of the most commonly used animal models in the search 
for effective AEDs (White, 1997). Due to the simplicity of the s.c. PTZ model, it was 
employed to evaluate the efficacy of combinations of new AEDs in the following 
studies. The loss of righting reflex was chosen as the endpoint, as it is possibly more 
reliable and easier to recognise.
6.2 AIMS
There are very few reports highlighting beneficial combinations of newer AEDs. 
Experimental studies may provide some insight into effective combinations of new 
AEDs with maximal efficacy and minimal toxicity. Three of the new AEDs, LTG, GBP 
and TPM are commonly used as add-on therapy for refractory partial seizures, with or 
without secondary generalisation (Dichter and Brodie, 1996). The aim of these studies 
was to investigate the effects of these drugs in single dose and in combination on 
experimental seizures induced by s.c. PTZ in mice, in an attempt to identify efficacious 
combinations of new AEDs.
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6.3 EXPERIMENTAL PROTOCOLS AND RESULTS
6.3.1 Effects of lamotrigine and gabapentin in single dose and in combination 
on pentylenetetrazol-induced seizures in mice
DRUG ADMINISTRATION: LTG and GBP were prepared for injection in 0.9% 
saline. Mice were randomised into groups (n = 8) and administered (mg/kg): LTG (0.5,
2.5, 12.5); GBP (2, 10, 50); GBP (2) + LTG (0.5, 2.5, 12.5); GBP (10) + LTG (0.5,
2.5, 12.5); and GBP (50) + LTG (0.5, 2.5, 12.5) i.p. A control group (n = 8) received 
vehicle alone. At one hour post-AED administration, mice were subjected to the PTZ 
test (section 2.13). A one-hour period was chosen (as opposed to four hours) to allow 
a greater number of animals to be subjected to the test in the mornings, and to 
minimise the effect of circadian rhythms by avoiding afternoon testing. All drug doses 
examined in this chapter were based on previous studies carried out in the laboratory.
RESULTS: In single dose, only LTG (12.5 mg/kg) significantly (P < 0.05) increased 
the time to the first PTZ-induced generalised seizure. Combinations of LTG (2.5 
mg/kg) with GBP (2 and 10 mg/kg) and LTG (12.5 mg/kg) with GBP (2, 10 and 50 
mg/kg) all significantly (P < 0.05) increased the seizure latency in mice (figure 81).
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FIGURE 81. Effects of lamotrigine (LTG) and gabapentin (GBP) in single dose and in 
combination on the time to the first generalised seizure induced by 85 mg/kg 
pentylenetetrazol (s.c.) in groups of (n = 8 - 24) mice. Results are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.). Statistical significance (* P < 0.05) was determined by one way 
analysis of variance with Dunnett correction for multiple comparisons.
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6.3.2 Effects of gabapentin and topiramate in single dose and in combination 
on pentylenetetrazol-induced seizures in mice
DRUG ADMINISTRATION: GBP and TPM were prepared for injection in 0.9% 
saline. Mice were randomised into groups (n = 8) and administered (mg/kg): GBP (2, 
10, 50); TPM (5, 25, 125); TPM (5) + GBP (2, 10, 50); TPM (25) + GBP (2, 10, 50); 
and TPM (125) + GBP (2, 10, 50) i.p. A control group (n = 8) received vehicle alone. 
At one hour post-AED administration, mice were subjected to the PTZ test (section 
2.13)
RESULTS: In single dose, GBP and TPM were without effect on PTZ-induced 
seizures in mice, at the doses examined. A combination of GBP (10 mg/kg) with TPM 
(25 mg/kg) was found to have a significant (P < 0.05) anticonvulsant effect when 
compared to control. All other combinations of GBP with TPM were without effect 
(figure 82).
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FIGURE 82. Effects of gabapentin (GBP) and topiramate (TPM) in single dose and in 
combination on the time to the first generalised seizure induced by 85 mg/kg 
pentylenetetrazol (s.c.) in groups of (n = 8 - 24) mice. Results are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.). Statistical significance (* P < 0.05) was determined by one way 
analysis of variance with Dunnett correction for multiple comparisons.
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6.3.3 Effects of topiramate and lamotrigine in single dose and in combination 
on pentylenetetrazol-induced seizures in mice
DRUG ADMINISTRATION: Mice were randomised into groups (n = 8) and 
administered (mg/kg): TPM (5, 25, 125); LTG (0.5, 2.5, 12.5); LTG (0.5) + TPM (5, 
25, 125); LTG (2.5) + TPM (5, 25, 125); and LTG (12.5) + TPM (5, 25, 125) i.p. A 
control group (n = 8) received vehicle alone.
RESULTS: In single dose, only LTG (12.5 mg/kg) significantly (P < 0.05) increased 
the time to the first generalised seizure. All combinations of TPM with LTG examined 
were found to have no effect on the latency to generalised seizures induced by PTZ, at 
one hour post-administration (figure 83).
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FIGURE 83. Effects of topiramate (TPM) and lamotrigine (LTG) in single dose and in 
combination on the time to the first generalised seizure induced by 85 mg/kg 
pentylenetetrazol (s.c.) in groups (n = 8 - 24) of mice. Results are expressed as the 
mean percentage of mean control values and error bars denote the standard error of the 
mean (S.E.M.). Statistical significance (* P < 0.05) was determined by one way 
analysis of variance with Dunnett correction for multiple comparisons.
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6.4 DISCUSSION
The aim of these studies was to identify potentially effective combinations of new 
AEDs for use in the treatment of refractory epilepsy. Administration (s.c.) of the 
chemoconvulsant PTZ was chosen to evaluate the effects of three new AEDs LTG, 
GBP and TPM, in single dose, and in combination, on experimentally-induced seizures 
in mice.
6.4.1 Effects of single antiepileptic drugs on pentylenetetrazol-induced seizures
When administered alone, only the highest dose of LTG examined significantly 
increased the latency to the first generalised seizure with loss of the righting reflex. 
Both GBP alone and TPM alone were without effect.
6.4.2 Effects of lamotrigine and gabapentin in combination on 
pentylenetetrazol-induced seizures
Five of the nine combinations of LTG with GBP were found to significantly increase 
the time to PTZ-induced generalised seizures when compared to control, suggesting 
that there is an additive interaction occurring between the AEDs. However, when 
combinations of LTG and GBP were compared to LTG alone they were not 
significantly different. LTG 12.5 mg/mg in combination with GBP 2, 10 and 50 mg/kg 
all significantly increased the time to PTZ-induced seizures. Similarly, LTG 2.5 mg/kg 
in combination with GBP 2 and 10 mg/kg also increased the time to PTZ-induced 
seizures. However, LTG 2.5 mg/kg in combination with the highest dose of GBP 
examined (50 mg/kg) failed to increase the time to the first generalised seizure when 
compared to control, suggesting that this particular combination has an infra-additive 
effect. These results suggest that there is an interaction occurring between the drugs
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which requires further investigation. In support of this, a recent study by De Sarro and 
colleagues (1998) reported that GBP potentiated the anticonvulsant activity of several 
AEDs including LTG, against audiogenic seizures in DBA/2 mice.
LTG is thought to exert its anticonvulsant effects by blockade of voltage-dependent 
sodium channels, thereby preventing the release of the excitatory neurotransmitters 
glutamate and aspartate (Leach et al, 1986). The mechanism of action of GBP is 
unclear (Wilson and Brodie, 1996), but in a similar manner to LTG, GBP has been 
shown to inhibit voltage-dependent sodium currents (Wamil and McLean, 1994). In 
addition to this, it has been reported to bind to a calcium channel in the brain (Gee et 
al, 1996), and recently it has been suggested that GBP may also exert effects on the 
GABAergic system (Leach et al, 1997a). In the search for pharmacological synergism 
in the management of refractory epilepsy, there is much speculation as to which AEDs 
should be examined in combination. It has been suggested that AEDs which target the 
same neurotransmitter system may be a logical approach in treating patients with a 
single seizure type, and those with differing modes of action may be beneficial in 
patients who experience a range of seizures (Leach and Brodie, 1994). With regard to 
this, the combination of LTG and GBP may be of value in treating patients with a 
single seizure type, as both drugs exert effects on voltage-dependent sodium channels. 
It may also be beneficial to patients with multiple seizure types, due to the additional 
reported effects of GBP on calcium channels and the GABAergic system.
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6.4.3 Effects of gabapentin and topiramate in combination on 
pentylenetetrazol-induced seizures
A combination of GBP (10 mg/kg) with TPM (25 mg/kg) was found to significantly 
increase the latency to the first PTZ-induced seizure when compared to control. All 
other combinations were without effect. The observation that only one of the nine 
combinations examined was effective questions the clinical relevance of this finding, 
and requires further detailed work to evaluate the use of this combination as an 
effective polytherapy regimen.
The precise mechanism of action of TPM remains to be fully elucidated, but it is 
thought to possess multiple anticonvulsant effects (Dichter and Brodie, 1996). TPM 
has been reported to have inhibitory actions on voltage-dependent sodium channels 
(Coulter et al, 1993; Zona et al, 1997). There is also evidence to suggest that the drug 
has inhibitory effects on the AMPA / kainate subtype of glutamate receptor (Coulter et 
al, 1995), and it has been shown to potentiate GABAergic responses at the GABAa 
receptor (White et al, 1997). As both GBP and TPM appear to share a common effect 
on sodium channels, and both appear to possess multiple mechanisms of action, one 
could speculate that this combination may be of benefit in treating both patients with a 
single seizure type, and those experiencing a range of seizure types.
6.4.4 Effects of lamotrigine and topiramate in combination on pentylenetetrazol 
induced seizures
In this study, all nine combinations examined of LTG with TPM failed to exert any 
significant anticonvulsant effect in preventing PTZ-induced seizures when compared to 
control. These results fail to reproduce the protectant effect reported by Stephen et al
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(1998), and suggest that the addition of TPM to LTG has a detrimental effect on 
seizure protection. LTG 12.5 mg/kg alone significantly increased the time to PTZ- 
induced seizures, however, when combined with TPM 5, 25 and 125 mg/kg the 
protective effect of LTG was lost, suggesting an infra-additive interaction. This study 
provides no evidence to suggest this combination may be of benefit in the treatment of 
refractory epilepsy. It is not known why the studies, which were conducted in the same 
laboratory under the same experimental conditions fail to agree. The only difference 
between the two studies is that different batches of TPM were employed in the 
investigations, and may account for the variation in results. No conclusions can 
therefore be drawn until further work is carried out to clarify the differences between 
the two studies.
6.4.5 Further work
For simplicity, this preliminary study examined only at a few doses for each drug, and 
combinations were examined in only the PTZ seizure model. Further combination 
studies are therefore required in additional seizure models. This study examined 
combinations of only three new AEDs, and as the newer drugs in general are reported 
to have fewer interactions than the older ones, future work should include 
combinations of the remaining new drugs. In support of this, a recent study has 
suggested that GBP may augment the antiepileptic effects of VGB in hippocampal 
slices (Lucke et al, 1998). It may also be of benefit to investigate combinations of the 
new drugs with the established ones. Indeed, in a recent clinical trial it has been 
observed that a combination of LTG with the established AED VPA may display 
synergism (Brodie et al, 1997). Finally, as this study only concentrated on acute 
administration, it would be of benefit to assess the effects of combinations of AEDs
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following chronic treatment, to ensure that any potential therapeutic benefits are not 
accompanied by an increase in toxicity.
6.5 CONCLUSIONS
In conclusion, this study fails to conclusively identify effective combinations of new 
AEDs. However, the results observed for combinations of LTG with GBP suggest that 
this combination may be of interest clinically, and warrants further detailed 
experimental and clinical investigation. There is also a hint that the combination of 
GBP and TPM may be of some interest clinically, whereas the effects of the 
combination of LTG with TPM require clarification.
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CHAPTER SEVEN
EFFECTS OF ANTIEPILEPTIC DRUGS ON THE TRANSPORT OF GABA IN 
PRIMARY CULTURES OF HUMAN CORTICAL ASTROCYTES
203
7.1 INTRODUCTION
Astrocytes account for more than half of the glial cell population in the brain and are 
actively involved in the uptake and metabolism of the major inhibitory neurotransmitter 
GABA (Kimelberg, 1983; Kimelberg and Norenberg, 1989). Primary cultures of 
astrocytes have been used extensively to study the transport of GABA (Schousboe et 
al, 1977; Larsson et al, 1981; Schousboe, 1981; Schousboe et al, 1983b; Hansson et 
al, 1985), and are ideal tools for investigating the mechanisms of action of AEDs.
SVP, VGB and TGB are three anticonvulsant drugs which exhibit effects on GABA 
neurotransmission. SVP is an established AED whose precise mechanism of action 
remains to be elucidated. It is thought to exert multiple actions, amongst which are 
several effects on the GABAergic system. These include an increase in the 
concentration of the GABA synthesizing enzyme GAD, and inhibitory effects on the 
GABA degrading enzymes GABA-T, succinic semialdehyde dehydrogenase and 
aldehyde reductase, leading to an increase in brain GABA concentration (Rogawski 
and Porter, 1990). VGB and TGB are two novel AEDs which exert their 
anticonvulsant actions via specific effects on the GABAergic system. VGB irreversibly 
inhibits the GABA degrading enzyme GABA-transaminase (Jacob et al, 1990) and 
TGB selectively blocks the glial and neuronal uptake of GABA (Suzdak and Jansen, 
1995).
The vast majority of AED neurochemical studies are performed using rodent brain and 
do not employ human brain tissue. In recent years, the use of animals for experimental 
purposes has become morally less acceptable. Moreover, there are differences between 
animal brain and human brain, and it is difficult to determine if an AED will have the
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same effect in humans as it has in an animal experiment. It is thought that the use of 
human brain tissue will afford a more representative insight into the clinical action of 
AEDs under investigation.
7.2 AIMS
The effects of AEDs have not previously been demonstrated in primary glial cultures 
from human brain. However, the supply of viable human tissue was not as abundant as 
hoped, and much of the tissue received was utilised in establishing the method. 
Therefore, only a limited number of AEDs were selected for investigation, and the only 
parameter examined was GABA uptake. The aim of this preliminary study was, 
therefore, to investigate the effects of SVP, VGB and TGB on the transport of GABA 
in cultured human astrocytes from adult and foetal brain, and to compare the results 
with those obtained from the rodent experiments (chapter 3).
7.3 EXPERIMENTAL PROTOCOLS AND RESULTS
7.3.1 Effects of sodium valproate, vigabatrin and tiagabine on the uptake of 
[14C]-GABA into primaiy cultures of human adult astrocytes
EXPERIMENTAL PROTOCOL: Adult brain tissue was obtained and cultured as 
described in section 2.4. Astrocytes were identified as positive for GFAP and 
photographed as described in section 2.5 (photograph 2). Dose / response curves could 
not be constructed due to insufficient amounts of tissue. Single drug concentrations 
which had a significant effect on GABA uptake in the rat cultures were therefore 
examined. Cultures were separated into three groups (n = 24) and exposed to SVP 
(1000 pM), VGB (100 pM) and TGB (200 nM) in BSS. A fourth group (control) was
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exposed to BSS alone. After a one hour incubation, cells were assayed for GABA 
uptake as described in section 2.7.
RESULTS: SVP (1000 pM), VGB (100 pM) and TGB (200 nM) significantly (P < 
0.05) reduced the uptake of [14C]-GABA into primary cultures of human adult 
astrocytes following a one hour exposure (figure 84).
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PHOTOGRAPH 2. Human adult cortical astrocytes in primary culture (day 21) 
stained with glial fibrillary acidic protein (GFAP) and examined using a fluorescent 
microscope (x 450).
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FIGURE 84. Effects of sodium valproate (SVP; 1000 pM), vigabatrin (VGB; 100 
pM), and tiagabine (TGB; 200 nM) on the uptake of GABA into primary cultures of 
human adult cortical astrocytes. Results (n = 24) are expressed as the mean percentage 
of mean control values and error bars denote the standard error of the mean (S.E.M.). 
Statistical significance (*P < 0.05) was determined by one way analysis of variance 
with Dunnett correction for multiple comparisons.
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7.3.2 Effects of sodium valproate, vigabatrin and tiagabine on the uptake of 
[14C]-GABA into primary cultures of human foetal astrocytes
EXPERIMENTAL PROTOCOL: Foetal brain tissue was obtained and cultured as 
described in section 2.4. Astrocytes were identified as positive for GFAP and 
photographed as described in section 2.5 (photograph 3). As in the foetal astrocyte 
experiments, drug concentrations which had a significant effect on GABA uptake in 
the rat cultures were chosen. An additional increased concentration of 500 nM of TGB 
was examined in this study as the 200 nM was without effect. Cultures were separated 
into four groups (n = 17) and exposed to SVP (1000 pM), VGB (100 pM), TGB (200 
nM) and TGB (500 nM) in BSS. A fifth group (control) was exposed to BSS alone. 
After a one hour incubation, cells were assayed for GABA uptake as described in 
section 2.7.
RESULTS: SVP (1000 pM) and VGB (100 pM) significantly (P < 0.05) reduced the 
uptake of [14C]-GABA into primary cultures of human foetal astrocytes following a 
one hour exposure. Both doses of TGB (200 and 500 nM) examined were without 
effect (figure 85) on the transport of GABA.
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PHOTOGRAPH 3. Human foetal cortical astrocytes in primary culture (day 21) 
stained with glial fibrillary acidic protein (GFAP) and examined using a fluorescent 
microscope (x 450).
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FIGURE 85. Effects of sodium valproate (SVP; 1000 pM), vigabatrin (VGB; 100 
pM), and tiagabine (TGB; 200 and 500 nM) on the uptake of GABA into primary 
cultures of human foetal cortical astrocytes. Results (n = 17) are expressed as the mean 
percentage of mean control values and error bars denote the standard error of the mean 
(S.E.M.). Statistical significance (*P < 0.05) was determined by one way analysis of 
variance with Dunnett correction for multiple comparisons.
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7.4 DISCUSSION
SVP, VGB and TGB are three AEDs which have previously been demonstrated to 
exert effects on the GABAeric system (Lippert et al, 1977; Larsson et al, 1986; 
Rogawski and Porter, 1990; Nielsen et al, 1991; Borden et al, 1994; Suzdak and 
Jansen, 1995). However, many studies employ rodent tissue to investigate AED 
mechanisms of action, and these drugs have not previously been examined in primary 
cultures of human astrocytes. The aim of this study was therefore to determine the 
effects of SVP, VGB and TGB on the uptake of [14C]-GABA into primary cultures of 
both human foetal and adult brain.
7.4.1 Effects of sodium valproate on the uptake of GABA into primary cultures 
of human adult and foetal astrocytes
At the concentration examined, SVP was found to significantly reduce the uptake of 
GABA into both adult and foetal astrocytes. A reduction of GABA uptake into rat 
cortical astrocytes was also observed with a similar dose of SVP (chapter 3, figure 4). 
In addition, this effect is consistent with a previous study carried out using primary 
cultures from rodent brain, where Nilsson and colleagues (1992) found that acute 
treatment of rat cortical astrocytes with SVP resulted in a decreased affinity, but not 
transport capacity, for GABA. SVP has also been demonstrated to inhibit GABA 
uptake in frog dorsal root ganglion cells (Klee et al, 1985). These results would 
suggest that adult and foetal human tissue, rodent and frog brain respond in a similar 
manner to SVP.
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7.4.2 Effects of vigabatrin on the uptake of GABA into primary cultures of 
human adult and foetal astrocytes
As well as the documented inhibition of GABA-T, work in our laboratory recently 
demonstrated that VGB reduced the uptake of GABA into primary cultures of 
astrocytes from rat neonatal tissue (Leach et al, 1996). This effect has again been 
demonstrated in primary cultures of rat cortical astrocytes in this thesis (chapter 3, 
figure 5). This study has confirmed that this additional effect of VGB also occurs in 
primary cultures of astrocytes from human adult and foetal brain, and further indicates 
that it may be involved in the antiepileptic mechanism of action of the drug.
7.4.3 Effects of tiagabine on the uptake of GABA into primary cultures of 
human adult and foetal astrocytes
It is well documented that TGB exerts its antiepijeptic effects via inhibition of GABA 
uptake (Giardina, 1994; Mengel, 1994; Suzdak and Jansen, 1995), as demonstrated in 
rat glial and neuronal cultures and rat brain synaptosomes. It is thought to specifically 
inhibit the GABA transporter GAT-1 (Borden et al, 1994). Results obtained using 
primary cultures of rat cortical astrocytes in this thesis (chapter 3, figure 10) reproduce 
this TGB-mediated reduction in GABA uptake at doses of TGB ranging from 10 to 
1000 nM. In contrast with the results obtained with SVP and VGB, TGB was found 
only to influence the transport of GABA in the adult human astrocytes, with no 
significant reduction in the uptake of GABA in the foetal cells at both doses of TGB 
examined. The apparent discrepancy in results between adult and foetal tissue may 
reflect incomplete development of the nervous system, in that the GAT-1 transporter, 
which TGB inhibits, may not be present in cells cultured from 16-24 week old foetal 
brain. Therefore, a lack of effect of TGB is observed. Further work is needed to clarify
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this. It is, however, interesting to note that SVP and VGB do not appear to 
discriminate between foetal and adult tissue. This would suggest that these drugs may 
be reducing the uptake of GABA via a different mechanism, possibly not specific and 
not involving the GAT-1 transporter. Differences in the transport of these drugs into 
cells has previously been described. It is thought that SVP is itself transported by a 
carrier mediated uptake (Nilsson et al, 1990), whereas it has been shown that TGB is 
not a substrate for the GABA uptake carrier (Mengel, 1994).
7.5 CONCLUSIONS
In conclusion, this preliminary study has demonstrated inhibition of GABA uptake by 
SVP, VGB and TGB in adult astrocytes, and by SVP and VGB in foetal cultures. The 
lack of effect of TGB in the foetal cultures may highlight a lack of development of the 
GAT-1 transporter in 16 - 24 week foetal brain tissue, and suggests that SVP and 
VGB reduce GABA uptake by a mechanism distinct from that of TGB. The effects of 
SVP and VGB on GABA uptake appear to be consistent in rat and human tissue. The 
reduction in GABA uptake exhibited by TGB in the rat experiments is consistent with 
that in the adult human tissue, but not in the foetal human tissue. This study has 
therefore confirmed that the drugs examined have similar effects in animal and human 
tissue, but may highlight an important difference in the mechanism of GABA uptake 
inhibition exhibited by these drugs. This is, however, a preliminary study and further 
research of this nature is required in order to draw more definite conclusions on the 
responses of AEDs in different species.
214
CHAPTER EIGHT
GENERAL DISCUSSION AND CONCLUSIONS
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8.1 MECHANISMS OF ACTION OF THE ESTABLISHED
ANTIEPILEPTIC DRUGS
8.1.1 Phenobarbitone
In addition to the documented effects of PB on the GABAa receptor, and more 
recently, effects on voltage-sensitive calcium and potassium channels, and blockade of 
NMDA-receptors, this study has revealed previously unreported effects o f the drug on 
glutamate neurotransmission. In primary cultures of rat cortical astrocytes PB, at low 
doses, was found to significantly reduce the transport of glutamate into the cells. This 
effect has not previously been reported and the contribution to its anticonvulsant 
efficacy remains to be determined. It may perhaps lead to a reduction in efficacy of the 
drug or may even contribute to the toxicity of PB. In support of this theory, PB was 
also found to significantly reduce the activity of the glutamate-metabolizing enzyme 
GS. This effect was observed in mouse brain following repeated administration of the 
drug and was consistent over a range of doses. Additionally, a single concentration of 
PB was found to inhibit the enzyme in primary cultures of rat cortical astrocytes, and 
was the only AED of the twelve examined to do so. This apparent reduction in 
glutamate uptake and inhibition of GS activity may account for the CNS-related 
adverse effects and increase in seizure frequency observed clinically with PB at high 
doses.
8.1.2 Phenytoin
PHT has been proposed to exert its anticonvulsant effects via several reported 
mechanisms, namely interaction with voltage-activated sodium channels, voltage- and 
frequency-dependent block of T-type calcium channels, inhibitory effects on non-T-
216
type calcium channels and potentiation of GABA-mediated synaptic inhibition. From 
experiments conducted in this thesis it would appear that like PB, PHT also exhibits 
inhibition of GS in mouse brain. However, whereas PB exerted effects following only 
chronic administration, PHT was found to decrease the activity of GS over a range of 
doses following both acute and chronic administration. PHT failed to exert the 
inhibition of GS demonstrated by PB in primary cultures of rat astrocytes. As with PB, 
it is unlikely that inhibition of this enzyme would contribute to the anticonvulsant 
effects of PHT, and may contribute to the phenomenon of paradoxical intoxication 
observed clinically with PHT at higher doses. PHT demonstrated no effects on GABA 
or glutamate uptake or on the activity of GABA-T in primary cultures of rat cortical 
astrocytes in this study.
8.1.3 Carbamazepine
A number of mechanisms are reported to be responsible for the anticonvulsant effects 
of CBZ. In a similar manner to PHT, CBZ exerts inhibition of voltage-dependent 
sodium channels and non-T-type calcium channels. In addition, it has also been 
reported to interact with brain adenosine Ai and A2 receptors, however, the clinical 
significance of this effect remains to be evaluated. CBZ is another of the established 
AEDs which exhibited a reduction in GS activity in this study. The reduction in enzyme 
activity was evident in mouse brain following both acute and chronic administration. 
Again, this effect is previously unreported, and may be related to the increase in seizure 
frequency seen clinically with CBZ at higher doses. No effects of CBZ on the transport 
of GABA and glutamate or the metabolism of GABA were noted in this study.
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8.1.4 Sodium Valproate
SVP is a broad spectrum AED thought to exert its anticonvulsant effects by a 
combination of mechanisms. It has been shown to exert numerous effects on the 
GABAergic system, blockade of voltage-dependent sodium channels, and to decrease 
aspartate levels in rodent brain. The extent to which each of these proposed 
mechanisms contributes to the antiepileptic efficacy of SVP remains to be determined. 
Experiments employing primary cultures of rat cortical astrocytes in this thesis 
demonstrated that SVP, at all concentrations examined, inhibited the transport of 
GABA into these cells. These results confirm a previous group’s findings. Additionally 
SVP inhibited the transport of GABA into primary cultures of both human foetal and 
adult cultured astrocytes adding to the increasing evidence that the GABAergic system 
is involved in the mechanism of action of SVP.
8.2 MECHANISMS OF ACTION OF THE NEW ANTIEPILEPTIC DRUGS
8.2.1 Vigabatrin
VGB was the first AED to be developed on the basis o f a targeted mechanism of 
action, and is one of the few reported AEDs with a single specific mechanism of 
action. VGB exerts its antiepileptic effects by irreversible inhibition of the GABA 
degrading enzyme GABA-T. However, in a recent study in our laboratory VGB was 
found to inhibit the uptake of GABA into cultured astrocytes, suggesting that it also 
possesses multiple mechanisms of action. The experiments carried out in this thesis 
demonstrate a VGB-induced inhibition of GABA-T therefore confirming the 
documented mechanism of action o f the drug. In addition, VGB demonstrated 
inhibition of the uptake of GABA into primary cultures o f rat cortical astrocytes, and
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also into primary cultures of human astrocytes from foetal and adult brain, further 
supporting the notion that like other AEDs VGB acts via multiple mechanisms of 
action.
8.2.2 Lamotrigine
In animal models LTG exhibits an experimental profile similar to that of PHT, 
suggesting a similar mechanism of action. In rat cerebral slices LTG potently inhibits 
veratrine-evoked glutamate and aspartate release. It has been shown to limit the high 
frequency firing of sodium-dependent action potentials in cultured mouse spinal cord 
neurones, suggesting a use- and frequency-dependent block of voltage sensitive 
sodium channels similar to PHT and CBZ. However, LTG possesses a broader 
anticonvulsant profile than the established AEDs with effects on sodium channels. 
More recently a number of studies have indicated that LTG also exhibits blockade of 
calcium channels. In this thesis, LTG, unlike PHT and CBZ, failed to reduce the 
activity of GS in mouse brain. This study highlights that although LTG has a similar 
profile to the established AEDs PHT and CBZ, differences in the drugs do exist. LTG 
was without effect on the transport and metabolism of GABA and glutamate in primary 
cultures of rat cortical astrocytes in this study.
8.2.3 Felbamate
As yet, the precise mechanism of action of FBM remains to be determined. It has been 
shown to enhance GABAa receptor-mediated chloride currents in rat hippocampal 
neurones, and to interact with the strychnine-insensitive glycine modulatory site of the 
glutamate NMDA receptor. In addition to effects on amino acid systems FBM is 
thought to block voltage-dependent sodium channels and to inhibit dihydropyridine-
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sensitive calcium channels. It therefore remains likely that FBM possesses multiple 
mechanisms of action. Experiments in this study found that FBM at all concentrations 
examined significantly reduced the uptake of GABA into primary cultures of rat 
cortical astrocytes. This effect has not been reported previously, and may reflect an 
additional mechanism which contributes to the antiepileptic efficacy of the drug. FBM 
was without effect on the uptake of glutamate, the activity of GABA-T and the activity 
of GS in primary cultures of rat cortical astrocytes. Similarly, both single and repeated 
administration of FBM was without effect on the concentrations of GABA, glutamate 
and glutamine, and on the activities of GABA-T and GAD in mouse brain. Repeated 
administration of FBM was, however, found to significantly reduce the activity of GS 
in mouse brain in this thesis. A reduction in GS activity may be expected to lead to a 
decrease in brain glutamine concentrations. The reduction in GS activity in this study 
was not, however, accompanied by a decrease in brain glutamine or an increase in brain 
glutamate levels. The reason for the apparent lack of effect of FBM on mouse brain 
neurotransmitter concentrations is unknown, but may reflect a compensatory 
mechanism such as an increase in the clearance of glutamate from the synapse, an 
increase in the synthesis of glutamine from glucose, or an increase in the uptake of 
glutamine direct from the blood.
8.2.4 Gabapentin
GBP is a hydrophilic analogue of GABA which can freely cross the blood-brain barrier. 
It has, however, demonstrated only limited effects on the GABAergic system, and has 
been reported to exert no effects at GABA receptors or uptake carriers in the brain. 
GBP has been shown to increase GABA turnover in rodent brain, and there is evidence 
to suggest that GABA levels were elevated in the cortex of patients. The drug has been
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reported to increase the activity of GAD, and in addition at high concentrations has 
been shown to inhibit GABA-T (an effect which is not thought to be clinically 
relevant). A recent study in our laboratory showed that repeated administration of 
GBP reduced whole brain glutamate levels in mice. In addition to effects on amino 
acids the drug has been reported to reduce sustained repetitive firing of neurones. GBP 
was recently reported to exert inhibitory effects on L-type voltage-gated calcium 
channels, and has been demonstrated to bind with high affinity to a calcium channel 
sub-unit in the brain. Despite the increasing evidence in the literature indicating 
multiple mechanisms of action of GBP, the results of this study failed to identify any 
novel or additional effects of the drug. GBP was without effect on the uptake of 
GABA and glutamate and on the activities of GABA-T and GS in primary cultures of 
rat cortical astrocytes. Similarly, the drug was without effect on the activity of GS in 
mouse brain.
8.2.5 Topiramate
TPM is thought to act by blocking the spread of seizure discharges. It appears likely 
that it too possesses multiple mechanisms of action. It has been reported to exert 
blockade of voltage-activated sodium channels and inhibitory effects on kainate- 
induced responses. In addition TPM reportedly potentiates responses to GABA at the 
GABAa receptor and may reduce abnormally high levels of glutamate and aspartate in 
the hippocampus of spontaneously epileptic rats. In this study, primary cultures of rat 
cortical astrocytes were employed to investigate the effects of TPM on the transport 
and metabolism of GABA and glutamate. TPM failed to exert any significant effect on 
the uptake or metabolism of GABA or glutamate in the cultured cells. Similarly, the 
chapter examining the GABA- and glutamate-related neurochemical effects of TPM
221
revealed no effect on mouse brain concentrations of GABA, glutamate and glutamine, 
and no significant effect on the activities of GABA-T and GAD. Repeated 
administration of TPM was, however, responsible for a significant decrease in the 
activity of GS in mouse brain. This effect has not previously been reported, and as 
discussed in chapter four, may indicate a toxic effect of the drug. However, as 
observed with FBM (which also reduced brain GS levels) the decrease in GS was not 
accompanied by a change in mouse brain concentrations of glutamate or glutamine. 
Again, it can only be speculated that compensatory changes are taking place, thereby 
preventing any alteration in neurotransmitter concentrations. Taken together, the 
results of this study and reports in the literature indicate that TPM does give rise to its 
effects by a multifactorial mechanism.
8.2.6 Tiagabine
TGB is said to be the most mechanistically precise AED in clinical use. It is a potent 
and selective inhibitor of the uptake of GABA into neurones and glia. It is thought to 
specifically inhibit the GAT-1 GABA transporter. It has no significant affinity for other 
uptake sites and does not affect sodium or calcium channels. To date no other 
mechanism has been proposed to explain its antiepileptic efficacy. TGB significantly 
inhibited the uptake of GABA into primary cultures of rat cortical astrocytes in this 
study, confirming the documented mechanism of action of the drug. However, at the 
highest concentration examined, TGB additionally reduced the activity of GABA-T in 
primary cultures of rat cortical astrocytes. The drug was also shown to reduce the 
transport of glutamate into the cells, however, as the effect appeared to be independent 
of dose and was evident following only two of the eight concentrations examined the 
clinical relevance is questionable. TGB had no significant effect on GS activity in
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cultured rat astrocytes or in mouse brain in this study. Therefore, although the 
reduction in GABA-T activity occurred only at the highest concentration examined, 
this effect cannot be ignored and questions the thinking that TGB acts by a single 
mechanism of action. This requires further investigation. In primary cultures of human 
adult astrocytes, TGB significantly inhibited GABA uptake into the cells. This is in 
agreement with the data for the rat cultures. However, an interesting observation in 
this thesis was the failure of the drug to affect GABA transport in cultured human 
astrocytes from foetal brain. This observation suggests that the GAT-1 transporter in 
human foetal brain is not developed sufficiently for the drug to be able to act. 
Additionally, the ability of SVP and VGB to inhibit GABA uptake in both adult and 
foetal human astrocyte cultures suggests a difference in the mode of action of GABA 
uptake inhibition exerted by the AEDs.
8.3 MECHANISMS OF ACTION OF THE EXPERIMENTAL STAGE 
ANTIEPILEPTIC DRUGS
8.3.1 Levetiracetam
As with many of the other novel AEDs, the precise mechanism of action of LEV 
remains to be determined. The drug fails to interact with the classical receptor and ion 
channel sites in the brain. LEV has, however, been proposed to bind in a stereospecific 
manner to a specific binding site in CNS membranes, where it is weakly displaced by 
PB and PTZ, suggesting that it may be GABA-related. Treatment with LEV has been 
reported to induce alterations in GABA metabolism and turnover in discrete areas of 
rat brain. The work carried out in this thesis fails to clarify the mechanism of action of 
LEV. In primary cultures of rat cortical astrocytes LEV failed to exert a significant
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effect on the uptake of GABA or glutamate, or on the activities of GABA-T or GS. 
Experiments carried out in mouse brain similarly failed to demonstrate a significant 
effect of LEV on the concentrations of GABA, glutamate or glutamine or on the 
activities of GS, GABA-T or GAD. These results would suggest that the mechanism of 
action of LEV is likely to exclude effects on GABA and glutamate neurotransmission, 
however, this remains to be determined.
8.3.2 Desglycinyl-remacemide
DGR is the desglycinyl metabolite of the novel AED RMD. This metabolite has a 
longer half-life and a more potent pharmacological profile than RMD. As with LEV, 
the precise mechanism of action of this novel compound remains to be determined. 
DGR has been shown to prevent sustained repetitive firing of cultured spinal cord and 
hippocampal CA1 neurones, and has also been shown to decrease the release of 
glutamate and aspartate from cortical slices. It is reported that DGR may also exert 
effects at the NMD A receptor, where it has been reported to displace [3H]-dizocilpine 
binding. A recent study in our laboratory showed that repeated administration of DGR 
at high dose significantly increased GABA-T and decreased GAD activity. Both effects 
have been postulated to contribute to the proconvulsant action of the drug seen 
clinically at higher doses. Several of the other AEDs examined reduced GS activity and 
this effect may account for their proconvulsant properties seen clinically at high doses. 
In this thesis, DGR had no significant effect on the activity of GS in either primary 
cultures of rat cortical astrocytes or in mouse brain, therefore, contributing no further 
experimental evidence to explain the proconvulsant effects of DGR seen clinically at 
high doses. In studies employing primary cultures of rat cortical astrocytes DGR had 
no significant effect on the transport of GABA into the cells. However, a reduction in
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glutamate uptake was evident following DGR treatment, suggesting that this effect 
may be involved in the clinical and/or toxic actions of the drug. DGR was found to 
significantly reduce the activity of GABA-T in the cultured astrocytes. This effect has 
not previously been reported and may indicate an additional mechanism of action 
contributing to the anticonvulsant effects of the drug.
8.4 CONCLUSIONS
From the literature, it is becoming increasingly evident that most AEDs have multiple 
mechanisms of action. The data presented in this thesis gained from experiments 
employing primary cultures of rat cortical astrocytes, human adult and foetal 
astrocytes, and mouse brain support the multiple mode of action theory, and have 
highlighted several previously unreported additional mechanisms for some of the 
AEDs. For the AEDs with reported single and specific mechanisms of actions this 
study has revealed that they too may possess multifactorial modes of action.
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